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Introduction and Aims
Arterial stiffness is a novel CVD risk factor that may offer additional preventive and 
therapeutic targets for two of the most debilitating conditions in elderly individuals: late-
life depression and cognitive dysfunction. The proportion of the world’s older adults is 
estimated to almost double from 12% to 22% between 2015 and 2050 [1]. More than 20% 
of adults aged 60 and over suffer from at least one neuropsychiatric disorder, which account 
for 17.4% of Years Lived with Disability (YLDs). The most common of these neuropsychiatric 
disorders are dementia and depression [1]. Both disorders are highly invalidating, due to 
their chronic course, poor prognosis and lack of successful therapies [2,3]. Thus, additional 
research into their pathophysiology is required in order to uncover additional therapeutic 
and preventive targets. Growing evidence suggests that cerebral (micro) vascular disease 
is an important contributor to cognitive dysfunction, dementia and depression in late life 
[4,5]. Arterial stiffness is a modifiable CVD risk factor, which has been associated with 
cerebral micro- and macrovascular disease independently of traditional CVD risk factors 
[6,7]. In part 1 of this thesis we will, therefore, explore the role of arterial stiffness in the 
development of late-life depression and cognitive dysfunction. In part 2 we will then focus 
on the pathophysiology of arterial stiffening, in particular on the role of advanced glycation 
end products (AGEs), which may offer a target for lowering arterial stiffness.  
PART 1: 
Arterial Stiffness and Neuropsychiatric Disorders in Middle Age and Late Life
A. Depression
Depression is a chronic and invalidating disorder, especially in late life. According to the 
WHO, 6.9% of the adult population aged 18 to 65 years suffers from a major depressive 
disorder (MDD) [1]. It is the leading chronic condition in Europe and is responsible for 11% 
of all years lived with disability. The prevalence of MDD is lower in late-life (age > 55 years) 
than in younger groups [8,9] with an average prevalence between 0.4% - 10.2% in the general 
community; which can, however, reach as high as 14-42% in nursing home residents [9,10]. 
Late-life depression (LLD) is associated with worse treatment outcomes, including partial 
response to antidepressant medication [11], high recurrence rates [2], and greater suicide 
and non-suicide mortality rates [12]. Furthermore, LLD is accompanied by cognitive deficits 
which may ultimately progress to dementia despite adequate anti-depressant treatments 
[13,14]. Thus, in view of the rapid increase in the numbers of older adults worldwide, LLD 
is an important public health concern with possible dire consequences.  
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The biological basis of LLD is multifactorial and involves neurodegenerative, immune and 
endocrine pathways [15,16]; however, the pathway which focuses on the role of vascular 
disease [4] has received growing scientific attention in the past twenty years. This “vascular 
depression” hypothesis proposed that cardiovascular disease (CVD) and its risk factors 
predispose, precipitate or perpetuate LLD [4] through the accumulation of cerebral small 
vessel lesions within the brain, which disrupt the deep and frontal brain structures that are 
involved in mood regulation [4,17]. These changes could explain the symptoms specific to 
“vascular depression”, such as cognitive deficits, psychomotor retardation, lack of insight, 
and disability disproportional to severity of depression. Consistent with this hypothesis, 
white matter hyperintensities (WMH) have been cross-sectionally and longitudinally 
associated with LLD [18]. Furthermore, a greater WMH load has been associated with and 
could explain the poor response of LLD to antidepressants as well as its poor prognosis 
[19,20].
Despite the growing evidence concerning the vascular origin of LLD, the adequate 
management of classic CVD risk factors, such as hypertension or hyperlipidaemia has not 
been successful in preventing LLD [21]. Arterial stiffness is a novel CVD risk factor, which 
has been consistently associated with cerebral (micro)vascular disease, including WMH [6], 
independently of traditional CVD risk factors, therefore it may offer additional insight in the 
development of LLD. Furthermore, stiffening of the large elastic arteries, such as the aorta 
and the carotids, may offer additional targets for the prevention and treatment of LLD.
 
Arterial stiffness and depression: open questions
1. The differential association of arterial stiffness with LLD according to age 
The association of arterial stiffness with LLD has been studied in three population-based 
studies [22-24], two of which found a significant association [22,23]. These studies included 
individuals > 60 years, however, arterial stiffness could be a relevant risk factor for LLD in 
individuals as young as 40-60 years old. Indeed, cerebral small vessel disease may develop 
as early as the 4th decade [25] and elastic arteries show progressive stiffening from middle-
age onwards [26]. Furthermore, arterial stiffness may be a more potent CVD risk factor in 
middle-aged than in elderly individuals [27], possibly due to a stronger confounding effect 
of blood pressure in the latter group. In the elderly aortic stiffening closely mirrors the 
rise in systolic and pulse pressures and adds little to models that include hypertension; 
whereas in middle-aged individuals blood pressure is mainly driven by an elevated cardiac 
output and is thus poorly correlated to arterial stiffness [27]. Therefore, the association 
of arterial stiffness with vascular depression could also be stronger in the middle-aged 
group. In line with this observation, the association of CVD with depression is stronger 
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in adults younger than 65 years as compared to those above [28,29]. Also, one cohort 
study did report a significant association of MDD with the augmentation index, which is an 
indirect measure of arterial stiffness in adults aged 22 to 66 years. Neither this, nor any of 
the previous studies [22-24,30,31] evaluated, however, whether the association between 
arterial stiffness and depression differed according to age.
2. The differential association of arterial stiffness with LLD in men and in women  
The association of arterial stiffness with LLD could differ according to sex. Arterial stiffness 
is known to be substantially higher in men than in women [32,33], therefore arterial 
stiffness could play a more prominent role in the development of “vascular depression” 
in men. Depression is, however, more prevalent in women [34], therefore in this group 
other biological factors, such as hormonal changes [35] could play a more prominent in 
the development of a depressive disorder. These differences in the aetiology of LLD could 
be greatest at middle-age when hormonal differences between sexes are most prominent. 
Three [22-24] of five [22-24,30,31] studies investigated sex differences in the association 
of arterial stiffness with depression or depressive symptoms, however these populations 
were above middle-age and none of them reported any significant differences. 
  
3. The longitudinal association of arterial stiffness with LLD and depressive symptoms   
To our knowledge, the association of arterial stiffness with LLD has never been studied 
in a longitudinal setting, therefore at current no definitive inferences can be made 
about causality. Also, most studies to date measured aortic [22-24,30], but not carotid 
artery [22,31] stiffness. Aortic stiffness, as measured by the carotid-femoral pulse wave 
velocity (cfPWV) is considered the gold standard to assess arterial stiffness; however, the 
carotid artery is the main blood supplier to the anterior cerebral circulation. Its stiffening, 
therefore, could be associated more strongly with cerebral (micro)vascular disease [36] 
and therefore, LLD. Of the two previous studies [22,31] that included carotid stiffness 
measurements, one [22] found a significant association with both LLD and sub-clinical LLD 
symptoms in individuals aged > 60 years; whereas the other did not report any significant 
associations in younger adults (aged between 22 and 66 years). In order to further analyse 
the etiologic role of carotid artery stiffness in LLD, we investigated the cross-sectional and 
longitudinal associations of several carotid stiffness parameters with depressive symptoms 
in elderly individuals.   
B. Cognitive Dysfunction
Cognitive dysfunction and dementia are alongside depression the major cause of care 
dependency and disability in individuals aged 60 years and older. From middle-age onwards, 
cognitive abilities gradually decline. These cognitive functions, which include information 
processing speed, attention & executive functions and memory are essential for goal-
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directed behaviour, such as planning, problem-solving and decision-making [37]. Although 
cognitive decline occurs naturally with old age, accelerated decrease of these functions 
can finally lead to cognitive dysfunction and ultimately dementia. In affluent countries, up 
to 36% of individuals above 70 years suffer from some form of cognitive dysfunction [39]. 
According to a recent WHO report, around 47 million people have dementia worldwide. 
Furthermore, the total number of people with dementia is projected to near 75 million in 
2030 and almost triple by 2050 to 132 million [1]. 
The pathophysiology of age-related cognitive dysfunction has yet to be elucidated, however, 
growing evidence suggests that cerebral (micro)vascular disease plays an important role 
[5]. Accumulation of cerebral (micro)vascular lesions may disrupt cerebral circuits and thus 
impair brain functions, leading to cognitive decline [40,41]. The aetiology of these small 
vessel lesions is in itself unknown, however, CVD risk factors, such as arterial stiffness most 
likely play a role. Indeed, a recent systematic review by our group has shown that arterial 
stiffness is consistently, but weakly, associated with both cerebral (micro)vascular disease 
and cognitive decline [6].
Arterial stiffness and cognitive dysfunction: open questions
Most research so far has focused on the carotid-to-femoral pulse wave velocity (cfPWV), 
which is a measure of aortic stiffness that is considered the gold standard to assess arterial 
stiffness [14]. The carotid artery, however, is the main supplier to the anterior cerebral 
circulation and may affect the cerebral circulation to a greater extent than the aorta. 
Research on the association of carotid artery stiffness with cognitive function is scarce 
and contradicting: while two [42,43] of three [42-44] population-based studies reported a 
significant cross-sectional association of carotid stiffness with lower cognitive performance, 
the largest of these cohort studies could not confirm these findings longitudinally [45]. 
This latter study, however, also did not find any significant longitudinal associations of 
the cfPWV with cognitive decline [44], contrary to previous findings [45-54]. To further 
elucidate the association of various markers of arterial stiffness with cognitive decline, we 
analysed the associations of carotid and aortic stiffness with cognitive dysfunction in a 
population-based cohort. 
 
C. Pathophysiological mechanisms linking arterial stiffness with depression and cognitive 
dysfunction
According to previous hypotheses, arterial stiffness could lead to either LLD [4,17,55], or 
cognitive dysfunction [40,41] through the development of cortical and subcortical cerebral 
(micro)vascular lesions, which directly affect and diminish cerebral functions. Cerebral small 
vessel disease manifests as lacunar infarcts, (large) white matter lesions, and microbleeds. 
The cerebral microcirculation has a low impedance that facilitates the high blood flow 
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required to meet the high metabolic demands of the brain [56]. Impairment of the 
cushioning function of the aorta and of the carotid arteries allows greater pressure and flow 
pulsatility to penetrate deeply into the cerebral microcirculation, thus directly damaging 
the microvascular tissue and through it the surrounding tissue [57-59]. Furthermore, the 
excessive pressure induces arteriolar remodelling and hypertrophy, which impairs vascular 
reactivity and contributes to repeated episodes of microvascular ischemia and tissue 
damage [58,59]. Lastly, increasing arterial stiffness may cause excessive blood pressure 
variability [60,61] which may further sensitize high-flow organs to the harmful effects of 
impaired microvascular vasoreactivity [59].
PART 2:
Pathophysiologic Mechanisms of Arterial Stiffening
Arterial Stiffness: Theory and Measurement
Arterial stiffness is one of the hallmarks of arterial aging. Arterial stiffness describes the 
(loss of) elastic properties, or rigidity of the arterial walls [62]. Compliance is the inverse 
of arterial stiffness. The arterial system has two main functions: 1) to deliver an adequate 
supply of blood to organs and tissues (the conduit function); and 2) to smoothen the 
flow and pressure pulsatility generated by the intermittent contractions of the heart into 
a constant, nearly steady capillary flow (the cushioning function) [63]. The wide arterial 
radius, which offers little resistance to blood flow, is essential for the conduit function, 
while arterial compliance is essential for the cushioning function [64]. Arterial compliance 
declines with increasing distance from the heart: the central arteries (i.e., the aorta and 
the carotids) are more compliant than the stiffer peripheral arteries (i.e., the brachial and 
femoral arteries). This is due to a decrease in the ratio of elastin to collagen and an increase 
in the number of smooth muscle cells (SMCs) per unit volume [65]. As the cushioning 
function declines from the ascending aorta to the more peripheral arteries, the conduit 
function becomes more prominent [23]. With ageing or hypertension, the central elastic 
arteries stiffen at a greater rate than muscular arteries, such that the stiffness gradient is 
attenuated or even reversed [66-68]. 
Measurements used to determine arterial stiffness 
Arterial stiffness can be measured regionally over the aorta, or locally at specific arterial 
sites, such as the carotid, femoral and brachial arteries [69].
Aortic stiffness
The carotid-femoral pulse wave velocity (cfPWV) is considered the gold standard 
measurement of arterial stiffness [70]. Its estimation uses the propagative model of 
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the arterial system. Pressure waveforms are determined at the right common carotid 
and right common femoral arteries by means of applanation tonometry. Simultaneous 
electrocardiogram (ECG) registration synchronizes the pressure waveforms with systolic 
contraction of the heart (R-wave of the ECG).  The pulse transit time is calculated by 
subtracting the time between the ECG and the proximal pulse from the time between ECG 
and distal pulse. The pulse wave travel distance is calculated as 80% of the straight surface 
distance between the two recording sites. cfPWV is calculated as the ratio between the 
travel distance (meters) and the transit time (seconds) [71].  
Local artery stiffness indices
Carotid, femoral and brachial artery stiffness indices can be estimated without using 
any model of the circulation.  The common carotid artery is visualized by means of an 
ultrasound device, which uses accurate radiofrequency signals to measure the diameter 
in end diastole (D), the distension, or stroke change in diameter (DD), and the intima-
media thickness (IMT) (Figure 1) [72]. Brachial systolic, diastolic, mean arterial pressure 
(MAP), and pulse pressure (PP) are determined repeatedly with a 5-min interval, using a 
blood pressure measurement device. Based on these measurements three indices can be 
derived. These arterial properties together with together with pulse pressure are used to 
Distensibility Coefficient (DC) = (2∆D ∙ D + ∆D2) / (PP ∙ D2) (10-3 kPa-1)
Compliance Coefficient (CC) = л ∙ (2D ∙ ∆D + ∆D2) / 4PP (mm2 kPa-1)
Young’s elastic modulus (YEM) = D / (IMT ∙ DC) (103 kPa)
Figure 1: Estimates of arterial stiffness as obtained by means of non-invasive ultrasonography. Adapted from 69
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calculate local stiffness indices, such as the Distensibility Coefficient (DC), the Compliance 
Coefficient (CC) and, in the case of the carotid artery, Young’s Elastic Modulus (YEM) [74]. 
The Distensibility Coefficient (DC) represents the elastic properties of the artery as a hollow 
structure. The Compliance Coefficient (CC) represents the buffering capacity of the carotid 
artery against rises in blood pressure during a systole. The carotid artery Young’s Elastic 
Modulus (YEM) represents the stiffness of the carotid wall material at operating pressure. 
Due to pulse wave amplification, peripheral pulse pressure is higher than the pulse pressure 
in the carotid artery, therefore central rather than brachial pulse pressures should be used 
to calculate carotid stiffness indices. In this thesis the carotid artery pulse pressure was 
estimated from the carotid artery distension wave-forms and the brachial pulse pressure, 
as described previously [73].
Differences between aortic stiffness and local stiffness indices
The measurement of aortic stiffness (cfPWV) reflects the elastic properties of several aortic 
components: from the highly elastic ascending aorta to the stiffer abdominal aorta and 
the increasingly muscular iliac and femoral arteries [74], whereas local stiffness indices 
reflect the properties of only one artery site. The carotid is a predominantly elastic artery, 
whereas the femoral and the brachial stiffness indices are indicative of muscular artery 
properties. Even though the carotid artery stems directly from the aortic arch, its behaviour 
more closely resembles that of the abdominal rather than of the thoracic aorta [75], as 
both are prone to develop atherosclerotic plaques [76] and have similar distensibilities in 
middle-aged and elderly individuals [77-80]. Stiffening of elastic and muscular arteries may 
differentially affect brain function, as the cushioning function of elastic arteries diminishes 
most with old age [66-68]. Furthermore, the carotid artery supplies the cerebral anterior 
cerebral circulation, therefore its elastic properties could be a better surrogate marker 
of middle-size cerebral artery stiffness than aortic stiffness. Finally, as the carotid artery 
is more prone to atherosclerosis its stiffening could reflect the parallel development of 
stenotic plaques [81], which can cause flow obstructions and thus damage the cerebral 
micro-circulation. In support of this hypothesis, the carotid artery appears to be more 
strongly associated with the outcome stroke [36], as compared to aortic stiffness. 
Advanced Glycation End-Products (AGEs) and Arterial Stiffness
Aortic and carotid stiffness indices are thought to reflect age-related degradation of 
predominantly elastic arteries [70]; however, aortic stiffness, as measured by the cfPWV, 
increases faster with age, hypertension and type 2 diabetes than carotid stiffness [74]. A 
possible factor involved in this accelerated stiffening could be the formation of advanced 
glycation end-products (AGEs). AGEs are reactive compounds which are formed when 
glucose reacts with the amino acid residues of proteins, lipids, or nucleic acids via the non-
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enzymatic Maillard process [82] and are thus found in greater concentrations in patients 
with type 2 diabetes. Higher AGE concentrations have indeed been associated with a higher 
cfPWV in patients with diabetes [83-86], ESRD [87], and even in the general population [88-
91]. The cfPWV, however, cannot distinguish between the elastic properties of the highly 
elastic descending thoracic aorta, the stiffer abdominal aorta and the increasingly muscular 
iliac and femoral arteries [74]. The use of local stiffness indices could, therefore, add more 
insight to AGE-associated aortic stiffening. 
Recently, our group has also reported that tissue AGEs, as measured by skin autoflorescence 
(SAF), as well as plasma pentosidine, are associated with aortic stiffness as well as central 
pulse pressure (a marker of ascending aortic stiffness) [85]. In order to further understand 
AGE-associated aortic stiffening, we investigated within the same cohort whether SAF 
and the plasma AGEs pentosidine, n{epsilon}-(carboxymethyl)lysine (CML), n{epsilon}-
(carboxyethyl)lysine (CEL) are associated with stiffness indices of the carotid, femoral and 
brachial arteries.  
Populations used in the study
Two study populations were used throughout the study.   
The Maastricht Study
The Maastricht Study is an observational prospective population-based cohort study [92] 
that focuses on the aetiology, pathophysiology, complications and comorbidities of type 
2 diabetes mellitus (T2D) and is characterized by an extensive phenotyping approach. 
Eligible for inclusion were individuals aged between 40 and 75 years, living in the southern 
part of the Netherlands. For reasons of efficiency individuals with T2D were oversampled 
by design. This study includes multiple elaborate measurements of CVD risk factors, 
including pulse wave velocity measurements of aortic stiffness, diabetic complications, 
and assessment of most important cognitive domains and depression. For chapters 2,3 
and 4 of the current thesis, we used cross-sectional data from the first 3451 participants, 
who completed the baseline survey between November 2010 and September 2013. For 
chapter five, we used data from the first 866 participants, who completed the baseline 
survey between November 2010 and March 2012. 
The Hoorn Study
The Hoorn study is a longitudinal population-based cohort study, which investigates 
glucose metabolism, as well as cardiovascular risk factors, in the general population [93]. 
The study started in 1989 and included 2484 men and women aged 50 to 74 years, of 
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whom 1513 participated in the second examination in 1996-98. For the current thesis, 
we used data from the third (2000-2001) and fourth (2005-2009) follow-up examinations. 
In 2000-2001, arterial stiffness and depressive symptoms measurements were carried 
out; whereas throughout the 2005-2009 examinations, data on depressive symptoms and 
cognitive performance was acquired. Arterial stiffness measurements had a belated onset 
and were carried out throughout the period 2007-2009. 
Aims and outline of the thesis
in part 1 of this thesis we will explore the vascular origins of two of the most disabling 
conditions in elderly individuals, namely late-life depression and cognitive dysfunction. In 
particular we will investigate the role played by arterial stiffness. In part 2 of this thesis 
we will focus on arterial stiffening, in particular on the differential response of elastic and 
muscular arteries to stiffening factors, such as advanced glycation end products (AGEs).   
Part 1
in chapter two of this thesis we assessed whether aortic stiffness is associated with a major 
depressive disorder or depressive symptoms in a population of middle-aged and elderly 
individuals; and whether the association differs according to age or sex.
in chapter three we investigated whether carotid artery stiffness is longitudinally associated 
with depressive symptoms in elderly individuals and whether the associations differs 
according to age or sex.
in chapter four we assessed whether either carotid artery or aortic stiffness is longitudinally 
associated with cognitive performance in elderly individuals.
Part 2
in chapter five we investigated arterial stiffening by evaluating the associations of advanced 
glycation end products (AGEs) with elastic and muscular artery stiffness indices. 
in chapter six the key findings of the present thesis and their clinical implications are 
discussed. Also, the main methodological issues and future research implications are 
discussed.   
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Abstract
Background
Arterial stiffening may underlie the association of depression with cardiovascular disease 
(CVD), but reported data are inconsistent. We investigated the associations of aortic 
stiffness with major depressive disorder (MDD) and depressive symptoms, and whether 
these differed by sex and age. 
Methods
We measured carotid to femoral pulse wave velocity (cfPWV) by applanation tonometry, 
and depression with the MINI diagnostic interview and PHQ-9 questionnaire in 2757 
participants from The Maastricht Study (51% men, age 59.8±8.1 years, 27% type 2 diabetes 
(T2DM)). Logistic and negative binominal models were adjusted for age, T2DM, MAP 
and CVD risk factors. Results are presented as ORs or rate ratios [95%CI] per 1 SD cfPWV. 
Interactions for sex and age were significant (p < 0.05).
Results
cfPWV was associated with MDD in men, but not women ≤ 60 years, fully adjusted ORs 
were 2.36 [1.45 – 3.84] and 1.57 [0.93 – 2.66], respectively. The ORs were not significant in 
individuals > 60 years (men: 1.03 [0.63 - 1.68], women: 0.64 [0.32 – 1.31]). Similarly, cfPWV 
was associated with a higher PHQ-9 score in men, but not women ≤ 60 years (rate ratio 
1.28 [1.09 - 1.52] and 1.11 [0.99 - 1.23], respectively). Associations were not significant in 
individuals > 60 years (men: 0.96 [0.84 – 1.08], women: 1.00 [0.90 – 1.12]).
Limitations
We cannot rule-out reversed causation in this cross-sectional study.
Discussion
Greater aortic stiffness is associated with MDD and depressive symptoms among middle-
aged men and to a lesser extent in women, while this association was not observed in old 
age.
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Introduction
Arterial stiffening is considered a potential mechanism that could underlie the consistently 
observed association of depression with cardiovascular disease (CVD)1-3. Arterial stiffening 
may cause damage to the cerebral vasculature which is characterised by low impedance, as 
it increases pressure and flow pulsatility which are harmful to the cerebral microcirculation4. 
The vascular depression hypothesis states that the accumulation of (micro)vascular 
damage in the frontal-subcortical mood regulatory circuit of the brain may ultimately cause 
depression5-6. High pulse wave velocity has indeed been associated with cerebral small 
vessel disease7, and could consequently be involved in the pathophysiology of depression.
Conflicting results have been reported on the association of aortic stiffness with both the 
presence of a major depression disorder8-10 and depressive symptoms11,12, which may be 
caused by suboptimal study designs and/or assessment of arterial stiffness and depression. 
A significant association of aortic stiffness with depression was observed in the population-
based Rotterdam Study10 and the AGES-Reykjavik Study11, while no association was found 
with depressive symptoms in the Health ABC Study12. This contradiction could be explained 
by differences in the age range between these study populations (55 years and over in 
the Rotterdam Study versus 70 to 79 years in the Health ABC Study), and by the use of 
questionnaire data in the latter study as an estimate of depressive symptoms, which is 
less accurate than a diagnostic interview. In addition, (borderline) significant associations 
between aortic stiffness and a major depressive disorder were found in two relatively 
small cross-sectional studies8,9. Both the statistical power and the generalizability of the 
results might have been hampered in these studies as they had a case-control design, and 
in one less accurate measures to assess aortic stiffness were used9, while the population 
of the other8 was rather small. Moreover, a recent systematic review, has shown that the 
association of depression with stroke is heterogeneous and differs among subgroups of 
age, BMI, smoking status, and type of depression measurement13. Furthermore, the 
Framingham Study has shown that the association of CVD with depression is stronger in 
middle-age (< 65 years), than in old age (≥ 65 years)14. The association of intermediate 
measures of cardiovascular risk, such as aortic stiffness, and depression could also differ 
in middle-age versus old age. However, none of the previous studies evaluated whether 
this association differs according to age. In addition, men and women appear to differ in 
both their cardiovascular risk profile and depressive symptoms. Aortic stiffness is known 
to be substantially higher in men than in women15,16, while depression appears to be 
more prevalent among women17. These sex differences may be even more prominent at 
middle age, when hormonal differences between sexes are greatest, and women may have 
the highest cardiovascular protection from reproductive hormones. To date, three out 
of four studies investigated sex differences in the association of cfPWV with depression 
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or depressive symptoms, but these populations were above middle-age; none of them 
reported any significant differences. Of these four studies, only the Rotterdam Study10 used 
a structured interview to diagnose a major depressive disorder.
In view of the above, we investigated the association of the cfPWV with both major 
depressive disorder (MDD) and with depressive symptoms in a Caucasian population-
based cohort study aged 40 to 75 years. We specifically examined whether any associations 
differed according to age and/or sex.
Methods
Study Population
We used data from The Maastricht Study, an observational prospective population-based 
cohort study. The rationale and methodology have been described previously18.  In brief, 
the study focuses on the etiology, pathophysiology, complications and comorbidities 
of type 2 diabetes mellitus (T2DM) and is characterized by an extensive phenotyping 
approach. Eligible for participation were all individuals aged between 40 and 75 years 
and living in the southern part of the Netherlands. Participants were recruited through 
mass media campaigns and from the municipal registries and the regional Diabetes Patient 
Registry via mailings. Recruitment was stratified according to known T2DM status, with 
an oversampling of individuals with T2DM, for reasons of efficiency. The present report 
includes cross-sectional data from the first 3451 participants who completed the baseline 
survey between November 2010 and September 2013. Participants were mainly Caucasian 
(98.6%). The examinations of each participant were performed within a time window of 
three months. The study has been approved by the institutional medical ethical committee 
(NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands 
(Permit 131088-105234-PG). All participants gave written informed consent. 
Figure 1 shows the flow diagram of the study population. After exclusion of individuals 
without data on cfPWV (n=572), the MINI diagnostic interview and PHQ-9 were available 
in 2757 and 2529 participants, respectively. Individuals with missing data on covariates, 
such as prior CVD, smoking status and alcohol use (n= 111) were older, had more T2DM and 
a higher cfPWV than the individuals included in the final models (Supplemental Table 1). 
Carotid to femoral pulse wave velocity
All measurements were carried out by trained vascular technicians unaware of the 
participants’ clinical or diabetes status, in a dark, quiet temperature controlled room (21-
23°C). Participants were asked to refrain from smoking and drinking coffee, tea or alcoholic 
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beverages three hours prior to the study. Parti cipants were allowed to have a light meal 
(breakfast or lunch). All measurements were performed in supine positi on aft er 10 minutes 
of rest. Talking or sleeping was not allowed during the examinati on.
Caroti d to femoral pulse wave velocity (cfPWV) was determined according to recent 
guidelines19 with the use of applanati on tonometry (SphygmoCor, Atcor Medical, Sydney, 
Australia). Pressure waveforms were determined at the right common caroti d and right 
common femoral arteries. Diff erence in the ti me of pulse arrival from the R-wave of 
the electrocardiogram between the two sites (transit ti me) was determined with the 
intersecti ng tangents algorithm. The pulse wave travel distance was calculated as 80% of 
the direct straight distance (measured with an infantometer) between the two arterial 
sites. The median of three consecuti ve cfPWV (defi ned as traveled distance/transit ti me) 
recordings was used in the analyses. Brachial systolic, diastolic, mean arterial pressure 
(MAP) and heart rate were determined repeatedly during cfPWV assessment with a 5-min 
interval, using an oscillometric device (Accutorr Plus, Datascope Inc., Montvale, NJ, USA) 
and the average of these measurements was calculated.
Reproducibility of cfPWV measurements was assessed in 12 individuals (6 men; 60.8±6.8 
years; 6 T2DM) who were examined by two observers at two occasions spaced one week 
apart. The intra- and inter-observer intra-class correlati on coeffi  cients (ICC) were 0.87 and 
0.69. 
Maastricht	Study	popula1on	
(n=3451)	
cfPWV	data	available	
(n=2879)	
No	cfPWV	data	
(n=572)	
MINI	data	available	(n=2757)	
Major	depressive	disorder	
(n=101)	
PHQ-9	data	available	
(n=2529)	
No	MINI	data	
available	(n=122)	
No	PHQ-9	data	
available	(n=228)	
Figure 1: Flow diagram
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Assessment of depression
Depressive disorder was assessed by the Mini-International Neuropsychiatric Interview 
(MINI)20. The MINI is a short diagnostic structured interview, used to assess the presence 
of minor or major depressive disorder (MDD) in the preceding 2 weeks according to the 
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)21. MDD was 
diagnosed if participants had at least one core symptom (depressed mood or anhedonia) 
and at least four other symptoms of depression (weight change, change in appetite, 
insomnia/hypersomnia, psychomotor agitation/retardation, fatigue/loss of energy, guilt/
worthlessness, diminished ability to think/concentrate or indecisiveness and suicidal 
thoughts/plans). For sensitivity analyses we defined a minor depression episode as the 
presence of at least one core symptom and one to three other symptoms of depression, 
and early onset depression as MDD prior to the age of 4022.
Depressive symptoms were assessed by a validated Dutch version of the 9-item Patient 
Health Questionnaire (PHQ-9)23. The PHQ-9 is a self-administered questionnaire based on 
the DSM-IV21 criteria for MDD. It comprises of nine items rated on a four-point scale, ranging 
from 0=“not at all” to 3=“nearly every day”. Response options can generate a continuous 
score ranging from 0 (no symptoms) to 27 (all symptoms present nearly every day). Both 
cognitive symptoms of depression, comprising thoughts about oneself and problems of 
the mind, and somatic symptoms, comprising various bodily sensations that a depressed 
individual perceives as unpleasant or worrisome, are measured with the PHQ-924. 
General characteristics and covariates
Web-based questionnaires were used to obtain information regarding smoking status 
(never/former/current), alcohol consumption, educational level, physical activity and prior 
CVD18.  Alcohol consumption was classified as none, low (1-7 glasses/ week for women, 
1-14 glasses for men), and high (>7 glasses/ week for women, >14 for men). Educational 
level was divided into three categories: [1] low (i.e. no education, primary education, lower 
vocational education); [2] intermediate (i.e. intermediate general secondary education, 
intermediate vocational education, higher general secondary education), and [3] high 
(i.e. higher vocational education or university). Physical activity was collected by means 
of a modified version of the Champs questionnaire18. Prior CVD was defined as a history 
of myocardial infarction, stroke, or vascular surgery (including angioplasty) of coronary, 
carotid, abdominal aortic, or peripheral arteries based on the Rose questionnaire25. 
Glucose metabolism status was defined according to the WHO 2006 Criteria26 by use of 
a 75 grams oral glucose tolerance test. Both fasting glucose and 2-hour post load glucose 
concentrations were analysed using a standard enzymatic hexokinase reference method. 
Serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, 
and triglycerides were measured using an automatic analyzer (Beckman Synchron LX20, 
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Beckman Coulter Inc., Brea, USA). Glomerular Filtration Rate (GFR) was estimated with 
the CKD-EPI equation based on the combination of serum creatinine and serum cystatin 
C.18 Body mass index (BMI), waist-to-hip ratio, and medication use were determined as 
described previously18. Exogenous oestrogen medication was defined as either hormone 
replacement therapy, or the contraceptive pill. Office blood pressure was calculated as the 
average of at least three blood pressure readings (Omron 705IT, Japan) performed after a 
minimum of 10 min of seated rest. Hypertension was defined as an office systolic blood 
pressure > 140 mmHg or as an office diastolic blood pressure > 90 mmHg and/or the use of 
blood pressure lowering medication.  
Statistical analysis
All analyses were performed with IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, 
USA). In order to account for the differences in the distribution of the cfPWV between the 
sexes, the cfPWV was introduced as a sex-specific Z-score in all models.
Baseline characteristics of the study population were compared between individuals with 
and without MDD, for normally distributed continuous variables by means of a t-test, for 
non-normally distributed variables by means of a Mann-Whitney test, and for dichotomous 
or ordinal variables by means of a chi-squared test. A two-tailed P value of less than 0.05 
was considered statistically significant. We used logistic regression analyses to investigate 
the association between cfPWV and MDD. We used negative binomial regression analyses 
to examine the association between cfPWV and depressive symptoms in order to account 
for the marked floor effect of the PHQ-9 distribution27. Both regression analyses were 
adjusted for multiple confounders according to the following models: model 1) crude, 
model 2) age, sex, T2DM, model 3) additionally adjusted for MAP, model 4) additionally 
adjusted for smoking, alcohol use, BMI, mean heart rate, hypertension, prior CVD and the 
use of lipid modifying medication. Models were adjusted for T2DM, in order to account 
for the oversampling of these individuals in the Maastricht Study. Also, T2DM has been 
associated with both a higher aortic stiffness28 and a greater chance of developing MDD29, 
therefore it was considered a confounder. MAP and mean heart rate directly influence 
stiffness measurements; therefore, they were accounted for in the models. The following 
cardiovascular risk factors, which have been associated with both arterial stiffening 
and depression, were also added as confounders: smoking, high alcohol intake, BMI, 
hypertension, prior CVD and the use of lipid modifying medication. Interactions for age, 
sex and T2DM were carried out in model 2 and were considered statistically significant with 
a p-value < 0.10.
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Demographics
Age, years
Female sex, %
Education level, low/medium/high, %
Cardio-metabolic risk factors 
BMI, kg/m2
Waist-to-hip ratio
Glucose metabolism status, NGM/IGM/DM2, %
Total cholesterol, mmol/L
HDL cholesterol, mmol/L
LDL cholesterol, mmol/L
Total to HDL cholesterol ratio
Systolic blood pressure, mmHg 
Diastolic blood pressure, mmHg
Mean arterial pressure, mmHg
Heart rate, beats per minute
Hypertension, %
Prior CVD, %
eGFR, mL/min per 1.73 m2
Life style factors
Smoking, never/former/current, %
Alcohol use, none/low/high, %
Physical activity per week (hours/week), 
  median [IQR]*
High-intensity physical activity per week 
(hours/week), median [IQR]*
Medication use 
Glucose lowering drugs, %
Anti-hypertensive drugs, %
Lipid modifying drugs, %
Antidepressive drugs, %**
Stiffness related indices
Carotid to femoral PWV, m/s
Pulse pressure, mmHg
Depressive symptoms 
PHQ-9 score
No Depressive Disorder 
(n = 2656)
59.9 ± 8.1
48.6
32 / 29 / 39
26.9 ± 4.3
0.94 ± 0.09
57 / 15 / 27
5.24 ± 1.16
1.52 ± 0.47
3.10 ± 1.03
3.70 ±1.18
135 ± 18
76 ± 10
97 ± 10
63 ± 9
55.2
16.1
88.3 ± 14.7
34 / 53 / 13
17 / 56 / 27
13.3 [8.3 – 18.8]
4.5 [2.3 - 8.0]
21.7
38.5
36.2
6.4 (170)
8.99  ± 2.14
51 ± 10
2.0 [0.0-4.0]
Major Depressive Disorder 
(n = 101)
58.6 ± 8.1
47.5
49 / 30 / 22
28.4 ± 5.1
0.96 ± 0.10
41 / 10 / 49
5.06 ± 1.13
1.36 ± 0.45
2.99 ± 1.14
4.03 ± 1.35
136 ± 18
77 ± 11
97 ± 11
65 ± 10
58.4
21.6
87.8 ± 16.0
22 / 52 / 27
35 / 43 / 22
10.5 [6.0 – 16.5]
3.0 [0.8 – 5.5] 
42.6
46.5
43.6
25.7 (26)
9.52  ± 2.84
51 ± 10
10.0 [7.0-16.0]
Table 1: Demographic and clinical characteristics of the study population
Results are presented as % (n), mean ± standard deviation or median [interquartile range]. 
* Data on physical activity was available in 2409 participants. ** Antidepressive drugs according to sex: 8.9% in non-
depressed women vs 4.0% in non-depressed men and 33.3% in depressed women vs. 18.9% in depressed in men   
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Results
General characteristics
Table 1 shows the general characteristics of the study population according to the presence 
of MDD. Mean age was 59.8 ± 8.1 years, and 48.8% of participants were women. In total 
101 (3.6%) participants had MDD. 
Participants with MDD smoked more often, used less alcohol, and were less physically active 
than participants without MDD. They had a worse metabolic risk factor profile, including 
more T2DM, higher BMI, lower HDL cholesterol and higher total cholesterol-to-HDL ratio. 
Other cardiovascular risk factors, such as the glomerular filtration rate, prior CVD, systolic 
and diastolic blood pressure, hypertension, the use of blood pressure lowering and lipid 
modifying medication were not different between individuals with and without MDD. 
CfPWV was slightly higher in patients with MDD than in those without (p = 0.07).  
Association of cfPWV with MDD
CfPWV was statistically significantly associated with MDD after adjustment for age, sex and 
T2DM: the OR [95%CI] per SD of cfPWV was 1.24 [1.01–1.51]. The association between 
cfPWV and MDD differed with age (p-interaction 0.043) and sex (p-interaction 0.015); 
no significant interaction was observed for T2DM (p-interaction 0.22). Analyses were, 
therefore, stratified according to age (in 5-year age-categories) and sex. Based on the 
results we stratified the analyses according to the median age of the population (≤ 60, > 60 
years; analyses for the full population, and according to the cut-offs 55, 60 and 65 years are 
shown in Supplemental Table 7).
Model 1
Model 2
Model 3
Model 4*
Men
(n = 612, 27 cases)
2.49 [1.64 – 3.78]
2.37 [1.54 – 3.64]
2.23 [1.42 – 3.52]
2.36 [1.45 – 3.84]
Women
(n = 746, 35 cases)
1.42 [0.95 – 2.10]
1.27 [0.84 – 1.93]
1.34 [0.84 – 2.15]
1.57 [0.93 – 2.66]
Men 
(n = 800, 21 cases)
1.41 [1.04 – 1.91]
1.37 [0.99 – 1.90]
1.33 [0.93 – 1.90]
1.03 [0.63 – 1.68]
Women
(n = 599, 18 cases)
0.72 [0.44 – 1.19]
0.54 [0.31 – 0.94]
0.60 [0.33 – 1.08]
0.64 [0.32 – 1.31]
Table 2: The association between cfPWV and major depressive disorder stratified by age and sex
 Age ≤ 60 years Age > 60 years
Results are expressed as OR [95% CI]; per standard deviation higher cfPWV the OR for major depressive disorder was 
2.49 [1.64 – 3.78] in men ≤ 60 years. Model 1 crude; Model 2: adjusted for age, type 2 diabetes; Model 3: additionally 
adjusted for mean arterial pressure; Model 4: additionally adjusted for heart rate, bmi, lipid medication, smoking, alcohol 
use prior CVD and hypertension;
* 111 participants (7 cases) equally distributed among the groups had missing values on covariates and dropped out of 
the analyses 
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As shown in Table 2, in men ≤ 60 years, cfPWV was significantly associated with MDD, after 
adjustment for age, T2DM and MAP: OR 2.23 [1.42–3.52]. This OR was slightly higher in the 
fully adjusted model: 2.36 [1.45–3.84]. In women ≤ 60 years, cfPWV was not significantly 
associated with MDD, after adjustment for age, T2DM and MAP: OR 1.34 [0.84–2.15]. The 
fully adjusted OR remained not significant: 1.57 [0.93–2.66]. In both men and women > 60 
years, cfPWV was not significantly associated with MDD and the fully adjusted ORs were 
considerably lower in women than in men (Table 2, Figure 2).
Associations of cfPWV with depressive symptoms   
CfPWV was significantly associated with more depressive symptoms, after adjustment for 
age, sex and T2DM the rate ratio (RR) per 1 SD higher cfPWV was 1.07 [1.01-1.13]. The 
association between cfPWV and depressive symptoms differed with age (p-interaction 
0.036); however, no significant interactions were observed for sex (p-interaction 0.59) or 
T2DM (p-interaction 0.94). For consistency reasons, we stratified the results according to 
both age and sex.   
As shown in Table 3, in men ≤ 60 years, 1 SD cfPWV was significantly associated with more 
depressive symptoms after adjustment for age, T2DM and MAP (RR 1.28 [1.09–1.52]). 
This association remained unchanged in the fully adjusted model (RR 1.28 [1.09-1.52]). In 
women ≤ 60 years, 1 SD cfPWV was significantly associated with more depressive symptoms 
in the crude model (RR 1.13 [1.03-1.23]). This association was attenuated by additional 
adjustments for age, sex and T2DM, especially by T2DM (RR 1.09 [0.996–1.21]). In both 
men and women >60, cfPWV was not significantly associated with depressive symptoms 
(Table 3, Figure 3). 
Model 1
Model 2
Model 3
Model 4*
Men
 (n = 582)
1.28 [1.11 – 1.48]
1.22 [1.04 – 1.42]
1.28 [1.09 – 1.52]
1.28 [1.09 – 1.52]
Women
(n = 722)
1.13 [1.03 – 1.23]
1.09 [0.996 – 1.21]
1.12 [0.996 – 1.25]
1.11 [0.99 – 1.23]
Men
(n = 761)
1.12 [1.01 – 1.23]
1.07 [0.96 – 1.20]
1.04 [0.92 – 1.17]
0.96 [0.84 – 1.08]
Women
(n = 579)
1.02 [0.93 – 1.12]
0.98 [0.90 – 1.07]
1.00 [0.90 – 1.11]
1.00 [0.90 – 1.12]
Table 3: The association between cfPWV and depressive symptoms stratified by age and sex
 Age ≤ 60 years Age > 60 years
Results are expressed as rate ratio [95% CI]; per standard deviation a higher cfPWV score was associated with higher 
depressive symptoms. Model 1 crude; Model 2: adjusted for age, type 2 diabetes; Model 3: additionally adjusted for 
mean arterial pressure; Model 4: additionally adjusted for heart rate, bmi, lipid medication, smoking, alcohol use prior 
CVD and hypertension;* 90 participants equally distributed among the groups had missing values on covariates and 
dropped out of the analyses  
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Figure 2: The assocation between cfPWV and major depressive disorder stratified by age and sex. Per SD higher 
cfPWV, men and women x 60 years have a higher risk of major depressive disorder, although this was not statistically 
significant for women. The presented ORs were adjusted for age, mean arterial pressure, heart rate, BMI, lipid medica-
tion, smoking, prior CVD, alcohol use and hypertension
Figure 3: The assocation between cfPWV and depressive symptoms stratified by age and sex. Per SD higher cfPWV, 
men and women x 60 years have a higher risk of depressive symptoms, although this was not statistically significant for 
women. The presented rat were adjusted for age, type 2 diabetes, mean arterial pressure, heart rate, BMI, lipid medica-
tion, smoking, prior CVD, alcohol use and hypertension
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Additional analyses
When we excluded individuals with extreme cfPWV values (± 3SD, outlier analyses) the 
association of cfPWV with MDD and depressive symptoms did not materially change. To 
acknowledge differences in etiology between early and late onset depression, we excluded 
individuals with a first depression episode before 40 years of age (n=407); this did not 
change the results (Supplemental Tables 2 and 3). Also, when we excluded all participants 
who used anti-depressants (n=196) the results did not materially change (Supplemental 
Tables 2 and 3). Anti-depressants could be prescribed for both depressive and anxiety 
disorders; therefore, the models were additionally adjusted for anti-depressant use and 
again this did not materially change the results (Supplemental Tables 4 and 5). Also, in 
order to adjust for various co-morbidities of depression, models were additionally adjusted 
for antipsychotic, anxiolytic and sleep medication, but this did not change the observed 
associations. When major and minor depression were combined as an outcome measure, 
the results did not change (Supplemental Table 6). Lastly, in order to exclude the possibility 
that T2DM oversampling biased the associations, the analyses were repeated in individuals 
without T2DM (n=2008) the results remained unchanged (Supplemental Tables 2 and 3).
When we additionally adjusted the analyses for education level and moderate to vigorous 
self-reported physical activity (available in n=2409), the results did not materially change 
(Supplemental Tables 4 and 5). Lastly, adjustment for the use of exogenous hormone 
replacement medication did not materially alter the observed ORs and rate ratios in women. 
Discussion
The present study shows that a higher aortic stiffness is associated with a major depressive 
disorder and the presence of depressive symptoms in men ≤ 60 years, and to a lesser extent 
in women of the same age, although not statistically significant. We found no association 
between aortic stiffness and depression in men and women > 60 years. 
The association in men ≤ 60 years was independent of other cardiovascular risk factors. 
Most studies to date have analysed the association in populations > 60 years. Only the 
NESDA study9 included participants between the ages of 20 and 66 years and observed 
an association between the augmentation index, which is a composite measure of early 
arterial wave reflection due to greater arterial stiffness, and MDD. However, the authors did 
not evaluate whether the association differed according to age due to the relative young 
sample. Of the studies that included participants > 60 years, two studies8,12 did not find 
significant associations between aortic stiffness and depression in old participants, one8 had 
a small sample size (n=46) including only few cases (n = 25), while the other12 only included 
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participants from a limited age range (70 to 79 years). Aortic stiffness was associated 
with both a depressive disorder and depressive symptoms in The Rotterdam Study10, and 
with depressive symptoms in the AGES-Reykjavik Study as diagnostic interviews were not 
available11. The observed associations were, however, relatively small as compared to our 
results in the ≤ 60 years group. It may be plausible to assume that the association between 
aortic stiffness and depression, may be overshadowed in later life by the development of 
CVD especially in individuals at risk due to greater aortic stiffness. In later life, other factors 
such as CVD and atherosclerosis, may play a more prominent role in the development of 
depression than aortic stiffness. In a longitudinal study, Kim et al.30 found, for example, that 
CVD, such as pre-existing heart disease and stroke, but not hypertension, was associated 
with incident depression in community participants aged 65 years and older. Stroke could 
directly lead to depression through the direct damage to the cortical and sub-cortical areas 
of the brain that are involved in mood regulation 31. In patients with myocardial infarction 
co-morbid carotid atherosclerosis32, rather than aortic stiffness, could accelerate micro-
vascular damage in the mood regulatory regions of the brain and thus lead to vascular 
depression. Myocardial infarction is, for example, associated with an increased risk of 
cerebrovascular disease independent of age or hypertension33. 
The association between aortic stiffness and depression was stronger in men than in 
women ≤ 60 years. Although, the association was only statistically significant in middle-
aged men, we cannot rule out the presence of an association in middle-aged women. 
Only a few previous large cross-sectional studies carried out interaction analyses for sex10-
12, and none reported any significant differences. However, the mean age of these study 
populations was ≥ 70 years, while our observed sex-interaction occurred in patients ≤ 60 
years of age. A possible explanation for the interaction might be that in women ≤ 60 years, 
hormonal fluctuations as seen during the menstrual cycle and the perimenopause, rather 
than aortic stiffness could predispose women ≤ 60 years to depression34. Reproductive 
hormones are also thought to have a protective effect on the vasculature, especially prior 
to menopause15,16 thus further diminishing the association of PWV with depression in 
women. Exogenous hormone supplementation such as hormone replacement therapy and 
contraception, could also be a confounder, but in our study such medication was infrequent 
and did not affect the observed associations. An alternative explanation may include the 
large heterogeneity of a depressive disorder, which might result in important differences 
of this diagnosis among men and women. Also, the possibility that the described sex 
differences are due to the play of chance cannot be ruled out.
Aortic stiffness was associated more strongly with MDD than with depressive symptoms. 
This could be attributed to the misclassification of depressive symptoms as MDD by the 
phq-910,24. Furthermore, the association of aortic stiffness with depressive symptoms may 
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not be linear: it could be stronger in individuals, who fulfil the diagnostic criteria for MDD. 
This threshold of severity could be captured better by a diagnostic instrument, such as the 
MINI. Finally, the weaker association of aortic stiffness with depressive symptoms could 
also explain the lack of an interaction with sex in these analyses. 
Multiple mechanisms could explain the association of aortic stiffness and depression. 
First, according to the vascular depression hypothesis, cardiovascular risk factors, such as 
arterial stiffness, may lead to the accumulation of cerebral small vessel lesions in the mood 
regulatory centres of the brain35, which may result in the development of depression5,6. 
A recent study by van Sloten et al.8 indeed showed that the presence of supra-tentorial 
cerebral white matter hyperintensities (WMH) and subcortical infarcts together explained 
part of the association between PWV and depression. Second, arterial stiffness may lead 
to greater oscillations in wall sheer stress, which may induce endothelial dysfunction 
as well as the production of low grade inflammatory markers by the endothelium36,. 
Endothelial dysfunction could lead to depression through a disturbance of the process 
of neurogenesis37,38, through small vessel disease39, or speculatively through decreased 
cerebrovascular reactivity40. Systemic low grade inflammation, on the other hand, could, 
via multiple pathways, stimulate the production of pro-inflammatory markers by microglial 
cells in the brain, which could induce symptoms of depression41-43. Fourth, other factors, 
such as autonomic and hypothalamic-pituitary-adrenal dysfunction may underlie both 
arterial stiffness44, 45 and depression46,47. Finally, behavioural risk factors, such as high alcohol 
intake, smoking, and physical inactivity are bi-directionally associated with depression3,48-50 
and may also lead to arterial stiffening51-53, thus confounding the association. However, in 
our study additional adjustments for alcohol use, smoking, and physical activity did not 
materially alter the results. 
Limitations
The strengths of this study include the large sample size, the large number of depression 
cases, and the advanced phenotyping, including the use of the gold standard method to 
assess aortic stiffness, the assessment of depression with the help of a questionnaire as 
well as a diagnostic interview, and the measurement of many potential confounding factors, 
which could be accounted for in the fully adjusted models. However, due to the cross-
sectional design, reversed causation cannot be ruled out.  For example, treatment for MDD 
has been shown to improve arterial stiffness54. Also, aortic stiffness has been associated 
with a current, but not a remitted depression9. Additionally, misclassification of MDD could 
have occured. Most participants who used anti-depressants (87%) did not have MDD. We 
could not discriminate between anti-depressants prescribed for anxiety, depression, or 
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neuropathic pain, since indications were not recorded. Yet, the exclusion of participants 
who used anti-depressants (n=196), or additional adjustments for antidepressant use, did 
not alter our results. Selection bias may have further influenced our results, as participants 
who suffer from severe MDD were unlikely to be included in the study. Therefore, our 
results may be an underestimation of the actual association. Also, the individuals with 
missing data on covariates were excluded in the final models. However, the percentage 
of missing data was fairly small (4%), therefore imputation of missing data is unlikely to 
influence the results 55. Further, above 60 years, competing risk could have resulted in an 
underrepresentation of depression cases, as participants with greater aortic stiffness are 
at increased fatal CVD risk. Although we have adjusted for multiple confounders, residual 
confounding due to other chronic medical conditions, such as asthma, COPD, cancer 
or arthritis, which may be comorbid to depression61 and, which could lead to arterial 
stiffening, cannot be ruled out. Lastly, the association of CVD markers with depression may 
differ according to race or ethnicity57-60, however, our study population mainly consists of 
Caucasians, therefore we could not investigate such effects.
Conclusion
This study shows that a higher aortic stiffness is associated with MDD and depressive 
symptoms in middle-aged men and to a lesser extent in middle-aged women, while this 
association was not observed in old age.
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Supplemental Table 1: Baseline characteristics of participants with available and with missing data on covariates
Demographics
Age, years
Female sex, %
Education level, low/medium/high, %
Cardio-metabolic risk factors 
BMI, kg/m2
Waist-to-hip ratio
Glucose metabolism status,  
NGM/IGM/DM2, %
Total cholesterol, mmol/L
HDL cholesterol, mmol/L
LDL cholesterol, mmol/L
Total to HDL cholesterol ratio
Systolic blood pressure, mmHg 
Diastolic blood pressure, mmHg
Mean arterial pressure, mmHg
Heart rate, beats per minute
Hypertension, %
Prior CVD, %
eGFR, mL/min per 1.73 m2
Life style factors
Smoking, never/former/current, %
Alcohol use, none/low/high, %
Medication use 
Glucose lowering drugs, %
Anti-hypertensive drugs, %
Lipid modifying drugs, %
Antidepressive drugs, %
Stiffness related indices
Carotid to femoral PWV, m/s
Pulse pressure, mmHg
Major depression disorder, %
Available Data  
(n = 2646)
59.7 ± 8.1
48.4
32.4/29.1/38.5
 
27.0 ± 4.3
0.94 ± 0.09
58/15/27
5.24 ± 1.16
1.52 ± 0.48
3.10 ± 1.04
3.71 ± 1.19
127 ± 14
76 ± 7
97 ± 10
63 ± 9
38.5
16.4
88.4 ± 14.7
33.6/52.8/13.6
18.0/55.0/27.0
21.8
38.5
36.2
7.0
8.98 ± 2.13
51 ± 10
3.6
Missing Data 
(n = 111)
61.4 ± 8.2 
57.7
30.0/31.4/38.6
27.2 ± 4.9
0.94 ± 0.11
49//10/41
5.11 ± 1.21
1.44 ± 0.44
3.06 ±1.01
3.77 ± 1.15
129 ± 16
76 ± 7
98 ± 12
63 ± 8
44.4
9.1
85.8 ± 17.5
37.7/47.5/14.8
17.9/60.7/21.4
36.1
44.4
39.8
11.1
9.67 ± 2.87
53 ± 11
6.3
Missing
0
0
57
2
1
0
0
0
0
0
1
0
0
0
3
89
0
 
50
55
3
3
3
3
0
1
0
p-value
0.034
0.056
0.812
0.572
0.734
0.009
0.249
0.092
0.653
0.589
0.130
0.579
0.138
0.392
0.215
0.358
0.063
0.732
0.545
<0.001
0.215
0.450
0.100
0.014
0.090
0.130
Results are presented as % (n), mean ± standard deviation or median [interquartile range].
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Model 4
Model 4
Model 4
Model 4*
Men
(n = 612, 27 cases)
2.36 [1.45 – 3.84]
Men
(n = 517, 18 cases)
1.79 [0.89 – 3.63]
Men
(n = 572, 17 cases)
2.39 [1.35 – 4.23]
Men
(n = 427, 9 cases)
2.48 [1.06 – 5.78]
Women
(n = 746, 35 cases)
1.57 [0.93 – 2.66]
Women
(n = 585, 24 cases)
1.51 [0.79 – 2.91]
Women
(n = 674, 28 cases)
1.50 [0.81 – 2.78]
Women
(n = 620, 25 cases)
1.54 [0.82 – 2.88]
Men 
(n = 800, 21 cases)
1.03 [0.63 – 1.68]
Men 
(n = 729, 15 cases)
1.20 [0.68 – 2.11]
Men 
(n = 768, 15 cases)
1.17 [0.69 – 1.96]
Men
(n = 458, 7 cases)
0.96 [0.33 – 2.83]
Women
(n = 599, 18 cases)
0.64 [0.32 – 1.31]
Women
(n = 519, 14 cases)
0.81 [0.38 – 1.71]
Women
(n = 544, 15 cases)
0.67 [0.31 – 1.45]
Women
(n = 436, 6 cases)
0.33 [0.08 – 1.44]
Supplemental Table 2: The association between cfPWV and a major depression disorder stratified by age and 
sex in the full population, after the exclusion of participants with early onset depression, after the exclusion of 
participants with anti-depression medication, and after the exclusion of participants with type 2 diabetes
 Age ≤ 60 years Age > 60 years
Results are expressed as OR [95% CI] per standard deviation higher cfPWV. Model 4: adjusted for age, type 2 diabetes, 
mean arterial pressure, heart rate, bmi, lipid medication, smoking, alcohol use prior CVD and hypertension. *Model 4 
was not adjusted for type 2 diabetes
Full population
Participants with early onset depression excluded
Participants with anti-depressive medication excluded
Participants with type 2 diabetes excluded
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Model 4
Model 4
Model 4
Model 4*
Men
 (n = 582)
1.28 [1.09 – 1.52]
Men
 (n = 480)
1.30 [1.07 – 1.57]
Men
 (n = 528)
1.20 [1.01 – 1.42]
Men
 (n = 344)
1.27 [1.03 – 1.57]
Women
(n = 722)
1.11 [0.99 – 1.23]
Women
(n = 546)
1.10 [0.97 – 1.27]
Women
(n = 632)
1.13 [0.997 – 1.26]
Women
(n = 465)
1.12 [0.99 – 1.28]
Men 
(n = 761)
0.96 [0.84 – 1.08]
Men 
(n = 660)
0.96 [0.84 – 1.09]
Men 
(n = 693)
-0.05 [0.95 – 1.08]
Men
(n = 388)
0.94 [0.79 – 1.12]
Women
(n = 579)
1.00 [0.90 – 1.12]
Women
(n = 482)
1.02 [0.91 – 1.14]
Women
(n = 503)
1.01 [0.91 – 1.12]
Women
(n = 357)
1.02 [0.90 – 1.15]
Supplemental Table 3: The association between cfPWV and depressive symptoms stratified by age and sex in the 
full population, after the exclusion of participants with early onset depression, after the exclusion of participants 
with anti-depression medication, and after the removal of participants with type 2 diabetes
 Age ≤ 60 years Age > 60 years
Results are expressed as rate ratio [95% CI] per standard deviation higher cfPWV. Model 4: adjusted for age, type 2 
diabetes, mean arterial pressure, heart rate, bmi, lipid medication, smoking, alcohol use prior CVD and hypertension. 
*Model 4 was not adjusted for type 2 diabetes.
Full population (as in article)
Participants with early onset depression removed
Participants with anti-depressive medication removed
Participants with type 2 diabetes removed
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Model 4
Model 4 + anti-depressive 
medication
Model 4 + educational level
Model 4 + moderate to  
vigurous physical activity*
Men
(n = 612, 27 cases)
2.36 [1.45 – 3.84]
2.21 [1.35 – 3.62]
2.25 [1.37 – 3.69]
2.69 [1.4 – 4.99]
Women
(n = 746, 35 cases)
1.57 [0.93 – 2.66]
1.54 [0.91 – 2.61]
1.57 [0.91 – 2.71]
1.53 [0.85 – 2.75]
Men 
(n = 800, 21 cases)
1.03 [0.63 – 1.68]
0.94 [0.57 – 1.57]
1.01 [0.62 – 1.65]
1.05 [0.62 – 1.78]
Women
(n = 599, 18 cases)
0.64 [0.32 – 1.31]
0.64 [0.31 – 1.29]
0.62 [0.31 – 1.27]
0.74 [0.26 – 2.07]
Supplemental Table 4: the association between cfPWV and major depressive disorder stratified by age and sex in 
the fully adjusted model as well as after additional adjustments for anti-depressive medication, education level, 
and moderate to vigorous physical activity
 Age ≤ 60 years Age > 60 years
Results are expressed as OR [95% CI] per standard deviation higher cfPWV. Model 4: adjusted for age, type 2 diabetes, 
mean arterial pressure, heart rate, bmi, lipid medication, smoking, alcohol use prior CVD and hypertension
* 429 participants (48 cases), mostly in the women ≤ 60 years and > 60 years categories had missing values and dropped 
out of the analyses 
Model 4
Model 4 + anti-depressive 
medication
Model 4 + educational level
Model 4 + moderate to  
vigurous physical activity*
Men
(n = 582)
1.28 [1.09 – 1.52]
1.23 [1.05 – 1.45]
1.27 [1.08 – 1.49]
1.28 [1.09 – 1.51]
Women
(n = 722)
1.11 [0.99 – 1.23]
1.10 [0.99 – 1.23]
1.08 [0.97 – 1.22]
1.08 [0.97 – 1.22]
Men 
(n = 761)
0.96 [0.84 – 1.08]
0.95 [0.84 – 1.07]
0.96 [0.85 – 1.08]
0.95 [0.84 – 1.08]
Women
(n = 579)
1.00 [0.90 – 1.12]
1.00 [0.91 – 1.10]
1.01 [0.91 – 1.12]
1.02 [0.92 – 1.13]
Supplemental Table 5: the association between cfPWV and depressive symptoms stratified by age and sex in the 
fully adjusted model as well as after additional adjustments for anti-depressive medication, education level, and 
moderate to vigorous physical activity
 Age ≤ 60 years Age > 60 years
Results are expressed as rate ratio [95% CI] per standard deviation higher cfPWV. Model 4: adjusted for age, type 2 
diabetes, mean arterial pressure, heart rate, bmi, lipid medication, smoking, alcohol use prior CVD and hypertension
*153 participants, equally distributed among the groups, had missing values on covariates and dropped out of the 
analyses 
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Model 4
Model 4
Model 4
Model 4*
Men
(n = 612, 43 cases)
1.99 [1.40 – 2.83]
1.83 [1.26 – 2.65]
1.91 [1.28 – 2.84]
1.84 [1.22 – 2.77]
Women
(n = 746, 46 cases)
1.35 [0.95 – 1.92]
1.17 [0.80 – 1.70]
1.16 [0.76 – 1.77]
1.28 [0.80 – 2.05]
Men 
(n = 800, 31 cases)
1.31 [0.99 – 1.71]
1.25 [0.93 – 1.68]
1.16 [0.84 – 1.60]
0.99 [0.64 – 1.52]
Women
(n = 599, 31 cases)
0.95 [0.68 – 1.32]
0.81 [0.57 – 1.17]
0.86 [0.58 – 1.28]
0.95 [0.61 – 1.47]
Supplemental Table 6: Association between cfPWV and minor and major depressive disorder stratified by age and sex
 Age ≤ 60 years Age > 60 years
Results are expressed as OR [95% CI]; per standard deviation increase in cfPWV the OR for major and minor depressive 
disorder was 1.99 [1.40 – 2.83] in men below 60 years of age. Model 1 crude; Model 2: adjusted for age, type 2 diabetes; 
Model 3: additionally adjusted for mean arterial pressure; Model 4: additionally adjusted for heart rate, bmi, lipid medi-
cation, smoking and alcohol use, hypertension and prior CVD.
* 119 participants (15 cases) equally distributed among the groups had missing values on covariates and dropped out of 
the analyses 
Model 1
Model 2
Model 3
Model 4*
Total 
population
(n = 2757, 
101 cases)
1.23
[1.03 - 1.46]
1.24 
[1.01 - 1.51]
1.23
[0.99 – 1.53]
1.20
[0.94 – 1.53]
Age ≤ 55
(n = 785,
35 cases)
1.84
[1.23 – 2.73]
1.57
[1.02 – 2.41]
1.38
[0.84 – 2.27]
1.60
[0.92 – 2.78]
Age > 55
(n = 1972,
66 cases)
1.21
[0.99 – 1.49]
1.18
[0.94 – 1.48]
1.23
[0.96 – 1.57]
1.14
[0.85 – 1.51]
Age ≤ 60
(n = 1358,
62 cases)
1.84
[1.40 – 2.41]
1.68
[1.26 – 2.25]
1.68
[1.22 – 2.32]
1.79
[1.27 – 2.53]
Supplemental Table 7: The association of aortic stiffness and a major depressive disorder in the full population and 
according to the following age cut-offs: 55, 60 and 65 years
Results are expressed as OR [95% CI]. Per standard deviation higher cfPWV the OR for major depressive disorder was 
1.23 [1.03-1.46] in the total population. Model 1: crude; Model 2: adjusted for age, type 2 diabetes; Model 3: additionally 
adjusted for mean arterial pressure; Model 4: additionally adjusted for heart rate, bmi, lipid medication, smoking, alcohol 
use prior CVD and hypertension; 
* 111 participants (7 cases) equally distributed among the groups had missing values on covariates and dropped out of 
the analyses
Age > 60
(n = 1399,
39 cases)
1.11
[0.85 – 1.46]
0.98
[0.72 – 1.31]
0.99
[0.72 – 1.37]
0.83
[0.57 – 1.23]
Age > 65
(n = 743,
22 cases)
0.95
[0.65 – 1.39]
0.80 
[0.53 – 1.21]
0.85
[0.55 – 1.32]
1.04 
[0.64 – 1.69]
Age ≤ 65
(n = 2014,
79 cases)
1.50 
[1.21 – 1.85]
1.52 
[1.20 – 1.92]
1.50
[1.15 – 1.94]
1.33
[0.98 – 1.80]
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Abstract
Introduction
Carotid stiffness is a risk factor for cerebral (micro-)vascular lesions; therefore, it could 
cause vascular depression. This hypothesis has never been studied longitudinally. We 
investigated the association of (changes in) carotid stiffness with depressive symptoms 
over 8 years of follow-up in a sample of the Hoorn Study.
Methods
In the Hoorn study (n=515, age 69.3±6.3, 49.3% women, 21.2% type 2 diabetes), carotid 
stiffness and depressive symptoms were measured in 2000-2001 and 2007-2009 with 
ultrasound and a CES-D questionnaire, respectively. We used linear regression to assess the 
associations of carotid stiffness with depressive symptoms. Analyses were adjusted for age, 
sex, glucose metabolism, education, mean arterial pressure, and CVD risk factors. Results 
are presented as regression coefficients [95%CI] per 1 SD lower Distensibility Coefficient 
(DC), or higher Young’s Elastic Modulus (YEM).
Results
Carotid DC and YEM were cross-sectionally associated with depressive symptoms at baseline 
in the crude, but not in the fully adjusted models: -0.15 [-0.88;0.58], 0.52 [-0.18;1.22]. 
Carotid DC and YEM were not associated with depressive symptoms at follow-up either in 
the crude, or in the fully adjusted models: -0.33 [-1.22;0.56], -0.41 [-1.23;0.41]. Changes in 
carotid DC and YEM over 8 years were not associated with depressive symptoms at follow-
up, either in the crude, or in fully adjusted models: 0.47 [-0.35;1.28], 0.47 [-0.37;1.30].   
Conclusion
Carotid stiffness was not associated with depressive symptoms in cross-sectional or 
longitudinal analyses over a follow-up period of 8 years. Our results may point to a modest 
association, thus our results should be replicated in larger cohorts. 
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Introduction
Arterial stiffness could play a role in the pathogenesis of vascular depression. The 
prevalence of late-life depressive symptoms ranges between 9% and 24% in individuals 
living in the general population and can reach up to 43.9% in nursing home residents 
[1-3]. Over 50% of individuals with late-life depressive symptoms show cerebral (micro)
vascular lesions on MRI, which define a vascular depression [4-8], as compared to 8% to 
28% of healthy individuals [8]. Due to its association with cerebral vascular disease, late 
life depression is less responsive to antidepressant drugs and has a poor prognosis [9]. It 
is possible, however, that drugs used for the prevention and treatment of cerebrovascular 
disease may reduce the risk for vascular depression or improve its outcomes. Arterial 
stiffness has been associated previously with cerebral small vessel disease [11,12] and 
stroke [13]. It impairs the cushioning function of the large elastic vessels, such as the 
carotid arteries or aorta, and therefore leads to greater pressure and flow pulsatility into 
the low-impedance microvasculature of the brain [14]. Since the brain microcirculation 
is particularly vulnerable to pressure fluctuations, this may cause microvascular damage 
[1,12] and result in disruption of the frontal-subcortical mood regulatory circuits of the 
brain [1,10]. 
To date, there is limited cross-sectional evidence of an association between arterial 
stiffness and depression. Four out of five studies [15-19] observed an association between 
aortic stiffness and either a depressive disorder [16-18] or depressive symptoms [15]. In 
addition, studies that specifically investigated the association between stiffness of the 
carotid artery, the artery that supplies the cerebral circulation, and depression have shown 
conflicting results [16,18]. Although the Rotterdam Study observed a significant association 
with both depressive symptoms and a major depressive disorder [16]; the NESDA Study 
did not confirm these findings [18]. Furthermore, the association of arterial stiffness 
with depression has never been studied in a longitudinal setting, therefore at current no 
inferences can be made about the causality of the association.
 
In view of these considerations, we used data from the population-based Hoorn study to 
investigate 1) the cross-sectional association of carotid stiffness with depressive symptoms; 
and 2) the longitudinal association of carotid stiffness with depressive symptoms after a 
follow-up period of 8 years. Lastly, we investigated whether changes in carotid stiffness 
over 8 years were associated with depressive symptoms at follow-up.
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Methods 
Study population
The Hoorn study is a longitudinal population-based cohort study, which investigates 
glucose metabolism, as well as cardiovascular risk factors, in the general population [20]. 
The study started in 1989, included 2484 men and women aged 50 to 74 years, of whom 
1513 participated in the second examination in 1996-98. For this study, we used data 
from the third and fourth follow-up examinations. In the third assessment in 2000-2001, 
648 individuals participated. Individuals with type 2 diabetes (T2D) were oversampled by 
design [21].  For the 2007-2009 examinations, all surviving participants of the 2000-2001 
cohort, who were still living in Hoorn (n = 485) were re-invited, of whom 371 agreed to 
participate. Carotid stiffness and depression screening measurements were carried out 
during the examinations in 2000-2001 and 2007-2009. In this paper, the 2000-2001 cohort 
was used as the baseline sample, while the 2007-2009 examination was used as the follow-
up measurement.   
Cross-sectional analyses
Of the 648 individuals included in the baseline examination, 588 had qualitatively 
satisfactory ultrasound data, of whom 515 had data on depressive symptoms. The main 
reason for missing ultrasound data was poor detection of the arterial wall attributable to 
obesity (BMI missing ultrasound data vs BMI available ultrasound data 30.5 vs. 27.0 kg/m2; 
p <0.001). 
Longitudinal analyses
Of the 588 participants with baseline carotid artery measurements 96 died before the 
follow-up examination, 44 had moved out of Hoorn, and 94 declined to participate. Of the 
remaining 354 participants, 318 had data on depressive symptoms at follow-up. In total 
295 participants had carotid stiffness data at baseline and follow up (Figure 1 ). 
Carotid Stiffness 
Carotid stiffness was assessed at the right common carotid artery according to international 
guidelines, as described previously [21]. Briefly, a single observer visualised each artery with 
an ultrasound scanner (350 Series [7.5-MHz linear probe], Pie Medical, the Netherlands) 
connected to a personal computer equipped with wall track software and an acquisition 
system (Wall Track System, Pie Medical). The carotid walls were detected by the software: 
the diameter and intima-media thickness (IMT) were assessed during the diastole, while 
the distension was defined as the movement of the carotid wall as a function of systolic 
duration. At each site, 3 consecutive 4-second measurements were carried out and the 
mean diameter, IMT and distension were used in the analyses. During the measurements, 
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brachial systolic and diastolic pressures were assessed during the vascular measurements 
in the left upper arm at 5-minute intervals with an oscillometric device (Collin Press-Mate, 
BP-8800).   
The distensibility coefficient were calculated as follows: 
Distensibility coefficient (DC) = (2ΔD•D + ΔD2)/(ΔP•D2) in 10-3•kPa-1
where ΔD is distension, D is diameter, and ΔP is pulse pressure (defined as systolic pressure 
– diastolic pressure). The Young’s elastic modulus (YEM) was calculated for the carotid 
artery, according to the formula:
YEM=diameter/(IMT • distensibility coefficient) in kPa  
DC represents carotid stiffness; and the YEM represents the stiffness of the carotid artery 
wall material at operating pressure. 
Depressive symptoms
Depressive symptoms were assessed by a validated Dutch version of the 20-item Centre 
for Epidemiologic Studies Depression Scale (CES-D) [22]. Scores on the CES-D range from 
0 to 60. Higher scores on this scale indicate the presence of more (severe) depressive 
symptoms. In the present study, the CES-D was used as a continuous variable. 
Figure 1: Flow Diagram
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Other measurements 
Education level, smoking, physical activity and medication use were assessed by means of 
a questionnaire [23]. Body mass index (BMI), office blood pressure, glucose metabolism 
status, micro-albuminuria, serum total, high- (HDL), and low-density lipoprotein (LDL) 
cholesterol and triglycerides were determined as described previously [24]. Glomerular 
filtration rate was estimated with the 4 variable MDRD equation (eGFRMdrd) [25]. Finally, 
prior CVD and hypertension were defined as described elsewhere [23,26]. 
Statistical analyses 
All analyses were performed with IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, 
USA). Characteristics of the study population were compared according to baseline CES-D 
tertiles by means of an ANOVA test for normally distributed continuous variables, and by 
means of a linear-by linear chi-squared test for dichotomous or ordinal variables. Continuous 
variables with a skewed distribution were log10-transformed. A two-tailed P value of less 
than 0.05 was considered statistically significant. 
We performed one cross-sectional and two longitudinal linear regression analyses to 
assess the association between carotid stiffness (determinant) and depressive symptoms 
(outcome). In cross-sectional analyses, we used carotid stiffness indices and depressive 
symptoms at baseline. In the first longitudinal analysis, carotid stiffness indices at baseline 
and depressive symptoms at follow-up were used. These analyses were adjusted for possible 
confounders as measured at baseline as follows: model 1) crude, model 2) age, sex, glucose 
metabolism status and education level, model 3) additionally adjusted for mean arterial 
pressure (MAP), model 4) additionally adjusted for smoking, BMI, hypertension, prior CVD, 
lipid modifying medication, triglycerides, total to HDL cholesterol ratio and eGFR
MDRD. 
The association of changes in carotid stiffness with depressive symptoms at follow-up was 
assessed as follows: carotid stiffness at follow-up was the main determinant, depressive 
symptoms at follow-up was the main outcome and the association was then adjusted 
for baseline carotid stiffness [27]. The models were further adjusted for confounders 
measured at baseline as follows: model 1) baseline carotid stiffness, model 2) additionally 
adjusted for age, sex, glucose metabolism status and education level, model 3) additionally 
adjusted for MAP at baseline and MAP at follow-up, model 4) additionally adjusted for 
smoking, BMI, hypertension, prior CVD, lipid modifying medication, triglycerides, total to 
HDL cholesterol ratio and eGFRMdrd. Due to the direct physical effects of MAP on carotid 
stiffness measurements [28], we adjusted our models for MAP as measured at baseline and 
at follow-up. We preferred to use linear regression over GEE for the longitudinal analyses as 
we only had data at two time points. Also the use of GEE would have accentuated between-
subjects relationships rather than within-subjects relationships [29].
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Arterial stiffness has been associated with depression in old-aged individuals (> 60 years) 
[15], but not in the oldest old (> 70 years) [19], therefore we introduced interaction terms 
for age. The association of subclinical vascular disease with depressive symptoms has 
been shown to be stronger old-aged men than in old-aged women [30], therefore we also 
introduced interaction terms for sex. Lastly, in order to account for the oversampling of T2D, 
we introduced interaction terms for glucose metabolism status. None of these interactions 
were statistically significant (p > 0.10).
Results
General characteristic
Table 1 shows the characteristics of the study population according to tertiles of the 
depressive symptom score at baseline. Mean age was 69.3 ± 6.3 years and 49.3% of 
participants were women. Participants with the highest depressive symptoms score were 
older, were more often women, had a lower education level and were less physically 
active than the participants who reported the least depression symptoms. They also had 
a more adverse cardio-metabolic risk factor profile, including a higher BMI, more T2D, and 
also more intensive use of blood pressure lowering medication. Other cardiovascular risk 
factors, such as the eGFRMdrd, prior CVD, the cholesterol to HDL ratio, triglycerides, and the 
use of lipid modifying medication did not differ across tertiles of depressive symptoms. 
Finally, the DC showed a decreasing trend, while the carotid YEM showed an increasing 
trend across the tertiles of depressive symptoms, however the p-trend for the DC was not 
statistically significant. The clinical characteristics of the study population with baseline 
carotid stiffness measurements (n = 588) according to the availability of follow-up data are 
shown in Supplemental Table 1. Individuals with follow-up data were younger and had a 
more favourable CVD risk profile than the individuals without follow-up data.
Cross-sectional association of carotid stiffness indices and depressive symptoms 
As shown in Table 2, the carotid DC and YEM were cross-sectionally associated with 
depressive symptoms in the crude model, but the associations were rendered non-
significant after adjustment for age, sex, glucose metabolism status and education level. 
Additional adjustments for mean arterial pressure (model 3) and other cardiovascular risk 
factors (model 4) did not change the associations.  
Longitudinal association of carotid stiffness with depressive symptoms at follow-up 
As shown in Table 3, neither the baseline carotid DC nor the YEM were associated with depressive 
symptoms at follow-up in any of the models. When we further adjusted these analyses for 
depressive symptoms at baseline the results remained unchanged (Supplemental Table 2).
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Age, years
Female sex, %
Education level low/medium/high, %
Smoking, never/former/current, %
Physical activity, hours/week
At least 2.5 hours of moderate to high 
intensity physical activity per week, %
BMI, kg/m2
NGM/IGM/DM2, %
Total-to-HDL cholesterol ratio
Triglycerides, mmol/L
Fasting glucose, mmol/L
HbA1c%
eGFRMDRD, ml/min/1.73m2
Hypertension, %
Prior CVD, %
Lipid modifying medication, %
Blood pressure lowering medication, % 
Anti-depressive medication, % 
Carotid DC, 10^-3/kPa  
Carotid YEM, 10^3 kPa  
Carotid artery diameter, mm
Carotid artery distension, mm
Intima media thickness (IMT) 
SBP, mmHg
DBP, mmHg
MAP, mmHg
Heart Rate, bpm
Brachial PP, mmHg 
Lower Tertile 
(CESD score 0 - 4) 
(n = 181) 
68 ± 6
42.0
74/8/18
36/50/14
24 [14 – 35]
77.9
26.7 ± 3.5
53/31/16
4.20 ± 1.20
1.3 [0.9 – 1.7]
5.99 ± 1.03
5.93 ± 0.64
65.2 ± 10.0
68.3
42.0
14.9
27.6
1.7
11.5 ± 4.1
0.93 ± 0.43
7.89 ± 1.13
0.36 ± 0.12
0.87 ± 0.17
140 ± 18
77 ± 9
98 ± 11
62 ± 9
63.2 ± 13.6 
Middle Tertile 
(CESD score 5-9)
(n = 166)
69 ± 6
48.2
79/9/12
34/49/18
19 [12 – 28]
74.7
26.7 ± 3.2
56/24/20
4.36 ± 1.17
1.3 [1.0 – 1.75]
6.09 ± 1.59
5.90 ± 0.77
63.7 ± 10.0
63.9
55.4
15.1
32.5
1.2
11.4 ± 4.0
0.94 ± 0.40
7.95 ± 1.14
0.36 ± 0.10
0.86 ± 0.16
140 ± 18
76 ± 10
97 ± 12
62 ± 9
64.0 ± 13.1
Upper tertile 
(CESD score 10-34)
(n =168)
71 ± 7
58.3
84/9/8
38/38/24
18 [9 – 31]
66.1
27.6 ± 4.0
40/32/28
4.31 ± 1.26 
1.3 [1.0 – 1.8]
6.42 ± 1.52
6.12 ± 0.74
62.7 ± 11.1
68.5
51.2
15.5
57.1
4.8
10.5 ± 4.4
1.09 ± 0.61
8.00 ± 1.15
0.34 ± 0.11
0.87 ± 0.18
144 ± 21
77 ± 9
99 ± 12 
63 ± 9
67.4 ± 16.7
p-trend
< 0.001
0.002
0.010
0.287
0.001
0.013
0.039
0.006
0.429
0.285
0.011
0.011
0.070
0.997
0.08
0.885
0.003
0.069
0.055
0.007
0.657
0.423
0.940
0.060
0.425
0.209
0.491
0.019
Table 1: Clinical characteristics of the study population according to tertiles of depressive symptoms at baseline
Data are presented as %, mean ± SD, or median [interquartile range]. CVD = cardiovascular disease; SBP = Mean 
systolic blood pressure during stiffness measurements; DBP = Mean diastolic blood pressure during stiffness measu-
rements; MAP = mean arterial pressure during stiffness measurements; Heart Rate = Mean heart rate during stiffness 
measurements, Brachial PP = mean pulse pressure during stiffness measurements 
Demographics
Lifestyle factors
Cardio-metabolic risk factors
Medication use
Stiffness indices
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Model
Model 1
Model 2
Model 3
Model 4*
Carotid DC  
(n = 515)
0.55 (0.02; 1.08)
-0.07 (-0.68; 0.54)
-0.11 (-0.80; 0.59)
-0.15 (-0.88; 0.58)
Carotid YEM  
(n = 510)
0.82 (0.28; 1.35)
0.48 (-0.13; 1.08)
0.58 (-0.10; 1.25)
0.52 (-0.18; 1.22)
Table 2: Cross-sectional association of carotid stiffness indices with depressive symptoms at baseline
Results are expressed as regression coefficients (95%CI) per 1 SD lower distensibility (DC) and 1 SD higher Young’s 
Elastic Modulus (YEM); for example  1SD lower carotid DC was associated with a 0.55 (0.02; 1.08) higher CES-D score in 
crude analyses.Model 1: crude; model 2: adjusted for age, sex, glucose metabolism status, education; model 3: model 
2 + mean arterial pressure; model 4: model 3 + BMI, hypertension, smoking, triglycerides, total-to-HDL ratio, lipid modi-
fying medication, eGFRMDRD, and prior CVD
Model
Model 1
Model 2
Model 3
Model 4*
Carotid DC  
(n = 318)
  0.24 (-0.43; 0.92)
- 0.38 (-1.14; 0.38)
- 0.27 (-1.12; 0.58)
- 0.33 (-1.22; 0.56)
Carotid YEM  
(n = 314)
-0.06 (-0.73; 0.61)
-0.40 (-1.11; 0.30)
-0.36 (-1.15; 0.43)
-0.41 (-1.23; 0.41)
Table 3: Longitudinal association of baseline carotid stiffness indices with depressive symptoms at follow-up
Results are expressed as regression coefficients (95%CI) per 1 SD lower distensibility (DC) and 1 SD higher Young’s 
Elastic Modulus (YEM); for example, 1SD lower carotid DC was associated with a 0.24 (-0.43;0.92) higher CES-D score 
at follow-up in crude analyses. Model 1: crude; model 2: adjusted for age, sex, glucose metabolism status, education; 
model 3: model 2 + mean arterial pressure; model 4: model 3 + BMI, hypertension, smoking, triglycerides, total to HDL 
ratio, lipid modifying medication, eGFRMDRD, and prior CVD
Model
Model 1
Model 2
Model 3
Model 4*
Change in Carotid DC 
(n = 295)
0.52 (-0.23; 1.25)
0.50 (-0.24; 1.23)
0.47 (-0.33; 1.26)
0.47 (-0.35; 1.28)
Change in Carotid YEM 
(n = 290)
0.51 (-0.22; 1.25)
0.53 (-0.19; 1.26)
0.49 (-0.31; 1.29)
0.47 (-0.37; 1.30)
Table 4: Longitudinal association of the change in carotid stiffness indices with depressive symptoms at follow-up 
Results are expressed as regression coefficients (95%CI) per 1 SD lower distensibility (DC) and 1 SD higher Young’s 
Elastic Modulus (YEM); for example, 1SD lower carotid DC was associated with a 0.24 (-0.43;0.92) higher CES-D score 
at follow-up in crude analyses. Model 1: crude; model 2: adjusted for age, sex, glucose metabolism status, education; 
model 3: model 2 + mean arterial pressure; model 4: model 3 + BMI, hypertension, smoking, triglycerides, total to HDL 
ratio, lipid modifying medication, eGFRMDRD, and prior CVD
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Longitudinal association of change in carotid stiffness with depressive symptoms at 
follow-up
The change in carotid DC was not associated with depressive symptoms at follow up in 
any of the models (Table 4). Similarly, the change in carotid YEM was not associated with 
more depressive symptoms at follow-up in any of the models (Table 4). When we further 
adjusted the analyses for depressive symptoms at baseline the results remained unchanged 
(Supplemental Table 3).
Additional analyses 
When individuals with clinically relevant depressive symptoms (CESD ≥ 16) (n= 22), and/
or the use antidepressant medication (n= 5), or with a missing baseline CESD score (n = 
32) were excluded from the analyses, the results were not altered (Supplemental Table 
4). When we excluded individuals with extreme values (± 3SD) in carotid stiffness the 
associations did not change. 
Additional adjustments for baseline heart rate, physical activity or micro-albuminuria did 
not alter the associations. When we additionally adjusted for baseline carotid intima media 
thickness as a marker of  subclinical atherosclerosis the results were not altered. Additional 
adjustments for newly prescribed antihypertensive medication throughout follow-up, did not 
materially change the results. When BMI was replaced by height and weight the results did 
not materially change. Lastly, when MAP was replaced by either the pulse pressure, or the 
mean systolic blood pressure during the vascular measurements the results were  not altered. 
Discussion
This study shows that carotid stiffness is not associated with depressive symptoms in 
cross-sectional analyses, or in longitudinal analyses over a follow-up period of 8 years. 
In addition, changes in carotid stiffness over 8 years are not associated with depressive 
symptoms at follow-up.
To our knowledge, we are the first to investigate the longitudinal association of carotid 
stiffness with depressive symptoms in elderly individuals, however, we did not find any 
statistically significant associations. In longitudinal analyses, one SD greater carotid stiffness 
at baseline was associated with a - 0.33 [-1.22; 0.56] lower CES-D score at follow-up; while 
an increase in carotid stiffness over 8 years was associated with a 0.47 [-0.35; 1.28] greater 
CES-D score at follow-up. As the CES-D score ranges from 0 to 60 points, these modest 
effect sizes, are unlikely to have been clinically relevant, even had they been statistically 
significant. 
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In the cross-sectional analyses, greater carotid stiffness was only modestly associated with 
more depressive symptoms in the crude models, however the associations were greatly 
attenuated after adjustment for confounding factors as age and sex. To date, only two cross-
sectional studies investigated the association of the carotid DC with a major depressive 
disorder [16,18] or with depressive symptoms [18]. In concordance with our results, the 
NESDA study [18] did not find a significant association of carotid DC with a major depressive 
disorder. However, the individuals included in this study were younger (mean age: 42 years 
as compared to 68 years in our study). Because vascular depression is hypothesised to 
occur especially in later life, any association with carotid stiffness may not be present in 
younger individuals with early onset depression. In contrast to our findings, the Rotterdam 
Study [16] did find a significant association of carotid stiffness with both a major depressive 
disorder and clinically relevant depressive symptoms (CESD ≥ 16). This study had a larger 
sample size than ours and included individuals with more severe depressive symptoms, 
therefore it may have had more power to detect any cross-sectional associations. 
The strengths of this study include its longitudinal design as well as the advanced 
phenotyping with the measurement of many potential confounding factors, which were 
accounted for in the fully adjusted models. However, our findings may have been hampered 
by several limitations. Firstly, we had a small sample size (n ~300-500), with relatively low 
levels of depressive symptoms, which limits the precision of our regression coefficients and 
reduces the chances to find any association. Secondly, the use of self-reported depressive 
symptoms instead of a diagnostic interview may have attenuated the associations, possibly 
due to the misclassification of symptoms of impaired daily functioning as depressive 
symptoms [31]. Thirdly, our study might have been hampered by survival bias, as a large 
proportion of the individuals with baseline carotid stiffness were not included in the 
follow-up measurements. These participants were older and had a more adverse CVD risk 
profile (including stiffer carotid arteries) than the individuals who were included in the 
longitudinal analyses, thus they had a greater chance of dropping out due to CVD related 
morbidity and mortality. In turn, this could have attenuated the longitudinal associations 
with vascular depression. Furthermore, survival bias could have been accentuated by the 
adverse CVD profile of the study population, which was due to the advanced age (mean age 
68 years), the high prevalence of prior CVD and of T2D. This more adverse CVD risk profile 
could have weakened the individual association of arterial stiffness with CVD and vascular 
depression [32,33].  Lastly, individuals with the stiffest arteries at baseline may have been 
treated more intensively for hypertension than the remainder of the population, due to 
their adverse cardiovascular risk profile [34]. As blood pressure lowering medication may 
improve arterial stiffness [35], this could have introduced bias towards the null. 
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Even though our results were not significant, the associations of carotid stiffness with 
depressive symptoms seemed plausible a priori. Cardiovascular risk factors, such as 
arterial stiffness, may lead to the accumulation of cerebral small vessel lesions in the mood 
regulatory centres of the brain [31,11], which may result in the development of depression 
[5,12]. Also, arterial stiffening could lead to depression through endothelial cell dysfunction 
[36-41] and low grade inflammation [42-46]. 
Conclusion
In conclusion, we have shown that carotid stiffness was not associated with depressive 
symptoms in cross-sectional analyses, nor in longitudinal analyses over a follow-up period 
of 8 years. In addition, changes in carotid stiffness over 8 years were also not associated 
with depressive symptoms at follow-up. Further studies with larger sample size and less 
attrition are needed to consolidate these results. 
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Age, years
Female sex, %
Education level low/medium/high, %
Smoking, never/former/current, %
Physical activity, hours/week
At least 2.5 hours of moderate to high 
intensity physical activity per week, %
BMI, kg/m2
NGM/IGM/DM2, %
Total-to-HDL cholesterol ratio
Triglycerides, mmol/L
Fasting glucose, mmol/L
HbA1c%
eGFRMDRD, ml/min/1.73m2
Hypertension, %
Prior CVD, %
Lipid modifying medication, %
Blood pressure lowering medication, % 
Anti-depressive medication, % 
Carotid DC, 10^-3/kPa  
Carotid YEM, 10^3 kPa  
Carotid artery diameter, mm
Carotid artery distension, mm
Intima media thickness (IMT) 
SBP, mmHg
DBP, mmHg
MAP, mmHg
Heart Rate, bpm
Brachial PP, mmHg 
Supplemental Table 1: Clinical characteristics of the individuals with baseline carotid stiffness according to 
follow-up status
Data are presented as %, mean ± SD, or median [interquartile range]. CVD = cardiovascular disease; SBP = Mean 
systolic blood pressure during stiffness measurements; DBP = Mean diastolic blood pressure during stiffness measu-
rements; MAP = mean arterial pressure during stiffness measurements; Heart Rate = Mean heart rate during stiffness 
measurements. * Data available in n = 515/233/282)
Demographics
Lifestyle factors
Cardiometabolic risk factors
Medication use
Stiffness indices
Depressive symptoms
Lower Tertile 
(CESD score 0 - 4) 
(n = 181) 
69.6 ± 6.4
51
80/8/12
37/46/18
23.2 [11.3 – 31.0]
72.7
27.0 ± 3.6
48/29/23
4.26 ± 1.24
1.47 [1.00 – 1.70]
6.19 ± 1.42
6.0 ± 0.7
63.8 ± 10.4
67
50.4
15.7
34.4
2.2
10.9 ± 4.2
1.02 ± 0.57
7.98 ± 1.13
0.35 ± 0.11
0.87 ± 0.17
142 ± 20
76 ± 9
98 ± 12
62 ± 9
7.0 [3.0-11.0]
Middle Tertile 
(CESD score 5-9)
(n = 166)
71.8 ± 6.7
51
85/6/9
32/45/23
21.7 [9.0 – 30.0]]
70.7
27.0 ± 3.7
42/31/27
4.25 ± 1.20
1.30 [1.00 – 1.73]
6.4 ± 1.6
6.1 ± 0.7
63.1 ± 10.6
73
54.1
17.4
41.1
2.6
9.6 ± 3.9
1.17 ± 0.68
8.13 ± 1.09
0.32 ± 0.10
0.89 ± 0.18
146 ± 21
77 ± 9
100 ± 12
63 ± 9.0
7.0 [3.0 – 12.0]
Upper tertile 
(CESD score 10-34)
(n =168)
67.8 ± 5.6
51
76/9/15
40/46/14
24.4 [13.0 – 31.5]
74.4
27.0 ± 3.5
53/27/19
4.27 ± 1.28
1.30 [1.0 – 1.7]
6.04 ± 1.20
5.9 ± 0.7
64.3 ± 10.2
62
47.3
14.2
28.7
1.9
12.0 ± 4.2
0.90 ± 0.42
7.85 ± 1.15
0.37 ± 0.11
0.84 ± 0.16
138 ± 18  
76 ± 9
97 ± 11
61 ± 9
6.0 [3.0-10.0]
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Model
Model 4
Model 4 + baseline 
CES-D score
Carotid DC  
(n = 318)
-0.33 (-1.22; 0.56)
-0.33 (-1.15; 0.49)
Carotid YEM  
(n = 314)
-0.41 (-1.23; 0.41)
-0.64 (-0.09; 1.38)
Supplemental Table 2: Longitudinal association of baseline carotid stiffness indices with depressive symptoms at 
follow-up, additionally adjusted for baseline depression symptoms
Results are expressed as regression coefficients (95%CI) per 1 SD lower distensibility (DC) and compliance coefficient 
(CC) and 1 SD higher Young’s Elastic Modulus (YEM); for example 1SD lower carotid DC was associated with a -0.15 
(-0.88; 0.58) higher CES-D score at follow-up in model 4. 
Model
Model 4
Model 4 + baseline 
CES-D score
Change in Carotid DC 
(n = 295)
0.47 (-0.35; 1.28)
0.29 (-0.49; 1.07)
Change in Carotid YEM 
(n = 290)
0.47 (-0.37; 1.30)
0.42 (-1.21; 0.36)
Supplemental Table 3: Longitudinal association of the change in carotid stiffness indices with depressive 
symptoms at follow-up, additionally adjusted for baseline depression symptoms
Results are expressed as regression coefficients (95% CI) per 1 SD lower distensibility (DC) and 1 SD higher Young’s 
Elastic Modulus (YEM) at follow-up adjusted for respective stiffness indices measured at baseline; for example 1SD 
lower carotid DC at follow-up, adjusted for carotid DC at baseline was associated with a 0.47 (-0.35; 1.28) higher CES-D 
score at follow-up in model 4.
Model
Model 1
Model 2
Model 3
Model 4
Model 5 
Carotid DC 
(n = 282)
0.16 (-0.53; 0.85)
-0.41 (-1.17; 0.36)
-0.39 (-1.25; 0.47)
-0.47 (-1.37; 0.44)
-0.33 (-1.14; 0.48)
Carotid YEM 
(n = 279)
-0.11 (-0.80; 0.57)
-0.39 (-1.09; 0.31)
-0.40 (-1.18; 0.39)
-0.45 (-1.26; 0.37)
-0.63 (-1.36; 0.09)
Supplemental Table 4: Longitudinal association of baseline carotid stiffness indices with depression symptoms at 
follow-up in participants free of depression at baseline
Results are presented as regression coefficients (95% CI) per 1 SD lower distensibility (DC) and 1 SD higher Young’s 
Elastic Modulus (YEM); for example, 1SD lower carotid DC was associated with a 0.16 (-0.53; 0.85) higher CES-D score 
at follow-up in crude analyses. Model 1: crude; model 2: adjusted for age, sex, glucose metabolism status, education; 
model 3: model 2 + mean arterial pressure; model 4: model 3 + BMI, hypertension, smoking, triglycerides, total to HDL 
ratio, lipid modifying medication, eGFRMDRD, and prior CVD, Model 5: model 4 + baseline depression score 
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Model
Model 1
Model 2
Model 3
Model 4
Model 5 
Carotid DC 
(n = 239)
0.36 (-0.38; 1.10)
0.38 (-0.36; 1.12)
0.44 (-0.36; 1.24)
0.47 (-0.37; 1.30)
0.34 (-0.44; 1.12)
Carotid YEM 
(n = 236)
0.18 (-0.53; 0.89)
0.25 (-0.45; 0.96)
0.31 (-0.49; 1.10)
0.31 (-0.53; 1.15)
0.24 (-0.54; 1.02)
Supplemental Table 5: Longitudinal association of the change in carotid stiffness with depression symptoms at 
follow-up in participants free of depression at baseline
Results are presented as regression coefficients (95% CI) per 1 SD lower distensibility (DC) and compliance coefficient 
(CC) and 1 SD higher Young’s Elastic Modulus (YEM) at follow-up adjusted for baseline stiffness; 1SD lower Carotid DC 
at follow-up, adjusted for baseline Carotid DC was associated with a 0.55 (0.02;1.08) higher CES-D score at follow-up.  
Model 1: adjusted for baseline carotid stiffness; model 2: model 1 + age, sex, glucose metabolism status, education; 
model 3: model 2 + mean arterial pressure at baseline and follow-up; model 4: model 3 + BMI, hypertension, smoking, 
triglycerides, total-to-HDL ratio, lipid modifying medication, eGFRMDRD, prior CVD; model 5: model 4 + baseline depression 
score 
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Abstract
Background
Arterial stiffness is a CVD risk factor, which could contribute to the development of cognitive 
decline. Aortic stiffness has been consistently associated with cognitive performance and 
decline. However, data on carotid arterial stiffness in relation to cognitive performance 
are scarce, eventhough carotid stiffening may particularly affect the cerebral (micro-)
circulation. 
Objectives
We investigated the association of carotid and aortic stiffness with cognitive performance 
at six years of follow-up. 
Design 
Prospective cohort study.
Setting 
The Hoorn Study, a population-based study, artificially enriched with type 2 diabetes (T2D) 
individuals.
Participants
364 participants (age 67.6±5.4 years, 49.3% women, 19 %T2D). 
Measurements
Carotid artery stiffness (distensibility coefficient (DC) and Young’s Elastic Modulus 
(YEM)) and aortic stiffness (carotid-femoral pulse wave velocity (cfPWV)) were assessed 
between 2000-2001 in n=364 and n=155 subjects respectively. Cognitive function tests for 
information processing speed, attention & executive function and memory were assessed 
between 2005-2009. Linear regression analyses adjusted for age, follow-up duration, sex, 
and baseline variables of glucose metabolism, IQ, mean arterial pressure and CVD risk 
factors were used. Results are presented as regression coefficients [95% CI] per 1 SD lower 
carotid DC, higher YEM or higher cfPWV.
Results
Lower carotid DC and higher YEM were significantly associated with lower processing speed 
and attention & executive function in crude analyses, carotid DC: -0.210 [-0.297; -0.122], 
-0.109 [-0.177; -0.040] and YEM: -0.167 [-0.257; -0.078], -0.089 [-0.158; -0.020]; but the 
association attenuated after adjustment for age and follow-up duration. Fully adjusted 
regression coefficients were -0.053 [-0.152; 0.046] for carotid DC and -0.008 [-0.091;0.076] 
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for YEM. Carotid DC and YEM were not associated with memory function. Higher cfPWV 
was significantly associated with lower processing speed both in the crude (-0.215 [-0.328;-
0.101]) and the fully adjusted models: -0.144 [-0.267;-0.021]. CfPWV was not associated 
with attention & executive function or memory function.   
Conclusion
Carotid artery stiffness was associated with lower processing speed and attention & 
executive function at six years of follow-up, however, the association greatly attenuated 
after adjustment for age and follow-up duration. Aortic stiffness was independently 
associated with lower processing speed at six years of follow-up, but not with attention & 
executive function, or memory function. 
Key Words
Aortic stiffness, carotid stiffness, cognitive decline, cognitive dysfunction.
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Introduction
In affluent countries, up to 36% of individuals above 70 years of age suffer from cognitive 
dysfunction [1] and thus are at an increased risk of developing dementia [2]. The above 
will have a considerable impact on the delivery of future health care in these countries, 
amongst others due to ageing of their populations [3]. 
Currently, there are no effective therapeutic strategies to treat cognitive dysfunction or 
to halt its progression to dementia. Consequently, there is a growing need to further 
elucidate its pathophysiology. Growing evidence suggests that arterial stiffness underlies 
the development of cognitive dysfunction in older individuals. Stiffening of the large elastic 
vessels, such as the aorta and the carotid arteries impairs their cushioning function, which 
allows greater pressure and flow pulsatility to reach the cerebral microvasculature [4], thus 
causing cerebral small vessel disease [4,5]. Accumulation of these (micro)vascular lesions 
may disrupt cerebral circuits and thus impair brain functions, leading to cognitive decline 
[6,7].  Indeed, in a recent meta-analysis by our group, greater stiffness of the aorta was 
associated with cognitive dysfunction [8]. 
Most previous studies on the association between arterial stiffness and cognitive 
dysfunction have focused upon aortic stiffness as measured by the carotid-to-femoral 
pulse wave velocity (cfPWV) [8]. It can be hypothesized, however, that stiffening of the 
carotid arteries, as measured by the distensibility coefficient (DC) and the Young’s Elastic 
Modulus (YEM) may affect pressure and flow pulsatility upon the cerebral vasculature to a 
greater extent than aortic stiffening, considering their localization, anatomy and function 
[9]. Data on the association between carotid arterial stiffness and cognitive dysfunction is 
scarce and the results published thus far are contradicting. For instance, out of the four 
cross-sectional studies [10-13] three [10-12] reported a significant association between 
greater carotid arterial stiffness and cognitive dysfunction, whereas the sole longitudinal 
study [13] did not. 
In view of these considerations we investigated whether carotid and aortic stiffness indices, 
such as the Carotid DC, Carotid YEM and the cfPWV, were associated with processing speed, 
attention & executive function, and memory function after a follow-up period of six years 
by using data from the population-based Hoorn study. 
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Methods
Study population
The Hoorn study is a longitudinal population-based cohort study, which investigates 
glucose metabolism, as well as cardiovascular risk factors, in the general population [14]. 
The study started in 1989, included 2484 men and women aged 50 to 74 years, of whom 
1513 participated in the second examination in 1996-98. For this study, we used data from 
the third and fourth follow-up examinations. In the third assessment in 2000-2001, 648 
individuals participated, individuals with impaired glucose metabolism and type 2 diabetes 
(T2D) were oversampled by design [15]. For the 2005-2009 examinations, all surviving 
participants of the 2000-2001 cohort, who were still living in Hoorn and could give an 
Figure 1: Flow Diagram
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informed consent (n = 505) were re-invited for neuropsychological examinations, of whom 
380 agreed to participate. Carotid artery stiffness and carotid-femoral pulse wave velocity 
(cfPWV) measurements were carried out during the third examination (2000-2001), while 
cognitive performance was measured in the fourth examination (2005-2009). 
Out of 648 participants in the third examination, 588 had a carotid artery measurement. 
During follow-up, 86 died prior to the fourth examination and 136 either declined to 
participate or had moved out of Hoorn. A total of 366 participants took part in the follow-
up examination, of whom 364 had satisfactory data on cognitive performance (see Flow 
Diagram, Figure 1). 
At the third examination, cfPWV was available in 239 participants, due to the belated 
acquisition of the device. Of these 36 died prior to the follow-up examination and 48 either 
declined to participate or had moved out of Hoorn. A total of 156 participants took part in 
the follow-up examination, of whom 155 had satisfactory data on cognitive performance.
Arterial Stiffness Measurements
Carotid artery stiffness indices 
Carotid artery stiffness was assessed at the right common carotid artery according to 
international guidelines, as described previously [15]. Briefly, a single observer visualized 
the right carotid artery with an ultrasound scanner (350 Series [7.5-MHz linear probe], Pie 
Medical, the Netherlands) connected to a personal computer equipped with wall track 
software and an acquisition system (Wall Track System, Pie Medical). The carotid artery 
walls were detected by the software: the diameter and intima-media thickness (IMT) were 
assessed during the diastole, while the distension was defined as the movement of the 
carotid artery wall as a function of systolic duration. At each site, 3 consecutive 4-second 
measurements were carried out and the mean diameter, IMT and distension were used 
in the analyses. During the measurements, brachial systolic and diastolic pressures were 
assessed during the vascular measurements in the left upper arm at 5-minute intervals 
with an oscillometric device (Collin Press-Mate, BP-8800).   
The distensibility coefficient was calculated as follows: 
Distensibility coefficient (DC) = (2ΔD•D + ΔD2)/(ΔP•D2) in 10-3•kPa-1
where ΔD is distension, D is diameter, and ΔP is the brachial pulse pressure (defined as 
systolic pressure – diastolic pressure). The Young’s elastic modulus (YEM) was calculated 
for the carotid artery, according to the formula:
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YEM=diameter/ (IMT • distensibility coefficient) in kPa  
DC represents carotid artery stiffness; and the YEM represents the stiffness of the carotid 
artery wall material at operating pressure. 
Calibrated carotid artery stiffness indices
In a sensitivity analysis, the carotid artery pulse pressure was estimated from the carotid 
artery distension wave-forms and the brachial pulse pressure, as described previously [16]. 
The calibrated stiffness indices of the carotid artery were re-calculated using the carotid 
pulse pressure instead of the brachial artery pulse pressure, according to the formulas 
described above. 
Carotid-femoral Pulse Wave Velocity (cfPWV)
The distance travelled by the pulse wave from the carotid artery, along the aorta, to the 
femoral artery was estimated using body height, as suggested by Weber et al. [17]. The 
carotid-femoral transit time was determined according to the time-decay method by using 
the distension curves of the right common carotid and the right femoral arteries and a 
simultaneous electrocardiograph trigger [18]. Pulse wave velocity was calculated as the 
ratio between distance travelled and travel time [19].  
Cognitive performance
An extensive standardized neuropsychological test battery was obtained at the follow-up 
examination, including twelve verbal and non-verbal tasks, administered in a fixed order.  The 
tasks were divided into six cognitive domains to reduce the number of neuropsychological 
variables and for clinical clarity. This division was made a priori, according to standard 
neuropsychological practice and cognitive theory, as described in detail in Lezak et al. [20]. 
In the current article, we focused on the cognitive domains which have been associated 
previously with arterial stiffness, namely information processing speed, attention & 
executive function, and memory function [4,21,22]. The domain ‘information processing 
speed’ was assessed by the Trail Making Test Part A, the Stroop Colour-Word Test (parts I 
and II), and the subtest Digit Symbol of the WAIS-III. The domain ‘attention and executive 
function’ was assessed by the Trail Making Test Part B, the Stroop Colour-Word Test (part III), 
the Brixton Spatial Anticipation Test, a verbal fluency test using the N and A, and category 
fluency using animal names. The domain ‘memory’ included tests for four subdomains: 
‘working memory’ assessed by the forward and backward digit span of the Wechsler Adult 
Intelligence Scale-III (WAIS-III) and the Corsi Block-Tapping Task; ‘immediate memory and 
learning rate’, including verbal memory assessed by the Rey Auditory Verbal Learning Test 
and ‘visual memory’ assessed by the Location Learning Test; ‘forgetting rate’ assessed by 
the delayed task of the Rey Auditory Verbal Learning Test and of the Location Learning 
Test, and ‘incidental memory’ assessed by the delayed trial of the Rey-Osterrieth Complex 
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Figure. Raw test scores were standardized into z-scores, after which cognitive domain 
scores were obtained by averaging the z-scores of the tests, which comprised that domain. 
Depressive symptoms were assessed with the validated Dutch version of the 20-item 
Centre for Epidemiologic Studies Depression Scale (CES-D) [23]. Scores on the CES-D range 
from 0 to 60. Higher scores on this scale indicate the presence of more (severe) depressive 
symptoms. The presence of a depressive disorder was defined as CES-D score ≥ 16 or the 
use of anti-depression medication at follow-up. Pre-morbid intelligence quotient (IQ) was 
estimated with the Dutch version of the National Adult Reading Test [24]. Estimated IQ was 
used instead of education level because, in the present population, access to education 
was linked to socio-economic factors instead of merit.
Other measurements 
Glucose tolerance was defined according to the 1999 WHO criteria [25], based on a glucose 
tolerance test, fasting glucose measurements, as well as the use of glucose lowering 
medication [14]. Education level, smoking, physical activity and medication use were 
assessed by means of a questionnaire [15]. Body mass index (BMI), office blood pressure, 
glucose metabolism status, (micro)albuminuria, serum total, high- (HDL), and low-density 
lipoprotein (LDL) cholesterol and triglycerides were determined as described previously 
[26]. Glomerular filtration rate was estimated with the 4 variable MDRD equation (eGFRMdrd) 
[27]. Finally, prior CVD and hypertension were defined as described elsewhere [14,28]. 
Statistical analyses
All analyses were performed with IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, 
USA). The associations of carotid stiffness or cfPWV with domains of cognitive performance 
six years later were assessed by means of linear regression analyses. Carotid artery 
stiffness and cfPWV were introduced as a sex-specific z-score [29]. Cognitive test scores 
were inversed if necessary, such that a lower score reflected lower cognitive performance 
and were introduced as z-scores. The analyses were adjusted for possible confounders as 
measured at baseline. Also, all models were adjusted for follow-up time in years, as the 
follow-up time had a range of 4 years (2005-2009). Lastly, depression is known to influence 
cognitive function, therefore, the models were also adjusted for depression at follow-
up. The analyses were carried out according to the following models: model 1) crude, 
model 2) adjusted for age, sex, IQ, follow-up duration, model 3) additionally adjusted for 
mean arterial pressure (MAP), model 4) additionally adjusted for the following baseline 
measures: glucose metabolism status, heart rate, smoking, height, weight, hypertension, 
prior CVD, lipid modifying medication, triglycerides, total to HDL cholesterol ratio, eGFRMdrd 
and depression at follow-up. Please note that lower values of Carotid DC but higher values 
of cfPWV and YEM reflect greater arterial stiffness.
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Results
Baseline characteristics
The clinical characteristics of the study population with carotid artery stiffness data (n = 
364) are shown in Table 1, mean age was 67.6 ± 5.4 years, 49.3% were women and the 
mean follow-up duration was 5.79 ± 1.08 years. Individuals with carotid artery stiffness 
measurements but without cognitive function data at follow-up (n = 224) were older and 
had a worse CVD risk profile than individuals with cognitive function data (Supplemental 
Table 1). The population with cfPWV data (n = 155) had comparable characteristics to the 
population with carotid artery stiffness data, but used less glucose lowering and blood 
pressure lowering drugs (Supplemental Table 1). 
Carotid artery stiffness and cognitive performance
As shown in Table 2, in the crude model, lower carotid DC was associated with lower 
information processing speed and attention & executive functions at follow-up, regression 
coefficients [95%CI] were -0.210 [-0.297; -0.122] and -0.109 [-0.177; -0.040] per SD, 
respectively. The associations were attenuated and no longer statistically significant after 
adjustments for age, sex, follow-up duration and IQ (model 2, Table 2), especially due to 
the addition of age and follow-up duration. Further adjustments for MAP, other CVD risk 
factors and the presence of a depression disorder at follow-up did not alter the results 
(models 3 and 4, Table 2). The carotid DC was not associated with lower memory function 
either in the crude, or in the fully adjusted models (Table 2). Similarly, a higher YEM was 
associated with lower information processing speed and attention & executive scores at 
follow-up, in the crude model, regression coefficients [95%CI] were -0.167 [-0.257; -0.078] 
and -0.089 [-0.158; -0.020], respectively. However, the associations were attenuated and 
no longer statistically significant after adjustment for age, sex, follow-up duration and IQ 
(model 2, Table 2). Further adjustments did not alter the results (models 3 and 4, Table 2). 
YEM was not associated with lower memory function either in the crude, or in the fully 
adjusted models.  
When we explored the association of individual elements of the stiffness indices with 
cognitive dysfunction neither the carotid diameter, carotid distension, nor the carotid or 
brachial pulse pressures were associated with any of the domains of cognitive performance 
(Supplemental Table 2).  
Carotid-femoral Pulse Wave Velocity and cognitive performance
As shown in Table 3, higher cfPWV was associated with lower information processing speed 
at follow-up in the crude model, the regression coefficient [95%CI] was -0.215 [-0.328; 
-0.101]. The associations were attenuated but remained statistically significant after 
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Table 1: Clinical characteristics of the study population at baseline
Demographics
Age, years
Female sex, %
Education level, low/medium/high, %
Cardio-metabolic risk factors 
BMI, kg/m2
Waist-to-hip ratio
Glucose metabolism status, NGM/IGM/T2D, %
Total cholesterol, mmol/L
HDL cholesterol, mmol/L
LDL cholesterol, mmol/L
Total to HDL cholesterol ratio
Triglycerides, mmol/L
Systolic blood pressure, mmHg 
Diastolic blood pressure, mmHg
Mean arterial pressure, mmHg
Heart rate, beats per minute
Hypertension, %
Prior CVD, %
MDRD, mL/min per 1.73 m2
Lifestyle factors
Smoking, never/former/current, %
Physical activity per week (hours/week), median [IQR]*
Medication
Glucose lowering drugs, %
Anti-hypertensive drugs, %
Lipid modifying drugs, %
Arterial Stiffness
Carotid Distensibility Coefficient (DC), 10^-3/kPa  
Carotid Young’s Elastic Modulus, 10^-3 kPa  
Carotid to femoral PWV, m/s*
Pulse pressure, mmHg
Follow-up (2005-1009)
Follow-up time, years
Intelligence Quotient (IQ) 
CES-D ≥ 16, %
Anti-depressive medication, %
Depression, %
 Study population with carotid artery stiffness data
(n = 364)
67.6 ± 5.4
49.3
20/40/40
27.1 ± 3.4
0.92 ± 0.10
54/28/19
5.72 ± 1.04
1.43 ± 0.41
3.61 ± 0.92
4.26 ± 1.25
1.3 [1.0-1.8]
138.1 ± 17.6 
76.0 ± 8.9
96.7 ± 10.8
61.6 ± 9.1
63.7
46.1
64.4 ±9.9
38/48/14
21.0 [13.0-31.8]
6.9
31.8
16.9
11.9 ± 4.2
0.90 ± 0.40
9.88 ± 3.28
62.2 ± 13.2
5.79 ± 1.08
98.00 ± 12.98  
8.8
3.8
11.3
Results are presented as % (n), mean ± standard deviation or median [interquartile range]. 
*Available in n= 155 individuals. 
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Table 2: Associations of carotid artery stiffness indices with cognitive performance domains at follow-up
Model 1
Model 2*
Model 3
Model 4**
Model 1
Model 2*
Model 3
Model 4**
Attention & Executive 
Functions
-0.109 [-0.177; -0.040]
-0.034 [-0.099; 0.031]
-0.028 [-0.103; 0.047]
-0.008 [-0.091; 0.076]
-0.089 [-0.158; -0.020]
-0.030 [-0.092; 0.033]
-0.026 [-0.096; 0.044]
-0.019 [-0.092; 0.055]
Information Processing Speed
-0.210 [-0.297; -0.122]
-0.074 [-0.006; 0.155]
-0.069 [-0.161; 0.023]
-0.053 [-0.152; 0.046]
-0.167 [-0.257; -0.078]
-0.063 [-0.140; 0.014]
-0.054 [-0.141; 0.033]
-0.036 [-0.123; 0.052]
Memory
-0.049 [-0.098; 0.001]
-0.002 [-0.051; 0.048]
0.005 [-0.052; 0.062]
0.010 [-0.053; 0.074]
-0.022 [-0.072; 0.028]
0.015 [-0.033; 0.062]
0.027 [-0.026; 0.080]
0.030 [-0.025; 0.086]
Carotid Distensibility Coefficient (n = 364)
Young’s Elastic Modulus (n = 358)
Results are presented as regression coefficients [95% Confidence Interval] per standard deviation lower sex adjusted 
Carotid Distensibility Coefficient or higher sex-adjusted Young’s Elastic Modulus. In the crude model, 1SD lower carotid 
distensibility was associated with -0.109 [-0.177; -0.040] lower attention & executive functions score. Model 1: crude, 
Model 2: age, follow-up time, sex, IQ, Model 3: Model 2 + map, Model 4: Model 3 +, glucose metabolism status, height, 
weight, heart rate, MDRD, Total-HDL ratio, triglycerides, lipid modifying medications, hypertension, smoking, prior CVD, 
depression at follow-up.  *5 missing in model 2, ** 20 missing in model 4
Table 3: Associations of carotid-femoral pulse wave velocity with cognitive performance domains at follow-up
Model 1
Model 2*
Model 3
Model 4**
Attention & Executive 
Functions (n = 154)
-0.042 [-0.125; 0.041]
0.024 [-0.050; 0.097]
0.038 [-0.037; 0.114]
0.044 [-0.038; 0.127]
Information Processing Speed
(n = 155)
-0.215 [-0.328; -0.101]
-0.120 [-0.226; -0.014]
-0.118 [-0.227; -0.008]
-0.144 [-0.267; -0.021]
Memory
(n = 155)
-0.086 [-0.166; -0.007]
-0.047 [-0.125; 0.031]
-0.054 [-0.135; 0.026]
-0.063 [-0.153; 0.026]
Results are presented as regression coefficients [95% Confidence Interval] per standard deviation higher sex adjusted 
carotid-femoral Pulse Wave Velocity (cfPWV). In the crude model, 1 sex adjusted SD higher cfPWV was associated 
with -0.043 [-0.127; 0.041] lower attention & executive funcion score. 
Model 1: crude, Model 2: age, follow-up time, sex, IQ, Model 3: Model 2 + map, Model 4: Model 3 +, glucose metabo-
lism status, height, weight, heart rate, MDRD, Total-HDL ratio, triglycerides, lipid modifying medications, hypertension, 
smoking, prior CVD, depression at follow-up. *3 missing in model 2,**6 missing in model 4
PS_VERONICA_vs1.indd   75 09-11-18   14:23
76
c h A p t e r 4
adjustments for age, sex, follow-up duration, IQ: -0.120 [-0.226; -0.014]. The association 
remained significant in the fully adjusted model: -0.144 [-0.267; -0.021]. Higher cfPWV was 
also associated with lower memory function at follow-up in the crude model, the regression 
coefficient [95%CI] was -0.086 [-0.166; -0.007]. However, the associations were attenuated 
and were no longer statistically significant after adjustment for age, sex, follow-up duration 
and IQ (model 2, Table 3). CfPWV was not associated with attention & executive function 
either in the crude, or in the fully adjusted model (Table 3).  
Calculations using the regression coefficients of age and aortic stiffness (from the fully 
adjusted model) showed that one standard deviation increase in aortic stiffness was 
comparable with 3 years of ageing in the domain of information processing speed. 
Additional analyses
When we excluded individuals with carotid artery (n = 5), or aortic (n = 2) stiffness values 
greater than or lower than 3SD (outlier analyses), the associations did not materially 
change. When carotid artery stiffness indices were calibrated for carotid pulse pressure 
(cPP, n = 326), the associations with domains of cognitive performance did not change 
(Supplemental Table 3). 
  
When IQ was replaced by education level, and when height and weight were replaced by 
BMI, the associations were not altered. When the models were additionally adjusted for 
incident stroke (n=7), the associations were not altered. Similarly, when the associations 
were adjusted for the start of anti-hypertensive medication through-out the follow-up 
period, the results did not change. 
Discussion
In this study, carotid artery stiffness was not significantly associated with any of the 
cognitive domains (information processing speed, attention & executive function, or 
memory function) as measured at six years of follow-up. Aortic stiffness was modestly 
associated with lower information processing speed, but not with executive functions or 
memory. 
To date, only few studies have investigated the association of carotid artery stiffness 
with cognitive performance [10-13]. Our findings are in accordance with the only other 
longitudinal population-based study available [13]. We found regression coefficients that 
were close to zero, with very broad confidence intervals, therefore it is unlikely that a larger 
study population would have yielded a significant association for carotid artery stiffness. 
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In contrast, we did observe that higher aortic stiffness was associated with information 
processing speed at follow-up. The associations remained significant even after adjustment 
for many potential confounding factors. These findings are in agreement with previous 
studies that have reported significant associations of aortic stiffness with at least one 
cognitive domain [30-33] or with global cognitive scores [34-39]. Only two of these studies 
did assess information processing speed, of which one [30] showed a significant cross-
sectional, but not a longitudinal association; while the other [13] did not report any 
significant associations. As opposed to our study, these studies used only one test to assess 
processing speed, which might have hampered the power of their estimations. Indeed, 
in this study aortic stiffness was significantly associated with the domain score, while the 
associations with individual tests were only borderline significant. 
There are several other potential reasons why we could not find a longitudinal association 
of carotid artery stiffness with cognitive performance. Firstly, our study might have been 
hampered by attrition bias, as a relatively large proportion of the individuals with baseline 
carotid stiffness did not participate in the follow-up measurements. These participants 
were older and had a more adverse CVD risk profile (including stiffer carotid arteries) than 
the individuals who were included in the longitudinal analyses, therefore they may have 
had a greater risk of cognitive dysfunction. This could have attenuated the longitudinal 
associations with cognitive dysfunction. Attrition bias could have been accentuated by the 
adverse CVD profile of the study population, which was due to the advanced age (mean 
age 68 years), the high prevalence of prior CVD and of T2D. Nonetheless, we did find 
an association of aortic stiffness with cognitive performance in a much smaller sample, 
therefore it is less likely that this played a decisive role. Secondly, competing risks could have 
resulted in an attenuation of the association with cognitive performance, as participants 
with greater arterial stiffness were also at increased risk of fatal CVD risk. Thirdly, individuals 
with the stiffest arteries could have been treated more intensively for hypertension than 
the remainder of the population due to their adverse cardiovascular risk profile [40]. As 
blood pressure lowering medication might improve arterial stiffness [41], this could have 
introduced bias towards the null. Finally, carotid stiffness may be less robust than aortic 
stiffness as its calculation requires the use of three ultrasound measured variables, each 
with its own measurement error. These short comings were partly compensated, however, 
by averaging data from three consecutive measurements. 
There are several pathophysiologic mechanisms through which arterial stiffness could lead 
to cognitive decline. Firstly, arterial stiffness can lead to the development of cerebral small 
vessel lesions [4,5]. The cerebral microcirculation has a low impedance that facilitates 
the high blood flow required to meet the high metabolic demands of the brain [42]. The 
impairment of the cushioning function of the aorta allows greater pressure and flow 
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pulsatility to penetrate deeply into the cerebral microcirculation, thus directly damaging 
the surrounding tissue [43-45]. Furthermore, the excessive pressure induces arteriolar 
remodelling and hypertrophy, which impairs vascular reactivity and contributes to repeated 
episodes of microvascular ischemia and tissue damage [44,45]. The accumulation of these 
(micro)vascular lesions may disrupt cerebral circuits and thus impair brain functions, 
leading to a decline in cognitive performance [6,7]. Secondly, arterial stiffness may lead 
to greater oscillations in wall shear stress, which may induce endothelial dysfunction as 
well as the production of low grade inflammatory markers by the endothelium [46-48]. 
Endothelial dysfunction could lead to cognitive decline through a disturbance of the 
process of neurogenesis [49,50], through small vessel disease [6,7], or through decreased 
cerebrovascular reactivity [51]. Systemic low-grade inflammation, on the other hand, could 
lead to cognitive decline by augmenting β amyloid deposits [42-54] or by enhancing small 
vessel disease by promoting atherosclerosis of the large vessels [55]. 
In this study, only aortic, but not carotid artery stiffness was associated with cognitive 
performance. A possible explanation for this effect could be that the measurement of 
aortic stiffness (cfPWV) includes both elastic and muscular artery properties, whereas 
carotid artery stiffness mainly measures elastic properties [19]. The middle-sized cerebral 
arteries, which supply the cerebral anterior cerebral circulation, also have a muscular wall, 
therefore the cfPWV could reflect their stiffness levels better than the more elastic carotid 
arteries. Also, the aorta stiffens at a disproportionate rate compared to the carotid artery 
in response to old age, hypertension and T2D [56]. Due to the adverse CVD risk profile of 
our study population, this would have allowed the better detection of any associations of 
aortic, rather than carotid stiffness with cognitive performance. 
Lastly, it is important to acknowledge that the modest effect sizes that we identified for 
aortic stiffness; however, reported associations may have been underestimated by potential 
over adjustment for multiple confounders, such as hypertension and other vascular risk 
factors that may lie in the causal pathway. Relatively speaking, one standard deviation 
higher pulse wave velocity was comparable with approximately 3 years of ageing in the 
domain of processing speed, which may be considered clinically relevant. 
In conclusion, this study shows that greater carotid stiffness is not longitudinally associated 
with lower processing speed, attention & executive function, or memory scores after 
a follow-up period of six years. Greater aortic stiffness, on the other hand, is modestly 
associated with lower information processing speed, but not with lower attention & 
executive function, or memory function.
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Supplemental Table 1: Clinical characteristics of the study population according with carotid stiffness or pulse wave 
velocity measurements
Demographics
Age, years
Female sex, %
Education level, low/medium/high, %
Cardio-metabolic risk factors 
BMI, kg/m2
Waist-to-hip ratio
Glucose metabolism status, NGM/IGM/T2D, %
Total cholesterol, mmol/L
HDL cholesterol, mmol/L
LDL cholesterol, mmol/L
Total to HDL cholesterol ratio
Triglycerides, mmol/L
Mean Systolic blood pressure, mmHg 
Mean Diastolic blood pressure, mmHg
Mean arterial pressure, mmHg
Heart rate, beats per minute
Hypertension, %
Prior CVD, %
eGFR, mL/min per 1.73 m2
Lifestyle factors
Smoking, never/former/current, %
Physical activity per week (hours/week), 
  median [IQR]*
Medication
Glucose lowering drugs, %
Anti-hypertensive drugs, %
Lipid modifying drugs, %
Arterial Stiffness
Carotid Distensibility Coefficient, 
Carotid Young’s Elastic Modulus 
Carotid to femoral PWV, m/s*
Pulse pressure, mmHg
Follow-up (2005-1009)
Follow-up time, years
Intelligence Quotient (IQ)
CES-D ≥ 16
Anti-depressive medication, %
Depression, %
Study population with  
cfPWV data
(n = 155) 
66.8 ± 4.9
49.4
16/37/47
26.4 ± 2.7
0 .92 ± 0.09
53/32/16
5.75 ± 0.98
1.42 ± 0.39
3.63 ± 0.85
4.33 ± 1.41
1.3 [1.0- 1.8]
136.9 ± 16.2
76.6 ± 8.4
96.7 ± 9.8
65.9 ± 7.9
58.3
42.9
64.7 ± 10.4
41/43/17
21.5[14.1–31.0]
4.5
23.1
14.7
12.0 ± 4.02
0.89 ± 0.40
9.75 ± 3.26
60.3 ±13.4
5.69 ± 0.97
98.00 ± 12.69 
8.4
3.6
11.0
Results are presented as % (n), mean ± standard deviation or median [interquartile range]. 
*Available in n= 83/individuals
Baseline data but no  
follow-up data 
(n = 224)
72.8 ± 6.6
53.1
48/40/12
26.8 ± 3.9
0.93 ± 0.09
39/31/30
5.76 ± 1.03
1.44 ± 0.42
3.68 ± 0.90
3.99 ± 1.24
1.3 [1.0 – 1.7]
147.6 ± 21.8
77.5 ± 9.5
100.6 ± 12.4
63.3 ± 9.2
72.8
57.1
62.3 ± 11.1
34/42/23
21.2 [8.13 – 29.8]
12.1
38.8
13.4
9.34 ± 3.8
1.23 ± 0.72
11.1 ± 5.50 
70.5 ± 17.0
-
-
-
-
-
PS_VERONICA_vs1.indd   79 09-11-18   14:23
80
c h A p t e r 4
Supplemental Table 2: Associations of carotid diameter, carotid distensibility, brachial and calibrated pulse pressures 
with cognitive performance domains at follow-up
Model 1
Model 2*
Model 3
Model 4**
Model 1
Model 2*
Model 3
Model 4**
Model 1
Model 2*
Model 3
Model 4**
Model 1
Model 2*
Model 3
Model 4**
Attention & Executive Functions
-0.055 [-0.123; 0.014]
-0.013 [-0.078; 0.052] 
-0.007 [-0.074; 0.060]
-0.018 [-0.092; 0.057]
-0.066 [-0.134; 0.003]
-0.019 [-0.080; 0.042]
-0.017 [-0.078; 0.044]
0.005 [-0.062; 0.071]
-0.090 [-0.158; -0.022]
-0.034 [-0.097; 0.030]
-0.028 [-0.109; 0.053]
-0.043 [-0.129; 0.042]
-0.071 [-0.001; 0.144]
0.004 [-0.063; 0.071]
0.024 [-0.060; 0.107]
0.019 [-0.076; 0.115]
Information Processing Speed
-0.157 [-0.247; -0.067]
-0.058 [-0.139; 0.022]
-0.051 [-0.134; 0.033]
-0.047 [-0.136; 0.041]
-0.108 [-0.198; -0.018]
-0.041 [-0.116; 0.035]
-0.038 [-0.114; 0.037]
-0.031 [-0.0110; 0.048]
-0.147 [-0.206; -0.028]
-0.033 [-0.112; 0.045]
-0.011 [-0.112; 0.090]
-0.026 [-0.128; 0.076]
-0.158 [-0.248; -0.067]
-0.082 [-0.162; -0.162]
-0.091 [-0.190; -0.008]
-0.071 [-0.182; 0.040]
Memory
-0.013 [-0.062; 0.037]
0.010 [-0.039; 0.059]
0.013 [-0.037; 0.064]
-0.008 [-0.064; 0.048]
-0.052 [-0.102; -0.003]
-0.026 [-0.072; 0.020]
-0.026 [-0.072; 0.021]
-0.016 [-0.066; 0.034]
-0.014 [-0.063; 0.036]
-0.031 [-0.017; 0.079]
0.056 [-0.005; 0.117]
0.048 [-0.017; 0.112]
-0.030 [-0.082; 0.022]
-0.015 [-0.035; 0.065]
-0.033 [-0.029; 0.096]
0.009 [-0.063; 0.081]
Carotid Distension (n = 363)
Carotid Diameter (n = 363)
Brachial Pulse Pressure (n = 363)
Carotid Pulse Pressure (n = 326)
Results are presented as regression coefficients [95% Confidence Interval] per standard deviation higher carotid 
diameter, brachial or calibrated pulse pressure and lower carotid distension. In the crude model, 1SD higher carotid 
diameter was associated with -0.055 [-0.123; 0.014] lower attention & executive function score. Model 1: crude, Model 
2: age, follow-up time, sex, IQ, Model 3: Model 2 + map, Model 4: Model 3 +, glucose metabolism status, height, weight, 
heart rate, MDRD, Total-HDL ratio, triglycerides, lipid modifying medications, hypertension, smoking, prior CVD, depres-
sion at follow-up.  *5 missing in model 2, ** 20 missing in model
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Supplemental Table 3: Associations of calibrated carotid stiffness indices with cognitive performance domains at 
follow-up
Model 1
Model 2*
Model 3
Model 4**
Model 1
Model 2*
Model 3
Model 4**
Attention & Executive Functions
-0.132 [-0.199; -0.066]
-0.047 [-0.110; 0.016]
-0.046 [-0.116; 0.024]
-0.034 [-0.110; 0.042]
-0.121 [-0.188; -0.054]
-0.044 [-0.105; 0.016]
-0.042 [-0.108; 0.025]
-0.033 [-0.102; 0.035]
Information Processing Speed
-0.175 [-0.264; -0.086]
-0.038 [-0.120; 0.044]
-0.029 [-0.121; 0.062]
-0.005 [-0.102; 0.092]
-0.175 [-0.264; -0.085]
-0.058 [-0.137; 0.021]
-0.052 [-0.139; 0.034]
-0.031 [-0.119; 0.056]
Memory
-0.035 [-0.086; 0.017]
0.016 [-0.036; 0.067]
0.025 [-0.033; 0.082]
0.024 [-0.039; 0.089]
-0.010 [-0.062; 0.042]
0.035 [-0.014; 0.085]
-0.049 [-0.006; 0.103]
-0.048 [-0.009; 0.104]
Calibrated Young’s Elastic Modulus (n = 322)
Calibrated Carotid Distensibility Coefficient (n = 326)
Results are presented as regression coefficients [95% Confidence Interval] per standard deviation lower sex adjusted 
Calibrated Carotid Distensibility Coefficient or higher sex-adjusted Calibrated Young’s Elastic Modulus. In the crude 
model, 1SD higher calibrated carotid distensibility was associated with 0.136 [0.069; 0.202] higher attention & executive 
function score. Model 1: crude, Model 2: age, follow-up time, sex, IQ, Model 3: Model 2 + map, Model 4: Model 3 +, 
glucose metabolism status, height, weight, heart rate, MDRD, Total-HDL ratio, triglycerides, lipid modifying medications, 
hypertension, smoking, prior CVD, depression at follow-up. *4 missing in model 2, ** 19 missing in model 4
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Abstract
Background
Stiffening of the carotid and femoral arteries is a cardiovascular disease (CVD) risk factor. 
Advanced Glycation End Product (AGE) accumulation in the vascular wall could contribute 
to this process. AGEs have been associated with the cfPWV, which represents the mixed 
elastic and muscular aorta; however, data on solely elastic or muscular arteries is lacking. 
We, therefore, investigated the associations of skin autofluorescence and plasma AGEs 
pentosidine, CML and CEL with the carotid, femoral and brachial artery stiffness indices. 
Method
In the Maastricht Study (age 60±9 years, 45% women, 29% type 2 diabetes, n=808), tissue 
AGEs were measured by Skin Autofluorescence (SAF), while and plasma pentosidine, 
n{epsilon}(carboxymethyl)lysine(CML), n{epsilon}(carboxyethyl)lysine(CEL) were measured 
in plasma. The Young’s Elastic Modulus (YEM) of the carotid, and distensibility coefficient 
(DC) of the carotid (n=808), femoral (n=762) and brachial arteries (n=740) were measured 
by ultrasound. Linear regression analyses were used to assess the association of AGEs with 
arterial stiffness parameters, adjusted for age, sex, glucose metabolism status, MAP and/
or PP, and other CVD risk factors. Results are presented as regression coefficients [95%CI] 
per unit higher AGEs.  
Results 
SAF was associated with the carotid DC and YEM in the crude models: -2.07 [-2.70;-1.43] 
and 0.11 [0.06;0.15], but not after full adjustments: 0.41 [-0.24;1.06] and -0.03 [-0.08;0.03]. 
SAF was associated with a larger carotid lumen diameter in the crude and fully adjusted 
models: 274.6 [179.8;369.4] and 169.4 [62.2;276.6]. SAF was not associated with the 
femoral or brachial DC. Of the plasma AGEs, pentosidine was associated with the carotid 
YEM in the crude: 0.23 [0.07;0.39] and fully adjusted models: 0.19 [0.02;0.36], however, 
these associations lost significance after exclusion of stiffness outliers (±3SD).     
Conclusion
SAF and plasma AGEs pentosidine, CML and CEL were not associated with either elastic or 
muscular artery stiffness; but SAF is associated with carotid artery dilatation. 
PS_VERONICA_vs1.indd   86 09-11-18   14:23
87
NEITHER SK IN NOR PALSMA AGES ARE ASSOCIATED WITH CAROTID, FEMORAL OR BRACHIAL ARTERY ST IFFNESS
Introduction
Arterial stiffening has been shown to be an independent cardiovascular (CVD) risk factor 
in the general population [1-4], as well as in patients with type 2 diabetes (T2D) [5] and 
end stage renal disease (ESRD) [6,7]. Loss of arterial elastic function steadily progresses 
throughout old age; however, it is accelerated in T2D and ESRD patients [8,9]. A possible 
mechanism of accelerated arterial stiffening could be the formation of advanced glycation 
end-products (AGEs). AGEs are reactive compounds which are formed at an accelerated 
rate in hyperglycaemic conditions, when glucose reacts with the amino acid residues of 
proteins, lipids, or nucleic acids via the non-enzymatic Maillard process [10]. Classically, this 
involves the formation of the reversible Amadori products, which then undergo additional 
reactions, such as dehydration, fragmentation, or oxidation resulting in the formation of 
irreversible AGEs [10].
The association of AGEs with aortic stiffness, as measured by the cfPWV has been shown 
in patients with diabetes [11-14], ESRD [15], and even in the general population [16-19], 
however the association of AGEs with carotid arterial stiffness has been investigated only 
in small, selected populations, which have yielded contradicting results. While one study 
showed that pentosidine was significantly associated with carotid artery stiffness in dialysis 
patients [20]; another did not find a significant association of CML with carotid artery 
stiffness in the general population [21]. Both these studies might have also been hampered 
by the measurement of plasma AGEs, which do not always reflect tissue AGE accumulation 
accurately [22]. Skin Autofluorescence (SAF) assesses accumulation of certain AGEs in 
the skin and may therefore offer an additional estimate of tissue AGE concentrations. 
Recently, our group has indeed shown in a population-based cohort that SAF and plasma 
pentosidine are associated with both aortic stiffness and central pulse pressure (ie. a 
marker of ascending aortic stiffness) [13]. Yet, the cfPWV is unable to distinguish between 
the properties of the aortic segments from the highly elastic descending thoracic aorta to 
the increasingly muscular abdominal aortic, iliac and femoral arteries. The use of stiffness 
indices of individual arteries could add more insight to AGE-associated aortic stiffening. 
The carotid is a predominantly elastic artery, which is stiffer than the thoracic aorta, but 
which is thought to resemble the elastic properties of the abdominal aorta [23]; whereas 
the femoral and the brachial stiffness indices are indicative of muscular artery properties. 
Both the carotid and the femoral stiffness indices have been shown to predict CVD events 
independent of each-other [4], which suggests that CVD risk factors, such as AGEs may 
differentially affect elastic and muscular arteries.  
 
PS_VERONICA_vs1.indd   87 09-11-18   14:23
88
C H A P T E R 5
In order to further understand AGE-associated arterial stiffening, we investigated whether 
SAF and the plasma AGEs pentosidine, n{epsilon}-(carboxymethyl)lysine (CML), n{epsilon}-
(carboxyethyl)lysine (CEL) are associated with local stiffness indices of the carotid, femoral 
or brachial arteries in a population-based cohort study. 
Methods
Study Population
We used data from The Maastricht Study, an observational prospective population-based 
cohort focuses on the aetiology, pathophysiology, complications and comorbidities of type 
2 diabetes mellitus (T2D) and is characterized by an extensive phenotyping approach. 
Eligible for participation were all individuals aged between 40 and 75 years and living 
in the southern part of the Netherlands. Participants were recruited through mass 
media campaigns and from the municipal registries and the regional Diabetes Patient 
Registry via mailings. Recruitment was stratified according to known T2DM status, with 
an oversampling of individuals with T2DM, for reasons of efficiency. The present report 
includes cross-sectional data from the first 866 participants, who completed the baseline 
survey between November 2010 and March 2012. The examinations of each participant 
were performed within a time window of three months. The study has been approved by 
the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, 
Welfare and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave 
written informed consent. 
Arterial stiffness
Arterial stiffness was assessed non-invasively by means of vascular ultrasound and 
applanation tonometry. All measurements (approximately 45 min) were done by trained 
vascular technicians unaware of the participants’ clinical or diabetes status. Measurements 
took place in a quiet temperature-controlled room (21-23 °C) and were performed in supine 
position, after 10 min of rest. Talking or sleeping was not allowed during the examination. 
A three-lead electrocardiogram was recorded continuously during the measurements to 
facilitate automatic signal processing. In addition, brachial systolic, diastolic, and mean 
arterial pressure (MAP), as well as the heart rate were determined repeatedly with a 5-min 
interval, using an oscillometric device (Accutorr Plus, Datascope Inc., Montvale, NJ, USA), 
and the average of these measurements was calculated.
Elastic properties of the left common carotid (at least 10 mm proximal to the carotid bulb), 
right common femoral and right brachial arteries were obtained by using an ultrasound 
scanner equipped with a 7.5-MHz linear probe (MyLab 70, Esaote Europe B.V., Maastricht, 
the Netherlands). This setup enabled the measurement of diameter (D), distension (DD) 
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and intima-media thickness (IMT) as described in more detail elsewhere [24,25]. In brief, 
during the ultrasound measurements, a B-mode image based on 19 M-lines was depicted 
on screen and an online echo-tracking algorithm showed real-time anterior and posterior 
arterial wall displacements. The M-mode recordings were composed of 19 simultaneous 
recordings at a frame rate of 498 Hz. The distance between the M-line recording positions 
was 0.96 mm, thus, a total segment of 18.24 mm of each artery was covered by the scan 
plane. For offline processing, the radiofrequency signal was fed into a dedicated PC-based 
acquisition system (ART.LAB, Esaote Europe B.V. Maastricht, the Netherlands) with a 
sampling frequency of 50 MHz Data processing was performed in MatLab (version 7.5, 
Figure 1. Flow Diafram
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Mathworks, Natick, MA, USA). The distension waveforms were obtained from the radio 
frequency data with the use of a wall track algorithm [24]. Carotid IMT was defined as 
the distance of the posterior wall from the leading edge interface between lumen and 
intima to the leading edge interface between media and adventitia [25]. The median Inter-
Adventitial Diameter (IAD), Lumen Diameter (LD), distension (systolic diameter change), 
and Intime Media Thickness (IMT) of three measurements were used in the analyses. 
Combined with brachial pulse pressure (PP), these measures were used to calculate the 
following conventional stiffness indices [26]:
Distensibility Coefficient (DC) 
DC = (2∆D ∙ IAD + ∆d2) / (PP ∙ IAD2) (10-3 kpa-1)
Young’s elastic modulus (YEM) (Carotid Artery Only):
YEM = IAD / (IMT ∙ DC)  (103 kPa)
, where D is the diastolic Carotid Diameter and ∆D is the carotid distension. The DC 
represents arterial stiffness, while the YEM represents the stiffness of the arterial wall 
material at operating pressure. Please note that lower values of DC, but higher values of 
YEM reflect greater arterial stiffness. 
Lastly, the diastolic Lumen Diameter was calculated for the carotid artery as follows:
(LD) = IAD – 2 * IMT.
Local carotid pulse pressure  
Pulse pressure at the carotid artery was calculated by calibrating the systolic-diastolic 
amplitude of the carotid artery tonometry waveform (sys-dias)tono to pressure, assuming 
a constant difference between mean arterial pressure (MAP) and diastolic pressure (DP) 
along the large arteries: PPcar = (sys-dias)tono * (MAP-DP)brach/(mean-dias)tono.
This procedure is the same as those described by Kelly and Fitchett. [27] and Van Bortel 
et al. [28], except that the MAP and DP values at the brachial artery were taken as the 
respective averages over the vascular measurements (i.e. over a 30 to 45 min period) as 
obtained with a validated commercial oscillometric device (Accutorr Plus, Datascope Inc., 
Montvale, NJ, USA). Cited procedures considered the mean-diastolic difference as obtained 
from a measured brachial artery pressure or diameter waveform.
The calibrated DC (Cal DC) and the calibrated (Cal YEM) were re-calculated for the carotid 
artery by replacing the brachial PP with the local carotid PP.
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Reproducibility
Reproducibility was assessed in 12 individuals (6 men; 60.8±6.8 years; 6 with type 2 
diabetes) who were examined by two observers at two occasions spaced one week apart. 
The intra- and inter-observer intra-class correlation coefficients were for the carotid DC 
0.85 and 0.73, for the YEM 0.72 and 0.71 and for the femoral DC 0.49 and 0.32, respectively. 
 
Skin Autofluorescence (SAF)
All participants were asked to refrain from smoking and caffeine at least 3 hours before 
the measurements. A light meal (breakfast or lunch), low in fat content, was allowed. 
SAF was measured with the AGE Reader (DiagnOptics Technologies BV, Groningen, The 
Netherlands). The AGE reader is a desktop device that uses the characteristic fluorescent 
properties of certain AGEs to estimate the level of AGE accumulation in the skin. Technical 
details of this non-invasive method have been described more extensively elsewhere [29]. 
In short, the AGE Reader illuminates a skin surface of 4 cm2 guarded against surrounding 
light, with an excitation wavelength range of 300 to 420 nm, with a peak excitation of 
370 nm. SAF was calculated as the ratio between the emission light from the skin in the 
wavelength range of 420 to 600 nm (fluorescence) and excitation light that is reflected by 
the skin (300–420 nm), multiplied by 100 and expressed in arbitrary units. Participants 
were asked not to use any sunscreen or self-browning creams on their lower arms within 
2 days before the measurement. SAF was measured at room temperature in a semidark 
environment, whereas participants were at rest in a seated position. The inner side of 
the forearm ≈4 cm below the elbow fold of a participant was positioned on top of the 
device, as described by the manufacturer. The mean of 3 consecutive measurements 
was used in the analyses. Reproducibility was assessed in 14 individuals without diabetes 
mellitus (6 men; 32.2±7.1 years). The intraclass correlation coefficient of 3 intraindividual 
consecutive SAF measurements was 0.83 (95% confidence interval [CI], 0.65–0.94). SAF 
was calculated offline by automated analysis using AGE Reader software, version 2.3, and 
was observer independent. There were no significant differences between fasting and 
nonfasting measurements (mean difference=0.01 arbitrary units; P=0.73). Reproducibility 
in individuals with T2DM has been evaluated previously [29] with an overall Altman error 
percentage of 5.03% for measurements taken over a single day. Skin pigmentation is known 
to influence the measurement of SAF [30]. Therefore, in participants with dark-coloured skin 
with a reflectance of 6% to 10%, a validated reflectance-dependent correction was made 
by the software [30]. Measurements in participants with dark-coloured skin and a mean 
reflectance below 6% are considered unreliable and are therefore not used to calculate 
SAF by the software. Therefore, these participants were automatically excluded (n=1). 
Additionally, a single SAF value above 10 arbitrary units was considered as unreliable; these 
individual measurements (n=3) were manually excluded, and the mean of the remaining 2 
measurements was used in analyses.
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Analysis of Protein-Bound AGEs and Lysine in Plasma
Plasma AGEs were measured in EDTA samples obtained from fasting venous blood, which 
were stored at −80 °C until analysis. Protein-bound pentosidine was quantified using high-
performance liquid chromatography with fluorescence detection, as described in detail 
elsewhere [31]. Intra- and interassay coefficients of variation, as analysed in this study, 
were 6.5% and 7.8% for pentosidine, respectively. Protein-bound Nε-(carboxymethyl)lysine 
(CML) and Nε-(carboxyethyl)lysine (CEL) and lysine were quantified using ultra-performance 
liquid chromatography tandem mass-spectrometry [32]. Intra- and inter assay coefficients 
of variation were 4.5% and 6.7% for CML, 6.2% and 10.3% for CEL, and 5.0% and 5.3% 
for lysine. Concentrations of protein-bound pentosidine, CML, and CEL were adjusted for 
levels of lysine and expressed as nmol/mmol lysine.
Covariates 
Height, weight and body mass index (BMI) were measured as previously described [33]. 
Smoking and prior CVD were assessed by means of web-based questionnaires. Smoking was 
divided into three categories: never, former and current smoking. Prior CVD was defined 
as a history of myocardial infarction, stroke, or vascular surgery (including angioplasty) of 
coronary, carotid, abdominal aortic, or peripheral arteries based on the Rose questionnaire 
[34]. The use of blood-pressure and glucose lowering, as well as, lipid modifying medication 
was inventoried during a medication interview as described previously [33]. Office blood 
pressure was calculated as the average of at least three blood pressure readings (Omron 
705IT, Japan) performed after a minimum of 10 min of seated rest. Hypertension was 
defined as an office systolic blood pressure > 140 mmHg or as an office diastolic blood 
pressure > 90 mmHg and/or the use of blood pressure lowering medication. To assess 
glucose metabolism status, all participants (except those who used insulin) underwent 
a standardized 2-hour 75-g oral glucose tolerance test after an overnight fast. For safety 
reasons, participants with a fasting glucose level above 11.0 mmol/L, as determined by a 
finger prick, did not undergo the oral glucose tolerance test. For these individuals, fasting 
glucose level and information about diabetes medication use were used to assess glucose 
metabolism status. Glucose metabolism status was defined according to the World Health 
Organization 2006 criteria as normal glucose metabolism (NGM), prediabetes, and T2DM 
[35]. Serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, 
and triglycerides were measured using an automatic analyser (Beckman Synchron LX20, 
Beckman Coulter Inc., Brea, USA). Glomerular Filtration Rate (GFR) was estimated with the 
CKD-EPI equation based on the combination of serum creatinine and serum cystatin C [36]. 
Albuminuria was based on the average of one or preferably two 24-h urine collections and 
was defined as an urinary albumin excretion ≥30 mg/24 h. 
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Statistical analyses
All analyses were performed with IBM SPSS Statistics Version 22.0 (IBM Corp., Armonk, NY, 
USA). Characteristics of the study population were compared according to Carotid YEM 
tertiles by means of an ANOVA test for normally distributed continuous variables, and by 
means of a linear-by linear chi-squared test for dichotomous or ordinal variables. Continuous 
variables with a skewed distribution were log10-transformed. A two-tailed P value of less 
than 0.05 was considered statistically significant. 
Firstly, we assessed the associations of AGEs with the carotid YEM and the DC of all 
arteries by means of linear regression analyses. The models were adjusted for possible 
confounders as follows: model 1) crude, model 2) adjusted for age, sex, glucose metabolism 
status (GMS), model 3) additionally adjusted for mean arterial pressure (MAP), model 4) 
additionally adjusted for heart rate, height, weight, smoking, lipid-modifying and blood-
pressure-lowering medication, triglycerides, total to HDL cholesterol ratio, prior CVD, eGFR 
and albuminuria. (Note that lower values of Carotid DC but higher values of YEM reflect 
greater arterial stiffness.)
Secondly, we analysed the association of AGEs with the arterial distension, which is an 
indirect measure of arterial stiffness. These models were additionally adjusted for the 
diastolic arterial diameter and PP as follows: model 1) adjusted for the diastolic arterial 
diameter, model 2) additionally adjusted for age, sex, GMS, model 3) additionally adjusted 
for mean arterial pressure (MAP), model 4) additionally adjusted for heart rate, height, 
weight, smoking, lipid modifying and blood pressure lowering medication, triglycerides, 
total to HDL cholesterol ratio, prior CVD, eGFR and albuminuria, model 5) additionally 
adjusted for PP. 
Thirdly, the associations of AGEs with arterial stiffness elements: the arterial IAD, the 
carotid IMT and the carotid lumen diameter was assessed by means of linear regression 
analyses, according to the models described above.
 
Due to its skewed distribution pentosidine was log10-transformed. Also, the observed 
associations of pentosidine with all outcome measures were not completely linear, therefore 
it was introduced in the regression analyses as both a continuous and as categorial variable 
(divided in tertiles: the lowest pentosidine tertile was used as the reference category). All 
other AGEs were introduced as continuous variables.
  
Finally, in order to account for the oversampling of T2D, we introduced interaction terms 
for GMS in all mode, however none of these were statistically significant (p > 0.10). Also, 
the stiffness of the carotid and femoral arteries increases more rapidly with age in women 
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than in men [37,38]; thus, suggesting that the associations of AGEs with local stiffness 
indices could differ according to sex. We, therefore added interaction terms for sex in the 
third model, but none were statistically significant (p > 0.10).  
Results 
Carotid artery stiffness measurements were available in 825 out of 866 participants. Of 
these, data on SAF and plasma AGES were available in respectively n=808 and n=796. Data 
on co-variates, such as prior CVD, smoking status and alcohol use were missing in n=50 
and n=64, respectively (see Flow Diagram). Missing carotid artery stiffness, AGEs and co-
variates data were mostly due to logistic reasons or technical failure. Femoral and brachial 
artery stiffness indices were computed in 778 and 754 individuals respectively, due to the 
lower quality of the ultrasound recordings as compared to carotid artery.
Table 1 shows the characteristics of the study population according to tertiles of Carotid 
YEM. Individuals with a higher YEM (i.e. stiffer arteries) were older and taller than the 
individuals with more elastic arteries. They also had a more adverse CVD risk profile with 
a greater weight and BMI, more T2D, higher triglyceride levels, more hypertension, higher 
eGFR, and higher prevalence of albuminuria, and use of blood-pressure-lowering, lipid-
modifying and glucose-lowering medication, in addition to a higher systolic and diastolic 
blood pressure and a higher heart rate during arterial stiffness measurements.
SAF and carotid artery stiffness and its elements
Higher SAF was associated with a higher carotid YEM and a lower carotid DC, unstandardized 
regression coefficients [95%CI] were 0.11(10^3 kPa) [0.06;0.15] and: -2.07(10^-3 kPa) 
[-2.70; -1.43], in the crude models; however, the associations were attenuated and were 
no longer significant after adjustment for age, sex and GMS: -0.01 [-0.06;0.04] and 0.21 
[-0.47;0.86], respectively. Additional adjustments for MAP and other CVD risk factors did 
not alter the associations (Models 3 and 4, Table 2). 
Higher SAF was significantly associated with a greater carotid IAD in the crude models, 
378.9µm [271.0;486.9], in the fully adjusted models 163.3 [42.2;284.4], as well as after 
additional adjustment for the brachial PP (Table 3) or the carotid PP (Supplemental Table 
4). Similarly, higher SAF was associated with a higher carotid Lumen Diameter in the crude: 
274.6µm [179.8;369.4] and in the fully adjusted models: 170.2 [63.2;277.1], as well as after 
additional adjustment for the brachial PP (Table 3) and the carotid PP (Supplemental Table 
4). SAF was not significantly associated with either the carotid distension, the carotid IMT, 
the brachial PP or the carotid PP in the fully adjusted models (Table 3). 
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Demographics
Age, years
Female sex, %
Cardio-metabolic risk factors 
Smoking, never/former/current, %
Height, m
Weight, kg
BMI, kg/m2
Glucose metabolism status, NGM/IGM/DM2, %
Total cholesterol, mmol/L
HDL cholesterol, mmol/L
LDL cholesterol, mmol/L
Total to HDL cholesterol ratio
Triglycerides, mmol/L
Systolic blood pressure, mmHg 
Diastolic blood pressure, mmHg
Mean arterial pressure, mmHg
Heart rate beats per minute
Hypertension, %
Prior CVD, %
eGFR, mL/min per 1.73 m2
Microalbuminuria, %
Medication use 
Anti-hypertensive drugs, %
Lipid modifying drugs, %
Glucose lowering drugs, %
Stiffness related indices
Carotid Artery Distensibility Coefficient (DC), 
10^-3/kPa  
Carotid Artery Distensibility, um
Carotid Artery Inter-Adventitia Diameter, um 
Carotid Artery Lumen Diameter, um
Carotid Artery Intima Media Thickness (IMT), um 
Brachial Pulse Pressure, mmHg
Calibrated Carotid Artery Pulse Pressure, mmHg 
Advanced Glycation End Products 
Pentosidine, nmol/mmol
CML, nmol/mmol
CEL, nmol/mmol
Skin Auto-Florescence (SAF), AU 
1st tertile
(n = 275)
55.8 ± 8.7
45.8
32.1/ 46.4/ 21.5
172.7 ± 8.2
78.2 ± 15.2
26.2 ± 4.6
64.0/15.6/20.4
5.2 ± 1.1
1.4 ± 0.5
3.3 ± 0.9
4.1 ± 1.3
1.1 [0.8 – 1.6]
120.9 ± 12.7
73.2 ± 6.6
92.1 ± 9.0
61.0 ± 7.7
40.7
14.8
91.3 ± 15.4
5.9
30.2
28.4
16.4
18.7 ± 4.0
416 [357 – 484]
7625.3 ± 805.7
5894.0 ± 666.7
865.7 ± 155.7
47.6 ± 9.0
45.6 ± 12.1 
0.46 [0.38 – 0.54]
75.5 ± 15.8
33.3 ± 9.9
2.6 ± 0.5 
2nd tertile
(n = 275)
60.5 ± 8.1
44.7
29.7/ 56.5/13.8
171.9 ± 9.6
81.9 ± 15.5
27.6 ± 4.2
54.5/14.9/30.5
5.3 ± 1.2
1.3 ± 0.4
3.3 ± 1.1
4.2 ± 1.2
1.2 [0.9 – 1.8]
130.2 ± 12.4 
77.7 ± 6.6
99.0 ± 9.0
63.6 ± 8.7
62.2
20.2
87.7 ± 15.1
7.3
40.7
38.9
24.7
13.1 ± 2.2
338 [284 - 401]
7860.8 ± 892.4
6154.5 ± 752.4
853.2 ± 144.7
52.5 ± 9.3
51.9 ± 13.4
0.47 [0.39 – 0.56]
74.9 ± 14.5
34.4 ± 9.8
2.7 ± 0.6
3rd tertile
(n = 275) 
63.5 ± 6.7
45.8
30.2/56.0/13.8
170.4 ± 8.5
81.8 ± 15.0
28.2 ± 4.5
45.5/17.5/37.1
5.2 ± 1.3
1.3 ± 0.4
3.2 ± 1.1
4.3 ± 1.2
1.4 [1.0 – 2.0]
135.6 ± 14.6
79.1 ± 8.0
102.3 ± 10.4
65.6 ± 9.3
71.2
20.0
84.8 ± 14.7
10.8
47.6
44.0
27.6 
8.9 ± 2.2
254 [209 - 304]
8012.2 ± 834.8
6333.4 ± 748.1
839.4 ± 155.1
56.5 ± 11.0
56.3 ± 15.0
0.48 [0.38 – 0.60]
73.0 ± 13.9
34.7 ± 11.0
2.8 ± 0.5
p-linear
< 0.001
1.00
0.310
0.01
0.01
< 0.001
< 0.001
0.823
0.093
0.811
0.449
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.121
< 0.001
0..037
< 0.001
< 0.001
0.002
< 0.001
< 0.001
< 0.001
< 0.001
0.129
< 0.001
< 0.001
0.204
0.127
0.243
< 0.001
Table 1: Baseline Characteristics according to tertiles of the Carotid Young Elastic Modulus (YEM) (n = 825)
Results are presented as %, mean ± standard deviation or median [interquartile range] 
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Table 2. The Association of plasma Advanced Glycation End Products (AGEs) and Skin Autofluorescence (SAF) 
with carotid, femoral and brachial stiffness indices
Pentosidine
CEL
 
CML
 
Skin Autofluor-
escence (SAF)
Model 1
Model 2
Model 3
Model 4*
Model 1
Model 2
Model 3
Model 4*
Model 1
Model 2
Model 3
Model 4*
Model 1
Model 2
Model 3
Model 4**
-2.75 (-4.85; -0.54)
-0.27 (-2.21; 1.66)
0.05 (-1.70; 1.79)
-0.52 (-2.46; 1.43)
-0.02 (0.05; 0.02)
-0.01 (-0.04; 0.02)
-0.01 (-0.04; 0.01)
0.01 (-0.02; 0.03)
0.02 (-0.01; 0.04)
0.02 (-0.00; 0.04)
0.02 (-0.002; 0.04)
0.003 (-0.02; 0.02)
-2.07 (-2.70; -1.43)
0.21 (-0.47; 0.86)
0.14 (-0.45; 0.72)
0.41 (-0.24; 1.06)
0.23 (0.07; 0.39)
0.14 (-0.02; 0.29)
0.12 (-0.03; 0.27)
0.19 (0.02; 0.36)
0.002 (0.00; 0.005)
0.002 (0.00; 0.004)
0.002 (0.00; 0.004)
0.001 (-0.002; 0.003)
-0.001 (-0.003; 0.001)
-0.001 (-0.002; 0.001)
-0.001 (-0.002; 0.001)
0.001 (-0.001; 0.003)
0.11 (0.06; 0.15)
-0.01 (-0.06; 0.04)
-0.01 (-0.06; 0.04)
-0.03 (-0.08; 0.03)
-1.93 (-5.70; 1.84)
-2.53 (-6.42; 1.35)
-2.09 (-5.82; 1.65)
-2.65 (-6.91; 1.61)
-0.06 (-0.12; -0.00)
-0.06 (-0.11; 0.02)
-0.06 (-0.12; -0.01)
-0.06 (-0.12; -0.00)
0.02 (-0.03; 0.06)
0.01 (-0.03; 0.05)
0.01 (-0.03; 0.05)
-0.001 (-0.05; 0.04)
-0.75 (-1.85; 0.36)
-0.84 (-2.11; 0.44)
-0.89 (-2.11; 0.34)
-0.40 (-1.80; 1.00)
-0.84 (-2.56; 0.88)
-1.12 (-2.90; 0.65)
-1.05 (-2.77; 0.68)
-1.72 (-3.77; 0.32)
-0.03 (-0.06; -0.01)
-0.03 (-0.05; 0.00)
-0.03 (-0.05; -0.02)
-0.03 (-0.05; 0.002)
-0.01 (-0.02; 0.01)
-0.01 (-0.03; 0.01)
-0.01 (-0.03; 0.01)
-0.01 (-0.03; 0.01)
-0.24 (-0.72; 0.23)
-0.30 (-0.84; 0.24)
-0.33 (-0.86; 0.20)
-0.40 (-1.01; 0.21)
Plasma AGEs  Models  Carotid Artery  Femoral Artery Brachial Artery
   (N = 808)   (N = 762) (N = 740)
  Distensibility   Young Elastic Distensibility Distensibility
  coefficient (DC)  Modulus (YEM) Coefficient (DC) Coefficient (DC)
Tissue AGEs   Models  Carotid Artery  Femoral Artery Brachial Artery
   (N = 796)   (N = 754) (N = 729)
  Distensibility   Young Elastic Distensibility Distensibility
  coefficient (DC)  Modulus (YEM) Coefficient (DC) Coefficient (DC)
* 50/44/45 additional individuals excluded due to missing data on co-variates for the carotid/femoral/ brachial stiffness 
models respectively
** 64/57/56 additional individuals excluded due to missing data on co-variates for the carotid/femoral/ brachial stiffness 
models respectively
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Table 3. The Association of plasma Advanced Glycation End Products (AGEs) and Skin Autofluorescence 
(SAF) with the carotid Inter-Adventitia Diameter (IAD), Lumen Diameter (LD), Distension (ΔD), Intima Media 
Thickness (IMT) and brachial and calibrated carotid Pulse Pressure (PP)
Plasma AGEs 
Pentosidine
CEL 
CML
Tissue AGEs 
Skin Auto-flore-
scence (SAF)
Models
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Models 
Model 1
Model 2
Model 3
Model 4**
Model 4 + 
brachial PP
Carotid IAD 
(n = 808)
428.1 
(52.1; 803.9)
186.5 
(-142.6; 515.7)
165.1 
(-159.5; 489.7)
333.5 
(-30.9; 698.0)
306.4 
(-57.0; 670.0)
0.12 
(-5.68; 5.93)
-0.89 
(-5.86; 4.09)
-0.84 
(-5.74; 4.07)
-2.83 
(-7.99; 2.34)
-3.31 
(-8.46; 1.84)
-4.18 
(-8.20; -0.17)
-1.74 
(-5.27; 1.80)
-1.78 
(-5.26; 1.71)
2.26 
(-1.62; 6.14)
2.09 
(-1.77; 5.95)
Carotid IAD 
(n = 797)
378.9 
(271.0; 486.9)
148.8 
(40.4; 257.2)
153.6 
(46.3; 260.6)
163.3 
(42.2; 284.4)
155.7 
(28.5; 262.2)
Carotid ΔD† 
(n = 808) 
-44.7 
(93.5; 4.01)
-5.52 
(-53.1; 42.1)
-4.45 
(-51.9; 43.1)
-16.9
 (-69.6; 35.8)
-27.9 
(-77.5; 21.8)
0.00 
(-0.75; 0.75)
-0.02 
(-0.74; 0.70)
-0.02 
(-0.74; 0.70)
0.46 
(-0.28; 1.21)
0.24 
(-0.47; 0.94)
0.20 
(-0.32; 0.72)
0.39 
(-0.12; 0.91)
0.40 
(-0.11; 0.91)
0.13 
(-0.43; 0.69)
0.06 
(-0.46; 0.59)
Carotid ΔD† 
(n = 797) 
-20.9 
(-35.7; -6.1)
10.2 
(-5.7; 26.0)
9.5 
(-6.3; 25.3)
14.2 
(-3.4; 31.9)
10.3 
(-6.3; 27.0)
Carotid IMT 
(n = 808)
89.4 
(23.8; 156.0)
34.5 
(-29.5; 98.4)
32.3 
(-31.5; 96.1)
26.5 
(-46.2; 99.2)
16.6 
(-54.9; 88.1)
-1.01 
(-2.04; 0.02)
-1.14 
(-2.10; -0.17)
-1.13 
(-2.09; -0.17)
-1.01 
(-1.98; 0.08)
-1.12 
(-2.13; -0.11)
0.40 
(-0.31; 1.11)
0.52
(-0.16; 1.21)
0.52 
(-0.17; 1.20)
0.43 
(-0.34; 1.21)
0.37 
(-0.39; 1.13)
Carotid IMT 
(n = 797)
52.2 
(32.9; 71.5)
3.31 
(-17.7; 24.3)
3.80 
(-17.1; 24.8)
-3.43 
(-27.5; 20.7)
-6.8 
(-30.6; 16.9)
Carotid LD 
(n = 808) 
249.2 
(-76.8; 575.1)
117.6 
(-173.2; 408.4)
100.5 
(-187.1; 388.1)
280.5
(-41.0; 602.1)
273.2 
(-48.8; 592.2)
2.15 
(-2.87; 7.17)
1.39 
(-3.01; 5.78)
1.43 
(-2.92; 5.77)
-0.93 
(-5.49; 3.63)
-1.07 
(-5.64; 3.50)
-4.98 
(-8.45; -1.51)
-2.78 
(-5.90; 0.34)
-2.82 
(-5.90; 0.27)
1.40 
(-2.03; 4.82)
1.35 
(-2.08; 4.77)
Carotid LD
(n = 796)
274.6 
(179.8; 369.4)
142.2 
(46.2; 238.2)
146.0 
(51.0; 241.1)
170.2 
(63.2; 277.1)
169.4 
(62.2; 276.6)
Brachial PP
(n = 808)
6.12 
(1.58; 10.75)
3.71 
(-0.60; 8.01)
2.62 
(-0.61; 5.84)
2.58 
(-1.07; 6.24)
-
0.05 
(-0.02; 0.12)
0.02 
(-0.04; 0.09)
0.03 
(-0.02; 0.08)
0.04 
(-0.01; 0.10)
-
-0.00 
(-0.05; 0.05)
0.02 
(-0.03; 0.07)
0.02 
(-0.02; 0.05)
0.02 
(-0.02; 0.06)
-
Brachial PP
(n = 796)
4.38 
(3.07; 5.70)
0.91 
(-0.51; 2.33)
1.16 
(0.09; 2.27)
0.94 
(-0.28; 2.15)
-
Carotid PP 
(n = 792)
7.01
(0.70; 13.3)
1.46
(-4.49; 7.39)
0.38
(-4.15; 4.91)
-2.04
(-6.95; 2.86)
-
0.03
(-0.08; 0.12)
-0.003
(-0.09; 0.08)
-0.01
(-0.07; 0.06)
0.04
(-0.02; 0.11)
-
0.02
(-0.05; 0.08)
0.03
(-0.04; 0.09)
0.02
(-0.03; 0.07)
-0.01
(-0.06; 0.04)
-
Carotid PP
(n =782)
5.84
(4.04; 7.65)
0.67
(-1.25; 2.59)
1.02
(-0.45; 2.48)
0.75
(-0.83; 2.33)
-
*50 additional individuals excluded due to missing data on co-variates     **64 additional individuals excluded due to 
missing data on co-variates     † Model 1 additionally adjusted for the Carotid IAD
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Plasma AGEs and carotid artery stiffness and its elements
When analysed as a continuous variable, higher pentosidine concentrations were 
significantly associated with a higher carotid YEM in the crude model: 0.23 (10^3 kPa) 
[0.07;0.39]. The association was attenuated but remained borderline significant after 
adjustment for age, sex and GMS: 0.14 [-0.02;0.29]. After additional adjustments for 
MAP and other CVD risk factors, the regression coefficient was enhanced and became 
significant: 0.19 [0.02;0.36]. This was especially due to the addition of heart rate, weight 
and triglycerides in the final model. Similarly, when pentosidine was analysed in tertiles, 
the highest pentosidine tertile was significantly associated with a higher carotid YEM, 
in the crude: 0.09 [0.03;0.15] and in the fully adjusted models: 0.09 [0.03;0.15]. Higher 
pentosidine concentrations were associated with a lower carotid DC in the crude model 
-2.75 [-4.85; -0.54], but not in the fully adjusted models (Table 2). Similarly, neither of 
the pentosidine tertiles were significantly associated with a lower carotid DC in any of the 
models (Supplemental Table 1a). 
The highest pentosidine tertile was significantly associated with a lower carotid distension 
after adjustment for the carotid IAD: -23.5µm [-42.3; -4.7] (Model 1, Supplemental Table 
1b). The association was attenuated in the fully adjusted models: -18.2 [-38.1;1.7], but 
became significant when the fully adjusted model was additionally adjusted for the brachial 
PP: -19.4 [-38.1; -0.61], but not when additionally adjusted for the carotid PP: -15.8 [-35.0; 
3.4]. 
Plasma CEL and CML were not associated with either the carotid DC, the carotid YEM or 
their elements in the fully adjusted models (Table 2). Although CEL was not significantly 
associated with the Carotid IMT in either the crude: -1.01µm [-2.04; 0.02], or the fully 
adjusted models: -1.01 [-1.98; 0.08]; the association became significant after the additional 
adjustment for the brachial PP: -1.12 [-2.13; -0.11], or the carotid PP: -1.10 [-2.13; -0.08]. 
Neither of the plasma AGEs were associated with the brachial PP or the carotid PP in any 
of the models.  
AGEs and muscular artery stiffness and their elements
SAF was not associated with either the femoral DC, the brachial DC or any of their elements 
in the fully adjusted models (Tables 2 and 4).  Higher pentosidine concentrations were 
also not associated with either the brachial DC or the femoral DC, when pentosidine 
was analysed as a continuous variable. The highest pentosidine tertile was, however, 
borderline significantly associated with a lower brachial DC in the crude model: -0.64 
(10^-3 kPa) [-1.29;0.02]. This association was enhanced and became significant after 
adjustment for age, sex and GMS: -0.77 [-1.45;-0.08] and additional adjustments for 
MAP and CVD risk factors did not alter the association (Supplemental Table 2). Higher 
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pentosidine concentrations were also significantly associated with a greater brachial IAD 
in the crude 402.3 µm [34.8;769.7] and fully adjusted models 425.3 [92.0;758.7] as well as 
after additional adjustment for the brachial PP: 448.7 [116.8;780.6] (Table 4). Similarly, the 
highest pentosidine tertile was significantly associated with a higher brachial IAD, in all the 
models (Supplemental Table 2).
Table 4. The Association of plasma Advanced Glycation End Products (AGEs) and Skin Autofluorescence (SAF) 
with the Inter-Adventitia Diameter (IAD) and Distension (ΔD) of the femoral and brachial arteries
 
Pentosidine
CEL
 
CML
Tissue AGEs 
Skin Autofluo-
rescence (SAF)
Models
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Models 
Model 1
Model 2
Model 3
Model 4**
Model 4 + 
brachial PP
Femoral IAD 
(n = 762)
864.7 [162.6; 1566.8]
582.4 [-77.8; 1242.6]
560.5 [-98.2; 1219.1]
587.1 [-132.2; 1306.4]
649.1 [-61.5; 1359.6]
-6.0 [-16.6; 4.6]
-1.6 [-11.4; 8.2]
-1.3 [-11.0; 8.5]
1.6 [-8.4; 11.6]
3.1 [-6.8; 13.0]
15.1 [7.8; 22.4]
13.7 [6.8; 20.6]
13.6 [6.7; 20.5]
13.7 [6.2; 21.2]
13.9 [6.6; 21.3]
Femoral IAD 
(n = 754)
-336.1 [-542.6; -129.6]
-366.1 [-711.9; -138.5]
-263.9 [-578.6; -149.2]
-223.6 [-458.5; 11.3]
-197.3 [-430.1; 35.4]
Femoral ΔD† 
(n = 762) 
1.5 [-102.5; 105.6]
-34.5 [-140.7; 71.7]
-30.9 [-136.7; 74.9]
-37.7 [-157.6; 82.2]
-41.4 [-161.4; 78.6]
-1.4 [-2.9; 0.2]
-1.2 [-2.8; 0.3]
-1.3 [-2.8; 0.3]
-1.2 [-2.8; 0.5]
-1.2 [-2.9; 0.4]
0.6 [-0.5; 1.7]
0.6 [-0.5; 1.7]
0.6 [-0.5; 1.7]
0.5 [-0.8; 1.8]
0.5 [-0.8; 1.7]
Femoral ΔD† 
(n = 754) 
-1.1 [-31.8; 29.5]
-30.4 [-65.4; 4.5]
-30.5 [-65.2; 4.3]
-17.8 [-57.2; 21.6]
-18.8 [-58.3; 20.6]
Brachial IAD 
(n = 740)
402.3 [34.8; 769.7]
307.1 [14.6; 600.0]
305.8 [70.5; 529.3]
425.3 [92.0; 758.7]
448.7 [116.8; 780.6]
5.0 [-0.6; 10.7]
4.2 [-0.2; 8.6]
4.3 [-0.1; 8.6]
2.5 [-2.2; 7.1]
3.0 [-1.6; 7.6]
-2.7 [-6.5; 1.2]
-0.1 [-3.1; 3.0]
-0.1 [-3.2; 3.0]
2.5 [-0.9; 5.9]
2.6 [-0.8; 6.1]
Brachial IAD 
(n = 728)
165.9 [59.7; 272.0]
37.5 [-57.1; 132.0]
38.1 [-56.6; 132.7]
85.0 [-21.6; 191.6]
92.2 [-14.1; 198.5]
Brachial ΔD¶
(n = 740) 
-1.5 [-27.8; 24.7
-7.3 [-34.2; 19.5]
-7.2 [-34.0; 19.7]
-15.6 [-46.8; 15.7]
-19.9 [-50.8; 10.9]
-0.25 [-0.65; 0.2]
-0.25 [-0.66; 0.2]
-0.26 [-0.66; 0.2]
-0.28 [-0.71; 0.2]
-0.36 [-0.78; 0.1]
-0.13 [-0.41; 0.14]
-0.12 [-0.40; 0.16]
-0.12 [-0.40; 0.16]
-0.14 [-0.46; 0.18]
-0.17 [-0.48; 0.15]
Brachial ΔD¶ 
(n = 728) 
6.1 [-1.2; 13.4]
-0.4 [-8.7; 7.8]
-0.5 [-8.8; 7.8]
-2.8 [-12.3; 6.7]
-4.2 [-13.5; 5.2]
*44/45 additional individuals excluded due to missing data on co-variates for the carotid/femoral/ brachial stiffness 
models respectively
**57/56 additional individuals excluded due to missing data on co-variates for the carotid/femoral/ brachial stiffness 
models respectively
† Model 1 additionally adjusted for the Femoral IAD
¶ Model 1 additionally adjusted for the Brachial IAD
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Higher CEL concentrations were significantly associated with a lower Femoral DC in the 
crude -0.06 (10^-3 kPa) [-0.12; -0.00] as well as in the fully adjusted models: -0.06 [-0.12; 
-0.00]. Similarly, CEL was significantly associated with a lower brachial DC in the crude -0.03 
(10^-3 kPa) [-0.06; -0.01], but not in the fully adjusted models, even though the size of 
the regression coefficient remained unaltered: -0.03 [-0.05; 0.002] (Table 2). CEL was not 
associated with any of the femoral DC and brachial DC components, or with the brachial PP 
in either the crude, or the fully adjusted models (Table 4).
CML was not associated with either the femoral DC, or the brachial DC in any of the statistical 
models (Table 2). Higher CML concentrations were, however, significantly associated with 
a greater femoral IAD in the crude:15.1 µm [7.8;22.4], in the fully adjusted models: 13.7 
[6.2;21.2], as well as after additional adjustment for the brachial PP: 13.9 [6.6;21.3] (Table 
4). 
Additional Analyses 
Firstly, carotid artery stiffness indices were replaced by calibrated carotid artery stiffness 
indices (n = 791). When pentosidine was used as a continuous variable, the association 
of plasma pentosidine with the calibrated carotid YEM was attenuated and was no longer 
significant in the fully adjusted models 0.08 (10^3 kPa) [-0.10;0.25] (Supplemental Table 1). 
The association of the third pentosidine tertile with the calibrated carotid YEM remained, 
however, significant in the fully adjusted models: 0.07 (10^3 kPa) [0.01;0.14].
Secondly, we re-evaluated all significant associations after the exclusion of individuals with 
extreme values of arterial stiffness and their formula elements (± 3SD). When carotid IAD 
outliers were removed (n = 8), the association with SAF was severely attenuated and was 
no longer significant. When the carotid Lumen Diameter outliers were removed (n = 6), the 
association with SAF remained significant: 126.3 µm [28.6;223.9]. When YEM outliers (n = 
10) were removed, the association with plasma pentosidine was attenuated and was no 
longer significant: 0.06 (10^3 kPa) [-0.07;0.19]. The association of the highest pentosidine 
tertile with the carotid YEM was also attenuated but remained borderline significant: 
0.04(10^3 kPa) [-0.00;0.09]. After the exclusion of carotid distension outliers (n = 7), the 
association with the third pentosidine tertile was attenuated but remained borderline 
significant: -17.0µm [-35.9;2.0]. When carotid IMT outliers (N = 11) were removed, the 
association with CEL was no longer significant: 0.56µm [-1.51;0.38]. After the exclusion 
of femoral DC outliers (n = 8), the association with CEL was no longer significant: -0.04 
[-0.09;0.01]. When femoral IAD outliers (n = 3) were excluded, the association with the 
CML was unaltered. After the removal of brachial DC (n = 10) outliers, the association with 
the highest pentosidine tertile was unaltered. Similarly, when brachial IAD outliers were 
excluded (n = 3), the associations with both the continuous pentosidine variable and the 
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third pentosidine tertile remained significant. Lastly, when plasma AGEs or SAF outliers 
were removed, none of the associations were altered. 
Discussion 
This study had four main findings. Firstly, SAF was not associated with any of the carotid, 
femoral or brachial stiffness indices, but was robustly associated with a greater lumen 
diameter. Secondly, higher pentosidine concentrations were significantly associated with 
a higher carotid YEM, a lower carotid distension and a lower brachial DC; however, these 
associations were (partly) dependent on outliers. Lastly, plasma pentosidine and CML were 
robustly associated with a greater brachial IAD and a greater femoral IAD, respectively. We 
did not find any evidence that these associations differed according to GMS status. 
We have shown that tissue AGEs, as measured by SAF, are not associated with the carotid, 
femoral or brachial artery stiffness. Of the plasma AGEs, only the cross-linking AGE 
pentosidine was associated with the carotid YEM, the carotid distension and the brachial 
DC. Most of these results were no longer significant after the removal of outliers, therefore, 
we cannot exclude that these findings are spurious. Most [11-16], but not all [39] previous 
studies have shown a significant association of SAF and pentosidine with aortic stiffness, as 
measured by the carotid-femoral Pulse Wave Velocity (cfPWV) in patients with diabetes [11-
13], ESRD [15], and even in the general population [15,16]. To date, only one previous study 
investigated the association of plasma pentosidine with carotid stiffness in dialysis patients 
[20] and reported a significant association with the carotid DC. Possibly the association 
of AGEs with carotid stiffness is stronger in high carbonyl environments, such as in ESRD 
patients than in individuals from the general population; therefore, we may have lacked 
the power to identify any associations. Nonetheless, our group has recently shown within 
this same study population that SAF and plasma pentosidine are significantly associated 
with a higher cfPWV as well as a higher central (ascending aortic) pulse pressure [13]. The 
lack of (consistent) associations with local stiffness indices in this study suggests that the 
aorta may be more prone to AGE-associated stiffening than any other artery. Although both 
the carotid and the aorta are considered elastic vessels, the carotid artery structurally and 
functionally resembles the stiffer abdominal aorta and thus may be less prone to ageing 
and stiffening than the more elastic thoracic aorta [40]. Indeed, the aorta has been shown 
to stiffen twice as fast as the carotid artery in T2D patients [23]. Muscular arteries seem 
less affected by stiffening factors, such as old age and hypertension than the carotid artery 
[41,42], and may, therefore, be least affected by AGE accumulation. Indeed, the association 
of pentosidine with the brachial DC was smaller than the association with the carotid YEM.
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In additional analyses, SAF was robustly associated with a wider carotid lumen diameter; 
but not with any of the other stiffness components. We also found a significant association 
of SAF with a larger carotid Inter-Adventitial Diameter (IAD), which was largely dependent 
on outliers and was, therefore considered spurious. Carotid artery dilation has been 
described in normal ageing [43], as well as in patients with ESRD [44,45] and T2D [46], 
though in most cases the IAD widens to a greater extent than the lumen diameter. These 
changes are thought to reflect a hypertrophic outward remodelling response of the 
carotid artery to either a rise in the distending pressure [46] or to flow obstruction by 
atherosclerotic plaque [47]. Our associations were independent, however of hemodynamic 
distending factors, such as PP, MAP and use of blood pressure lowering medication. Also, 
atherosclerotic associated dilation is aimed at maintaining a constant lumen diameter 
despite obstructive atherosclerotic plaque and it is achieved through IAD widening [48]; 
whereas in our study SAF was robustly associated with a widening of the lumen diameter 
but not of the IAD. Furthermore, our associations were independent of the carotid IMT and 
were also present after we excluded individuals with an IMT > 0.9 mm as well as those with 
prior CVD, therefore it is less-likely that our associations are mediated by plaque formation. 
This might suggest that tissue AGE accumulation plays an intrinsic role in carotid artery 
dilation. SAF is a non-specific measure of tissue AGE concentrations, which has been shown 
to correlate with both fluorescent (ie. pentosidine) and non-fluorescent (ie. CML, CEL) 
AGE concentrations in the skin [29], as well as in cardiovascular tissue [49]. Plasma AGE 
concentrations, however, may not reflect adequately tissue AGE levels; as they are formed 
through the glycation of plasma proteins, which are metabolized considerably faster (days 
to weeks) than the long-lived proteins of the skin or vascular tissue [22]. In our study, only 
plasma pentosidine correlated weakly, though significantly with SAF (r = 0.17, p < 0.001), 
whereas CEL and CML did not. The lack of significant associations of plasma AGEs with the 
carotid lumen diameter does not exclude therefore, that the accumulation of any, or all, of 
these AGEs contributes to carotid dilatation.  
In our study, SAF was associated carotid artery dilation, but not with a concomitant 
thickening of the arterial wall, as measured by the IMT or the IAD. This points to a defect 
in mechano-transduction, which is the feedback system that maintains circumferential 
wall stress by stimulating arterial wall thickening in response to increases in the arterial 
diameter or the PP through collagen deposition and smooth muscle cell proliferation [44]. 
Although the mechanisms of defective mechano-transduction have yet to be elucidated, 
such maladaptive IMT changes have been described previously in T2D [46] and chronic 
kidney disease [44] patients, in response to increasing PP and arterial diameter, respectively. 
This defect in arterial wall thickening could be due to use of lipid-modifying or blood-
pressure lowering medication (especially RAS inhibitors). Such medication is known for its 
anti-proliferative properties [50] and is extensively prescribed especially in high CVD risk 
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groups, such as T2D patients. Our associations were, however, independent of medication 
use. Another possible explanation would be that IMT hypertrophy occurs more readily in 
response to a higher (local) PP [46], than in response to a larger diameter [44] as carotid 
dilation allows the artery to increase its compliance and thus decrease its pulse pressure 
[51]. Nevertheless, despite these changes, elastic fibre degradation ought to ultimately lead 
arterial stiffening, as pulsatile stress is transferred to the more rigid collagen fibres in the 
arterial wall [52]. AGE formation could further augment arterial stiffening by stimulating 
the production of collagen by smooth muscle cells (SMCs) or by cross-linking with collagen, 
thus making it less susceptible to degradation [53]. Possibly, we may have captured these 
processes in their incipient phase when the carotid artery was still able to maintains its 
compliance. Alternatively, the relative thinning of the arterial wall could have also allowed 
the carotid artery to maintain its distensibility despite any stiffening. Indeed, although the 
associations were not significant, a higher SAF tended to be associated with both a higher 
DC and a lower YEM of the carotid artery in the fully adjusted models, which suggests a 
paradoxical improvement in its elastic properties with AGE accumulation.
Besides these pathophysiological considerations, the lack of significant associations of AGEs 
with local stiffness indices could be attributed to several methodological shortcomings. 
Firstly, the study sample was relatively small, therefore it may not provide adequate 
power to accurately detect any associations of AGEs with local stiffness indices. Secondly, 
individuals with T2D could have been treated more intensively with blood-pressure-
lowering and lipid-modifying medication than the remainder of the population as indicated 
by current guidelines [54]. As these medications could decrease arterial stiffness [55], 
oxidative stress [56], as well as AGEs [57] this might have attenuated any associations. 
Thirdly, measurement error of local stiffness indices could have distorted the associations. 
The calculation of local stiffness requires the use of three ultrasound measured variables, 
each with its own measurement error. Although we tried to compensate for these short 
comings by averaging data from three consecutive measurements, these errors might have 
resulted in the large number of influential outliers observed in our study. Lastly, associations 
with muscular artery stiffness indices might have further been attenuated by the relatively 
lower intra- and interobserver reproducibility of their measurement as compared to 
carotid artery measurements. Due to the high concentrations of SMCs within their walls, 
which allows short-term alterations in smooth muscle tone to influence arterial diameter 
and stiffness [58]. Even though only two individuals carried out these measurements; it is 
more likely the associations with elastic artery stiffness indices are more robust as they are 
not prone to such limitations.   
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Conclusion
This study shows that the accumulation of tissue AGEs, as measured by SAF is not associated 
with the stiffness of either the carotid, femoral or brachial arteries; but is associated with 
carotid artery dilatation. Of the plasma AGEs, higher pentosidine concentrations might 
be associated with both carotid and brachial artery stiffening, however, our results were 
largely dependent on outliers, thus additional research is required to confirm our findings. 
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Supplemental Table 1a. The association of plasma Pentosidine tertiles with carotid artery stiffness indices cali-
brated with either the brachial or the carotid pulse pressure
Plasma Pentosidine 
Models
Model 1
Model 2
Model 3
Model 4*
Plasma Pentosidine 
Models
Model 1
Model 2
Model 3
Model 4**
Carotid Distensibility Coefficient 
(DC) (n = 808)
0.15 [-0.68; 0.98]
-1.15 [-1.98; -0.31]
0.21 [-0.52; 0.95]
-0.11 [-0.86; 0.65]
-0.02 [-0.68; 0.65]
-0.04 [-0.72; 0.64]
-0.32 [-1.01; 0.37]
-0.55 [-1.29; 0.19]
Calibrated Carotid Distensibility 
Coefficient (DC) (n = 791)
0.51 (-0.56; 1.57)
-1.34 (-2.40; -0.27)
0.68 (-0.24; 1.60)
0.18 (-0.76; 1.12)
0.29 (-0.50; 1.09)
0.34 (-0.47; 1.14)
-0.06 (-0.88; 0.77)
-0.31 (-1.20; 0.57)
Carotid Young Elastic Modulus 
(YEM) (n = 808) 
-0.02 [-0.08; 0.05]
0.09 [0.03; 0.15]
-0.01 [-0.07; 0.05]
0.05 [-0.01; 0.11]
0.002 [-0.06; 0.06]
0.05 [-0.01; 0.10]
0.03 [-0.03; 0.09]
0.09 [0.03; 0.15]
Calibrated Carotid Young 
Elastic Modulus (YEM) (n = 791)
-0.02 (-0.09; 0.04)
0.10 (0.03; 0.16)
-0.02 (-0.08; 0.04)
0.04 (-0.02; 0.10)
-0.01 (-0.06; 0.05)
0.04 (-0.02; 0.09)
0.01 (-0.05; 0.07)
0.07 (0.01; 0.14)
* 50 participants excluded due to missing data on various co-variates 
** 49 participants excluded due to missing data on carotid pulse pressure
T2
T3
T2
T3
T2
T3
T2
T3
T2
T3
T2
T3
T2
T3
T2
T3
Supplemental Table 1b. The association of plasma Pentosidine tertiles with the carotid artery Distension (ΔD), 
Lumen Diameter (LD) and calibrated carotid Pulse Pressure
Plasma Pentosidine 
Models
Model 1
Model 2
Model 3
Model 4*
Model 4 + 
brachial PP
Carotid ΔD†
(n = 808)
-13.5 [-32.3; 5.2]
-23.5 [-42.3; -4.7]
-9.6 [-27.8; 8.4]
-6.1 [-24.6; 12.4]
-10.5 [-28.6; 7.5] 
-5.7 [-24.1; 12.8]
-17.6 [-36.2; 0.9]
-18.2 [-38.1; 1.7]
-15.2 [-32.7; 2.2]
-19.4 [-38.1; -0.61]
Carotid Pulse Pressure 
(n = 792)
-2.94 [-5.34; -0.53]
2.11 [-0.29; 4.52]
-2.89 [-5.12; -0.66]
-0.09 [-2.34; 2.19]
1.87 [-3.57; -0.16]
-0.38 [-2.12; 1.35]
-1.57 [-3.26; 0.11]
-1.07 [-2.87; 0.73]
-
-
T2
T3
T2
T3
T2
T3
T2
T3
T2
T3
Carotid LD 
(n = 808) 
-91.9 [-217.9; 34.1]
4.51 [-121.6; 130.6]
-75.8 [-186.4; 34.8]
-56.6 [-169.7; 56.4]
-63.6 [-173.1; 45.9]
-60.2 [172.0; 51.6]
35.7 [-78.3; 149.7]
26.1 [-96.1; 148.2]
37.1 [-76.9; 151.1]
25.3 [-96.9; 147.6]
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Supplemental Table 2. The association of plasma Pentosidine tertiles with the brachial Artery Distensibility  
Coefficient (DC), Inter-Adventitia Diameter (IAD), Distension (ΔD) and brachial Pulse Pressure (PP) 
Plasma 
Pentosidine
Model 1
Model 2
Model 3
Model 4*
Model 4 + PP
Brachial DC 
(n = 740)
0.03 [-0.63; 0.69]
-0.64 [-1.29; 0.02]
0.04 [-0.71; 0.63]
-0.77 [-1.45; -0.08]
-0.17 [-0.82; 0.49]
-0.74 [-1.40; -0.07]
-0.24 [-0.94; 0.47]
-0.83 [-1.59; -0.07]
-
-
Brachial IAD 
(n = 740)
-27.1 [-168.0; 113.7]
161.7 [20.7; 302.7]
-24.3 [-135.1; 86.4]
115.4 [2.6; 228.1]
-22.4 [-133.4; 88.6]
115.0 [2.1; 227.8]
5.6 [-109.2; 120.5]
163.9 [40.5; 287.3]
2.8 [-111.5; 117.1]
165.1 [42.4; 287.9]
Brachial ΔD†
(n = 740)
-3.4 [-13.4; 6.7]
-6.2 [-16.3; 3.9]
-3.4 [-13.5; 6.7]
-9.2 [-19.5; 1.2]
-3.7 [-13.9; 6.4]
-9.1 [-19.4; 1.2]
-4.6 [-15.3; 6.1]
-9.8 [-21.4; 1.8]
-4.2 [-14.7; 6.4]
-10.3 [-21.7; 1.1]
Brachial PP
(n = 826)
-1.50 [-3.21; 0.22]
1.91 [0.19; 3.63]
-1.01 [-2.71; 0.51] 
0.84 [-0.81; 2.49]
-0.42 [-1.63; 0.80]
0.52 [-0.81; 2.49]
-0.25 [-1.52; 1.03]
0.36 [-1.01; 1.74]
-
-
† Model 1 additionally adjusted for the Brachial IAD
*45 additional individuals excluded due to missing data on co-variates 
T2
T3
T2
T3
T2
T3
T2
T3
T2
T3
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Supplemental Table 3. The Association of plasma and tissue Advanced Glycation End Products (AGEs) with caro-
tid stiffness indices calibrated for the carotid pulse pressure 
Plasma AGEs
Pentosidine
CEL
 
CML
Tissue AGEs
Skin  Auto-Florescence 
(SAF)
Models
Model 1
Model 2
Model 3
Model 4*
Model 1
Model 2
Model 3
Model 4*
Model 1
Model 2
Model 3
Model 4*
Models 
Model 1
Model 2
Model 3
Model 4**
Calibrated Carotid Distensibility 
Coefficient (DC) 
(N = 791)
-2.97 [-5.80; -0.14]
0.72 [-1.75; 3.19]
1.13 [-1.00; 3.25]
0.56 [-1.89; 3.00]
-0.01 [-0.06; 0.03]
-0.01 [-0.05; 0.03]
-0.01 [-0.04; 0.02]
0.01 [-0.03; 0.04]
0.02 [-0.01; 0.05]
0.02 [-0.03; 0.05]
0.02 [0.02; 0.05]
0.01 [-0.01; 0.04]
Calibrated Carotid Distensibility 
Coefficient (DC) 
(N = 781)
-2.72 [-3.52; -1.92]
0.28 [-0.52; 1.07]
0.17 [-0.52; 0.85]
0.21 [-0.56; 0.97]
Calibrated Carotid 
Young Elastic Modulus
(YEM) (N = 791)
0.19 (0.02; 0.36)
0.06 (-0.11; 0.22)
0.04 (-0.12; 0.19)
0.08 (-0.10; 0.25)
0.002 [-0.001; 0.004]
0.001 [-0.001; 0.004]
0.001 [-0.001; 0.004]
0.001 [-0.002; 0.003]
0.000 [-0.002; 0.001]
0.000 [-0.002; 0.001]
0.000 [-0.002; 0.001]
0.000 [-0.002; 0.002]
Calibrated Carotid 
Young Elastic Modulus 
(YEM) (N = 781)
0.11 [0.06; 0.16]
-0.02 [-0.07; 0.03]
-0.02 [-0.06; 0.03]
-0.02 [-0.07; 0.04]
*39 additional individuals excluded due to missing data on co-variates
**53 additional individuals excluded due to missing data on co-variates
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Supplemental Table 4: The association of Skin Auto-Florescence (SAF) with the carotid Inter-Adventitia Diameter 
(IAD), Distension (ΔD), Intima Media Thickness (IMT) and Lumen Diameter (LD) adjusted for the carotid pulse 
pressure (PP)
Tissue AGEs 
Skin  Auto- 
Florescence 
(SAF)
Models 
Model 4 + PP
Model 4 +  
calibrated PP*
Carotid IAD 
(n = 797)
155.7 (28.5; 262.2)
144.1 (24.2; 264.1)
Carotid ΔD†
(n = 797) 
10.3 (-6.3; 27.0)
12.6 (-4.3; 29.4)
Carotid IMT 
(n = 797)
-6.8 (-30.6; 16.9)
-5.1 (-29.2; 19.0)
Carotid LD 
(N = 797)
169.4 (62.2; 276.6)
154.3 (48.7; 260.0)
† Model 1 additionally adjusted for the Carotid IAD
*13 additional individuals excluded due to missing data on co-variates
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PART I: 
Arterial Stiffness and Neuropsychiatric Disorders
Main Findings and Clinical Implications
Arterial stiffness and depression in middle-aged individuals 
in chapter 2 of this thesis we found that aortic stiffness, as measured by the carotid-
femoral pulse wave velocity (cfPWV), was cross-sectionally associated with depression and 
depressive symptoms in middle-aged (40 – 60 years) men and to a lesser extent in middle-
aged women. Most studies to date have concentrated on elderly populations (> 60 years) 
[1-4], therefore this is the first study to show that aortic stiffness, which is the gold standard 
of arterial stiffness measurements, could contribute to the development of depression 
in individuals as young as 40-60 years. Although we only found a statistically significant 
association in middle-aged men, we cannot rule out the presence of an association in 
middle-aged women. This thesis highlights, therefore the need to incorporate CVD risk 
factor screening and management in the treatment of depression in middle-aged patients; 
though middle-aged men may profit from arterial de-stiffening therapies more than middle-
aged women. Unfortunately, due to the cross-sectional design of our study we cannot 
prove causality, nor can we exclude reverse causality as more severe depressive symptoms 
have been associated with greater arterial stiffness even in teenagers [5], and treatment of 
a major depressive disorder can improve arterial stiffness [6], as well as hypertension [7]. 
Thus, our results need to be confirmed by other (longitudinal) population-based studies 
before they are implemented in clinical practice. 
Anti-hypertensive drugs are currently the most efficient arterial de-stiffening therapy 
available. All tension lowering drugs can indirectly lower arterial stiffness by reducing blood 
pressure [8]. However, ACE-inhibitors, angiotensin receptor blockers and calcium-channels 
antagonists are also thought to have artery-modifying properties, thus reducing arterial 
stiffness beyond blood pressure [9,10]. Nonetheless, recent evidence suggests that blood 
pressure control, rather than the use of any specific antihypertensive drugs delays arterial 
stiffness progression over ten years of follow-up [11]. In patients with depression, two trials 
have shown that the calcium-channel inhibitor nimodipine reduces the time to remission of 
a major depression episode in a population of middle-aged and elderly individuals [12,13], 
however these studies were small and have yet to be confirmed in larger settings. Arterial 
stiffness may also be reduced through life-style interventions, such as aerobic exercise [14-
17], dairy enriched [18] and low-sodium diets [19,20]. 
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Lastly, new arterial de-stiffening drugs are being developed [21]. Several pre-clinical trials 
have shown the beneficial effects of A-II type 2 receptor activation by compound 21 [22]. 
Also, specific AGE reducing therapies [23] could reduce arterial stiffness without affecting 
mean arterial pressure, however, additional research is required to confirm their safety and 
effectiveness in the general population.
Arterial stiffness and depression in elderly individuals (> 60 years) 
in chapter 2 of this thesis we found that aortic stiffness was not associated with either a 
late-life depression (LLD), or with more self-reported depressive symptoms in elderly (aged 
between 60 and 78 years) individuals. Also, in chapter 3 we found that carotid stiffness was 
not associated with depressive symptoms either cross-sectionally or longitudinally over 
a follow-up period of 8 years in a population- based cohort of even older individuals (age 
69.3±6.3). Our findings may not necessarily contradict the vascular depression hypothesis 
[24] as we may have lacked the power to detect any significant associations due to the 
small number of depression cases in each cohort. Furthermore, the added value of arterial 
stiffness as a CVD risk factor decreases with old age as systolic hypertension reflects arterial 
stiffness more accurately than in younger age groups [25]. Indeed, the larger Rotterdam 
Study did show that both aortic and carotid artery stiffness indices are associated with LLD, 
as well as sub-clinical depressive symptoms [2]. Similarly, aortic stiffness was associated 
with more depressive symptoms in the large AGES-Reykjavik Study [3].
Nevertheless, the modest associations in our study, as well as in the aforementioned 
studies might indicate that population-wide interventions that reduce arterial stiffness 
or hypertension may not be efficacious in preventing LLD in the elderly. Indeed, despite 
intensified CVD risk factor management in the past 20 years, the prevalence of LLD was 
similar in our study as to that reported by Beekman et al. in a systematic review in 1999 
[26] and to that reported by Tiemeier et al. in the Rotterdam population between the 
years 1997-1999 [2]. Furthermore, several large population-based trials have shown that 
intensified hypertension management in the elderly does not lead to significant decreases 
in clinically relevant depressive symptoms, despite lowering the risk of developing overt 
CVD, such as stroke, MI or PAD [27-30]. 
Carotid artery stiffness and cognitive performance in elderly individuals
in chapter 4, we found that carotid artery stiffness was significantly associated with 
lower processing speed and attention & executive function, but not with memory in 
crude analyses; however, the associations were attenuated and no longer statistically 
significant after adjustment for age and follow-up duration. Aortic stiffness, however, was 
independently associated with lower processing speed, but not with a lower attention 
& executive function, or memory function at six years of follow-up. Our findings are in 
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accordance with previous studies that showed that the cfPWV is consistently, though 
weakly longitudinally associated with cognitive performance and decline [31]; whereas 
carotid stiffness is not [32]. In our study, one standard deviation higher aortic stiffness was 
comparable with approximately 3 years of ageing in the domain of information processing 
speed; therefore, the association seems clinically relevant. Nevertheless, mild cognitive 
impairment and dementia may not necessarily form a continuum [33], as most individuals 
with mild cognitive impairment will not develop dementia [34]. Therefore, additional 
research is required to confirm the role of aortic stiffness in the development of dementia. 
Pathophysiological mechanisms behind the associations of arterial stiffness with 
neuropsychiatric disorders
Arterial stiffness and depression
Arterial stiffness could lead to depression through the development of (micro)vascular 
disease, which directly affects and diminishes cerebral functions [35]. Stiffening of the large 
elastic vessels, such as the carotid arteries or the aorta impairs their cushioning function, 
which allows greater pressure and flow pulsatility to penetrate the low impedance cerebral 
(micro)vasculature, thus directly damaging the cerebral microcirculation and, through it 
the surrounding tissue [36-38]. Furthermore, the excessive pulsatile pressure induces 
arteriolar remodelling and hypertrophy, which impairs vascular reactivity and contributes to 
repeated episodes of microvascular ischemia and tissue damage [37,38]. Lastly, increasing 
arterial stiffness may cause excessive blood pressure variability [39,40], which may further 
sensitize high-flow organs to the harmful effects of impaired microvascular vasoreactivity 
[38]. 
Differential roles of aortic and carotid artery stiffness in the development of cognitive 
dysfunction
Similar considerations can be made regarding the role of arterial stiffness in the 
development of cognitive dysfunction. Indeed, LLD is associated with MCI [35] and may 
progress to dementia [41], thus reflecting their shared biologic substrate of cerebral (micro)
vascular disease. Yet, in chapter 4, we found that aortic, but not carotid artery stiffness 
was longitudinally associated with cognitive dysfunction. This could be explained through 
several mechanisms. Firstly, the aorta has been shown to stiffen faster than the carotid 
artery in response to old age, hypertension and type 2 diabetes (T2D) [42]. Due to the 
adverse CVD risk profile of the Hoorn Study population, the cfPWV may have, therefore, 
been more able to detect any differences in cognitive performance than carotid artery 
stiffness. Secondly, aortic stiffness could reflect the elastic properties of the middle-sized 
muscular cerebral arteries more accurately than the carotid arteries, due to its muscular 
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artery components [43]. Thirdly, aortic stiffness is a more accurate marker of (sub-clinical) 
heart failure and CHD than carotid artery stiffness [44]. These, in turn, are risk factors 
for cerebral (micro)vascular disease and cognitive decline[45], which may enhance any 
associations of aortic stiffness with cognitive dysfunction. Lastly, aortic stiffening has also 
been associated with amyloid-β deposition and may therefore play a more direct role in 
Alzheimer dementia [46]. Nevertheless, we were only able to compare aortic and carotid 
stiffness within the same study population in one small study and we were unable to carry 
out any (meaningful) interaction analyses with for example T2D due to the small sample 
size. Therefore, our results must be confirmed by other large population-based studies.  
PART 2: 
Pathophysiological mechanisms of arterial stiffening
Advanced Glycation End Products (AGEs) and local stiffness indices 
in chapter 5 we explored the pathophysiological mechanisms behind arterial stiffening in 
old age and type 2 diabetes (T2D) by investigating the associations of tissue and plasma 
advanced glycation end-products (AGEs) with stiffening of the carotid, femoral and brachial 
arteries. In our study, tissue AGE accumulation, as measured by Skin Auto-Fluorescence 
(SAF), was associated with a greater carotid lumen diameter but not with the stiffening of 
any of the included arteries. Of the plasma AGEs, only pentosidine was associated with the 
absolute distension and the Young Elastic Modulus (YEM) of the carotid artery, as well as 
with the distensibility coefficient (DC) of the brachial artery. However, these results were 
largely dependent on several outliers and were, therefore, considered spurious. 
Our lack of significant results could, nevertheless, offer additional insight into AGE 
associated arterial stiffening. We cannot exclude the presence of any associations as we 
may have lacked the power to detect them due to the relatively small study sample and the 
preferential attenuation of both arterial stiffness and AGE concentrations in T2D patients 
due to the use of more intensive use of blood-pressure-lowering and lipid-modifying 
therapies [10,47]. Yet, despite these limitations, van Eupen et al. [48] found within the 
same study population that both SAF and plasma pentosidine are significantly associated 
with a higher cfPWV, as well as a higher central (ascending aortic) pulse pressure. Thus, 
taken together, these results suggest that aortic stiffness is more prone to AGE-associated 
stiffening than any other elastic or muscular artery. As AGEs are thought to contribute to 
arterial stiffening in old age and T2D, our results are in line with previous observations that 
in elderly individuals [49] and T2D patients [50,51] elastic arteries preferentially stiffen over 
muscular arteries; and that of these elastic arteries, the aorta is more prone to stiffen than 
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the carotid artery in response to stiffening factors [42]. Thus, our results suggest that AGE 
reduction through dietary or pharmacologic interventions [23] could be less effective in 
reducing carotid artery stiffness than aortic stiffness in the general population or in patients 
with well controlled T2D; however, our findings should be confirmed by larger cohorts 
Our results also suggest that AGE accumulation induces maladaptive changes of the carotid 
artery that could ultimately lead to arterial stiffening. In this study, SAF was robustly 
associated with an enlargement of the lumen diameter but not with a concomitant 
dilation of the IAD or a thickening of the intima media thickness (IMT). This suggests 
that while the carotid artery dilates, its wall mass remains unchanged and is stretched 
over a larger diameter, which results in a relative thinning of the arterial wall as well as 
higher circumferential wall stress [52]. These changes may ultimately lead to carotid artery 
stiffening by accelerating elastic fibre degradation [53] and could, therefore, also be a 
potential therapeutic target for the treatment of arterial stiffness; however, our findings 
have yet to be confirmed by larger observational cohorts. 
Pathophysiological mechanisms of AGE associated changes of elastic and muscular 
arteries
The association of SAF with carotid artery dilatation is pathophysiologically plausible and 
may be explained by the degradation of elastin fibres by any or all of the plasma AGEs 
included in our study. Indeed, SAF correlates well with both fluorescent (ie. pentosidine) 
and non-fluorescent (ie. CML, CEL) tissue AGE concentrations [54,55]; whereas plasma 
AGEs may not adequately reflect tissue concentrations in individuals with a good liver and 
kidney function [56]. Pentosidine can cross-link with elastin, which decreases its quality and 
accelerates its degradation [57,58]. Secondly, CEL can induce endothelial dysfunction and 
thus reduce nitrogen oxide release [59], which in turn, inhibits the production of elastin by 
smooth muscle cells (SMCs) [60] and stimulates the release of enzymes, which degrade the 
elastin fibres [61]. Thirdly, CML induces the production of reactive oxygen species (ROS) and 
pro-inflammatory cytokines by macrophages, mesangial and endothelial cells [59] through 
RAGE activation. ROS directly reacts with elastin cross-links, thereby accelerating their 
degradation [62], while pro-inflammatory cytokines activate MMPs and other elastases that 
digest broken elastin molecules [63]. CML can also directly accumulate in elastin fibres [64]; 
where it causes fenestration of elastic laminae [65]. Nevertheless, elastic fibre degradation 
ought to ultimately lead arterial stiffening, as pulsatile stress is transferred to the stiffer 
collage fibres [66]. In our study we may have captured these processes in their incipient 
phase, in which the carotid artery is still able to maintain its compliance. Alternatively, the 
relative thinning of the arterial wall could have allowed the carotid artery to maintain its 
distensibility despite any stiffening. As the aorta has the highest elastin: collagen ratio of all 
arteries [67], it could be most prone to AGE-associated stiffening. 
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Methodological Considerations
The findings of the present thesis need to be interpreted in light of the following 
methodological considerations.
A. Confounding bias and over-adjustment bias
Confounding is a major concern in most observational studies [68] as inappropriate 
adjustment for confounders can distort the reported associations. One of the main 
strengths of the study populations used in this thesis was the measurement of many 
potential confounding factors, which were accounted for in the fully adjusted models. 
However, this may have also resulted in the underestimation of any associations due to the 
overadjustment for confounders, that lie in the causal pathway (ie. mediators) [69], such as 
hypertension, blood pressure lowering medication and prior CVD.
B. Selection Bias
Selection bias could have also attenuated the associations of arterial stiffness with either 
depression (chapters 2 and 3) or cognitive dysfunction (chapters 4) as patients suffering 
from severe forms of either depression or cognitive dysfunction were more likely to refuse 
to participate in the study. 
C. Bias in longitudinal studies 
Selective attrition and competing risks
The longitudinal analyses based on the Hoorn Study (chapters 3 and 4) could have been 
influenced by selective attrition, as a large proportion of the individuals with baseline data 
did not participate in the follow-up measurements. These persons were older and had 
a more adverse CVD risk profile (including stiffer arteries) than the individuals who did 
participate in the follow-up measurements. Attrition bias could have been accentuated 
further by the adverse CVD profile of the study population, caused by the advanced 
age (mean age 68 years), the high prevalence of prior CVD and of T2D. This would have 
attenuated the longitudinal associations of arterial stiffness with either depressive 
symptoms or cognitive performance. Competitive risks and survivorship bias could have 
further attenuated the associations as individuals with stiffer arteries at baseline are more 
likely to develop fatal CVD and were, thus, not included in the follow-up measurements. 
yet, in chapter 4 we did find an association of aortic stiffness with cognitive performance 
in a subsample of the Hoorn Study, therefore it is less likely that this selection played a 
decisive role, though it may have attenuated our associations.
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Follow-up time 
It may be argued that the longitudinal associations of arterial stiffness with either 
depression or cognitive dysfunction in Chapters 3 and 4 may have been hampered by the 
relatively short follow-up duration. Although we are the first to investigate the longitudinal 
association with depression, previous longitudinal studies that reported significant 
associations of aortic stiffness with cognitive dysfunction had similar follow-up durations 
to our study (4-7 years) [70-72]. Furthermore, age-related cognitive dysfunction develops 
after the age of 60 years when neurodegenerative changes of the brain start to occur [73]. 
As the average age of the population included in chapters 3 and 4 was 68 years, six to 
eight years follow-up should have offered a long enough interval to detect any changes 
in cognitive function or depressive symptoms. Furthermore, longer follow-up durations 
in elderly cohorts could, in fact, bias any associations due to selective attrition of patients 
with a more adverse cardiovascular risk profile. For example, in the Hoorn Study, where 
only 50% of the population was included in the follow-up analyses either due to mortality 
or due to unwillingness to participate. Yet, longer follow-up periods may be of use to detect 
the effects of arterial stiffness on incident dementia [74].  
D. Information Bias 
Non-differential and differential misclassification of individuals may have occurred due to 
measurement error (information bias).
Measurement of arterial stiffness
Aortic stiffness, as assessed by the cfPWV, is considered the “gold standard” measurement 
of arterial stiffness and was measured according to international standards [75]. Also, 
both in the Maastricht Study and the Hoorn Study, data on carotid, brachial and femoral 
artery distensibility indices were obtained using a validated and standardized echo-tracking 
ultrasonography technique [76]. Brachial systolic and diastolic blood pressure was measured 
at 5-minute intervals with an oscillometric device and the means of these values were used 
to calculate brachial pulse pressure (PP). In order to account for the amplification of the PP 
from central to peripheral arteries, carotid artery PP was also estimated from the carotid 
artery distension wave-forms and the brachial pulse pressure, as described previously [77]. 
Carotid artery stiffness indices were, thus computed using both brachial and calibrated PP, 
therefore improving the validity of our findings. In chapter 5, femoral and brachial artery 
stiffness measurements were shown to be more prone to measurement error as their intra- 
and interobserver reliability were lower than those of the carotid artery measurements. 
This is likely due to the high concentrations of SMCs within their walls, which allows short-
term alterations in smooth muscle tone to influence arterial diameter and stiffness [78]. It 
is therefore, more likely that the associations with elastic artery stiffness indices are more 
robust as they are not prone to such limitations.   
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Measurement of depression
A major depressive disorder was identified by means of a diagnostic interview (MINI) [79], 
whereas depressive symptoms were measured with screening instruments (PHQ9 or the 
CES-D) [80,81]. Screening instruments can misclassify depression as they do not account 
for the diagnostic prerequisites of having at least one core symptom of depression, or 
the presence of an underlying medical condition. In the elderly (> 60 years), symptoms of 
impaired daily functioning due to chronic illnesses, could be misclassified as depressive 
symptoms, especially apathy, sleep or eating problems [26]. Therefore, the association of 
arterial stiffness with depressive symptoms may be smaller the association with a major 
depressive disorder. In view of these considerations, the associations found in chapter 4 
should be interpreted with care as only depressive symptoms data was available.      
Measurement of cognitive function
Cognitive dysfunction can be identified through global cognitive function scores or by 
means of neuropsychologic test batteries. Global cognitive scores, such as the MMSE 
screen for overall cognitive dysfunction [82], thus changes in this score are more likely 
to represent large decreases in cognitive performance. Neuropsychologic tests offer a 
more detailed quantification of the individual cognitive domains and are, therefore, more 
suited to detect the subtle changes in cognitive dysfunction, which are encountered in 
population-based studies, such as the Hoorn Study [82]. In chapter 4 in the Hoorn Study, 
individual neuropsychologic tests were grouped into the three cognitive domains, which 
have been associated previously with cardiovascular disease (CVD) [45,83,84]. Some 
have argued that the use of individual tests is preferred above the use of cognitive 
domain scores as many individual tests provide information on multiple domains and the 
classification of neuropsychologic tests into cognitive do mains is subjective, however 
in the Hoorn Study the division into cognitive domains was made a priori, according to 
standard neuropsychological practice and cognitive theory [85]. Another reason to use 
cognitive domains is to improve the statistical power of any associations [86]. For example, 
in chapter 4 we found that aortic stiffness was significantly associated with the domain 
score information processing speed, even though the associations with the individual tests 
of this domain were only borderline significant. Thus, the reliability of our findings could 
have been improved by the merging of several individual cognition tests.
Measurement of Advanced Glycation End Products (AGEs)
1. Plasma AGEs
Protein-bound pentosidine was quantified using high-performance liquid chromatography 
[87]; whereas protein-bound Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)
lysine (CEL) and lysine were quantified using ultra-performance liquid chromatography 
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tandem mass-spectrometry [88]. This is the current method of choice to measure both 
free and protein-bound AGEs [89] and, in our study had very intra- and inter assay 
coefficients of variation < 10%. Plasma AGE concentrations may not reflect adequately 
tissue AGE levels; as it is thought that most AGEs are intracellularly or in interstitial 
tissues [90]. Furthermore, plasma AGEs are bound to plasma proteins, which have a very 
short half-life and are cleared by the kidney and the liver, therefore, their concentrations 
may fluctuate over time [91-93], thus measures of tissue AGE accumulation were also 
included in the study.
2. Skin Auto-Florescence (SAF) 
The AGE ReadertM measures AGE concentrations in the skin by utilizing the fluorescent 
properties of some of these AGEs [54]. As opposed to plasma proteins, skin tissue has a 
considerably longer half-life (14.8 years); thus, SAF may give a more accurate indication 
of AGE accumulation in the skin [54], as well in cardiovascular tissue [55]. However, SAF 
is a non-specific marker of AGE accumulation as it correlates with the concentrations of 
both the fluorescent pentosidine, as well as, of the non-fluorescent CML and CEL in skin 
biopsies [54]. Also, other skin fluorophores, such as keratin, vitamin D, lipofuscin, ceroid, 
NADH and pyridoxine, have overlapping excitation and emission spectra, which could 
therefore artificially enhance or influence SAF [94]. Nonetheless, a previous study has 
shown that most of the SAF variance was explained by pentosidine concentrations in the 
skin [95].  
Statistic Bias 
Computation of the Young Elastic Modulus (YEM)
The carotid YEM is meant to measure the intrinsic stiffness of the arterial wall independent 
of its geometry and it is calculated according to the following formula: YEM = D/IMT * 1/
DC, where D is the diastolic inter-adventitial diameter, IMT is the Intima Media Thickness, 
and the DC is the distensibility coefficient of the carotid artery [77]. The DC is itself a 
stiffness parameter and smaller values represent stiffer arteries. The inversion of the DC 
(ie. 1/DC term) reduces the larger DC values (more compliant arteries) to a greater extent 
than the smaller DC values (stiffest arteries). This can result in disproportionately high YEM 
values for individuals with the stiffest arteries in the population as compared with those 
with more compliant arteries, thus creating outliers. If significant associations are (partly) 
dependent on these outliers, as in chapter 5, it may be difficult to discern between true 
biologic relevance and statistic misinterpretation. However, the YEM may overestimate any 
associations with arterial stiffness due to the enhancement of the lower (stiffer) part of 
the DC distribution. Therefore, it is best to consider associations biologically relevant only 
when there are also concomitant associations with the DC or the distension. In chapter 
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5, plasma pentosidine was associated with both the YEM and the carotid distension, but 
not with the DC; therefore, we may have identified a biologically relevant phenomenon, 
however larger samples are required to confirm our findings.  
Arterial stiffness in longitudinal data analysis 
Arterial stiffness is dependent on the distending pressure at the time of the measurement. 
At a higher mean arterial pressure (MAP), the systolic stress is transferred to the more rigid 
collagen fibres, which results in a higher arterial stiffness [66]. Most arteries are, therefore, 
more compliant at lower pressures than at higher pressures, thus a difference in stiffness 
values may not be due to a change in the arterial viscoelastic properties. Thus, any analyses 
regarding differences or changes in arterial stiffness should account for the MAP at the 
time of the measurement.  
In cross-sectional analyses this is readily achieved through the adjustment for MAP. In 
longitudinal analyses, both mixed models and GEE also allow for the adjustment of the 
MAP at each time point [96]. Yet, neither of these techniques can separate the effects 
of longitudinal changes within an individual from those between individuals [97]. Testing 
within-subject associations may be a challenge. For example, (percentage)changes in 
arterial stiffness measurements may exaggerate any associations as they do not account 
for the blood pressure at the time of the measurement. Additional adjustments for either 
baseline MAP, or for the change in MAP may not sufficiently adjust for this bias and thus 
may not be able to identify solely pressure independent changes. Possibly, the use of 
pressure-independent stiffness markers, such as the beta-stiffness index [98] may offer a 
more accurate estimation of longitudinal changes in local arterial stiffness. Alternatively, an 
autoregressive technique, whereby all models are adjusted for the MAP at the same time 
point as the arterial stiffness measurement (ie. t-1) [99] could offer an elegant solution for 
longitudinal data analyses of all stiffness indices.  
in chapter 3 of this thesis we only had data at two time points, therefore GEE was not 
necessarily indicated. We, therefore, analysed the longitudinal associations of changes in 
arterial stiffness with (changes in) depressive symptoms by means of linear regression. 
The follow-up depression score was the main outcome variable and the arterial stiffness at 
follow-up was the main determinant. The models were then adjusted for baseline arterial 
stiffness [100] as well as for the MAP both at both time points. This technique allowed us 
to reliably assess the effect of the pressure independent changes in arterial stiffness on any 
(changes in) self-reported depressive symptoms. 
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Outliers 
All arterial stiffness indices and their components, as well as all advanced glycation end 
products (AGEs) variables were normally distributed, however they also had several 
observations which were significantly different from the total population. As linear 
regression analyses have been shown to give biased estimations when extreme values 
are present we included additional outlier analyses in all our chapters. Outliers were 
identified by means of classic standardization [101]. Due to the large study samples (> 
100), which according to the central limit theorem would tend to be normally distributed 
even if the population distribution is skewed [102], only Z-scores that exceeded 3 or -3 
were considered outliers. We did not exclude these outliers from the main analyses as 
their values were biologically plausible and may therefore be also found in the general 
population. However, we carried out additional sensitivity analyses without these outliers 
in order to test the robustness of our statistical models. In line with previous observations, 
the significant linear associations in chapter 5 were largely dependent on arterial stiffness 
outliers, whereas the associations of the logistic regression analyses in chapter 2 were 
not. Thus, in chapter 5, it was difficult to discern between true biologic relevance and 
statistic misinterpretation; though the fact that the regression coefficients were greatly 
diminished after the removal of several extreme values (< 2% of the data) makes statistic 
misinterpretation more likely.  
Missing data
Regression analyses cannot deal with missing data, therefore cases with missing values on 
one or more variables incorporated in the statistical models are excluded by default and 
may thus constitute a source of bias. Due to the large percentage of missing data this could 
have been an issue in chapters 2 and 3 of this thesis. In chapter 2 aortic stiffness was not 
measured, either due to lack of personnel (13%), or due to measurement errors caused by 
obesity, the presence of tachyarrhythmias or of type 2 diabetes (1%). Missing data due to 
lack of personnel could be considered Missing Completely At Random (MCAR) [103] and 
may therefore not represent a source of bias. Yet, in our cohort some selection may have 
taken place as individuals with missing data had a more adverse CVD risk profile with a 
higher BMI and more hypertension than individuals with aortic stiffness measurements. 
Even though the data seems to be Missing At Random (MAR) [103], imputation techniques 
were not used, as the Maastricht Study is still ongoing and is currently attempting to retrieve 
its missing data. Its policy is therefore not to use these techniques until this process is 
completed. Also, missing data on aortic stiffness did not differ with respect to depression, 
depressive symptoms or the use of anti-depressive medication, thus it is less likely that our 
associations were biased. 
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in chapter 3, CES-D data was missing in 14% of individuals both at baseline and at follow-
up. Individuals with missing baseline CES-D data had more T2D, higher mean arterial 
pressure and lower (stiffer) carotid artery stiffness, but no difference in use of depression 
medication. This may have introduced bias towards the null in the cross-sectional analyses, 
however in the main longitudinal analyses this effect was probably minimal as most cases 
with missing CES-D data at baseline were also not included in the follow-up measurements 
either because they were deceased or because they refused to participate. Thus, selective 
attrition may have been a more prominent source of bias than selection bias due to missing 
data in chapter 4. Nonetheless, in order to ensure the validity of our findings, our models 
were only adjusted for baseline CES-D scores in sensitivity analyses.  
Future research
Arterial stiffness and depression
In this thesis, we were the first to investigate whether arterial stiffness is longitudinally 
associated with late-life depressive symptoms, however our study was hampered by the 
small sample size, the use of self-reported depressive symptoms and the low prevalence of 
clinically relevant depressive symptoms. In the future, larger observational studies should 
focus on the longitudinal association of arterial stiffness with clinically relevant depressive 
symptoms or with a depressive disorder as identified by a diagnostic instrument. Also, the 
causality of the association of aortic stiffness with depression in middle-aged individuals 
should be confirmed by other (longitudinal) observational studies, as should be the 
differential association in middle-aged men as compared to middle-aged women. Lastly, it has 
been previously shown that higher blood pressure in middle-aged but not elderly individuals 
is longitudinally associated with cognitive decline in in old age [104]. Due to their shared 
aetiology of cerebral micro-vascular disease, it would be of interest to analyse whether the 
same applies to the longitudinal association of arterial stiffness with LLD in the elderly. 
 
Clinical trials could offer additional insight into the benefits of CVD risk factor management 
in the treatment outcomes of LLD. According to the vascular depression hypothesis CVD 
risk factors may also precipitate or perpetuate LLD symptoms. For example, depression 
in later life may increase the risk of developing dementia in patients with hypertension 
and stroke [105]; thus, high CVD risk patients may benefit from blood pressure lowering 
and de-stiffening therapies. Such improvements may not be well quantified by population-
based trials, where the prevalence of LLD is low. Two small trials have indeed shown that 
nimodipine reduces the time to remission of a major depression episode in a population 
of middle-aged and elderly individuals [12,13]. Additional replication in larger settings is, 
however required. 
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Arterial stiffness and cognitive dysfunction
This thesis identifies aortic, but not carotid artery stiffness as a risk factor for a slower 
information processing speed. Our results are in concordance with a recent systematic 
review that has shown that greater aortic stiffness is consistently associated with cognitive 
decline [31]. Data on carotid artery stiffness and cognitive performance is scarce [106-108]; 
however, our findings are in accordance with the only other longitudinal population-based 
study available [32]. Yet, in contrast with previous findings [109-111], this latter study 
[32] also did not find a significant association of aortic stiffness with cognitive decline, 
possibly due to the measurement of cognitive function at only two time points. Possibly, 
larger observational studies that measured carotid artery stiffness and cognitive function 
at multiple time points would offer a better chance of identifying any associations. Also, as 
some have suggested that mild cognitive impairment and dementia may not necessarily 
form a continuum [33], the association of arterial stiffness with dementia should also be 
researched longitudinally in a similar fashion. 
Clinical trials to date have shown a limited, though consistent benefit of arterial de-stiffening 
therapies on preserving cognitive function in the elderly. A recent systematic review has 
shown, for example, that blood pressure reduction with the diuretic indapamide or with 
the calcium channel blocker nitrendipine (moderately) reduces the risk of developing 
dementia in the elderly [112]; while another study concluded that angiotensin receptor 
blockers (ARBs) protect best against any type of cognitive decline, including cognitive 
dysfunction and dementia [113]. These effects could have been underestimated as intensive 
blood pressure lowering in the elderly, which is predominantly defined by isolated systolic 
hypertension, may excessively lower diastolic and mean arterial pressure [114-116], which, 
in turn, may adversely affect cognitive function [117]. Possibly, AGE reducing drugs, which 
improve arterial compliance without influencing mean arterial pressure, could be a safer 
alternative [23], however larger population-based trials are required to investigate its 
safety and effectiveness in the prevention of cognitive decline and dementia.     
Our studies were carried out in elderly individuals (age 68 ± 5 years). It would be of 
interest, however, to assess the effects of middle-age arterial stiffness on cognitive 
dysfunction. For example, previous studies have suggested that middle-age hypertension 
is a stronger predictor of cognitive decline at an advanced age than old-age hypertension 
[104]. In middle-aged individuals, systolic or pulse pressures are poor surrogates for 
arterial stiffness, therefore arterial stiffness could be a more potent CVD risk factor in 
these individuals than in the elderly [25]. It would be of interest, therefore, to assess the 
presence and the clinical relevance of the association of arterial stiffness in middle-age 
with cognitive decline in old age in longitudinal population-based studies. 
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Lastly, in chapter 4 we have found that aortic stiffness is associated more strongly with 
cognitive dysfunction and, possibly cerebral (micro)vascular disease, than carotid artery 
stiffness. Nevertheless, our study was small, and we were unable to carry out any 
(meaningful) interaction analyses with for example T2D. Therefore, more such comparisons 
in larger observational studies are required in order to identify any differential associations 
of aortic and carotid artery stiffness indices with cerebral (micro)vascular disease and 
neuropsychological disorders.  
Advanced Glycation End products (AGEs) and arterial stiffness
Our results on the associations of plasma and tissue AGE accumulation with carotid, 
femoral and brachial artery stiffness and remodelling should be replicated in larger 
population-based cohorts. Observational studies could also focus on the effects of AGEs 
on carotid artery stiffness and remodelling in patients with prolonged exposure to high 
concentrations of AGEs, such as T2D patients with micro- and macrovascular complications 
or end stage renal disease patients [118]. Indeed, plasma pentosidine was associated 
with carotid artery stiffness in dialysis patients [119]. Observational studies that measure 
both tissue and plasma AGE concentrations could give additional information on the 
pathophysiological mechanisms behind AGE mediated changes as SAF is only a global 
marker of tissue AGE accumulation, which has been shown to correlate well with both 
fluorescent (ie. pentosidine) and non-fluorescent (CML, CEL) AGE concentrations [54].
in chapter 5 of this thesis we found that AGE accumulation is associated with a wider 
carotid lumen diameter, but not with its stiffness. It might be, therefore be of interest to 
investigate any associations with aortic geometry as well. Previous research has already 
shown that plasma and tissue AGEs are associated with a higher cfPWV [120-127], as well as 
a higher (central) pulse pressure [48, 128-130]. Although the cfPWV is relatively insensitive 
to aortic geometry; the central pulse pressure has been shown to be inversely associated 
with the aortic lumen diameter [53, 131-135]. Thus, as opposed to the dilation described 
by us in the carotid artery, AGE accumulation could induce a maladaptive narrowing of the 
ascending aorta, which may not allow it to compensate for any concomitant stiffening of its 
walls. Such changes may explain the disproportionate stiffening of the aorta as compared 
to the carotid artery in T2D patients and may potentially offer additional targets for the 
treatment of isolated systolic hypertension. 
Lastly, our results regarding the differential associations of AGEs with central PP, aortic and 
carotid artery stiffness might suggest that clinical trials on AGE reducing therapies should 
primarily focus on their effects on aortic rather than carotid artery stiffness. 
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The proportion of the world’s older adults is estimated to almost double from 12% to 22% 
between 2015 and 2050 [1]. More than 20% of adults aged 60 and over suffer from at 
least one neuropsychiatric disorder, which account for 17.4% of Years Lived with Disability 
(YLDs). The most common of these neuropsychiatric disorders are dementia and depression 
[1]. Both disorders are highly invalidating, due to their chronic course, poor prognosis and 
lack of successful treatments [2,3]. Thus, additional research into their pathophysiology is 
required in order to uncover additional treatment and preventive targets. Arterial stiffness 
is a novel cardiovascular disease risk factor that may be causally related  to depression 
and cognitive dysfunction in elderly individuals. Growing evidence suggests that arterial 
stiffening is involved in the development of cerebral (micro) vascular disease, which 
is known to contribute to the development of depression, cognitive dysfunction and 
dementia in late life [4,5]. Arterial stiffness is a treatable cardiovascular disease risk factor, 
which has been associated with cerebral micro- and macrovascular disease independently 
of traditional cardiovascular disease risk factors [6,7]. 
in part 1 of this thesis we examined whether arterial stiffness is associated with depression 
and cognitive dysfunction. Most previous research on this topic has concentrated on 
the role of aortic stiffness, which is the gold standard of arterial stiffness measurement. 
However, the carotid artery is the main blood supplier to the brain, therefore its stiffening 
could affect the cerebral (micro)vascular circulation more directly than aortic stiffening. 
We therefore investigated both aortic and carotid artery stiffness. In part 2 of this thesis 
we focused on potential causes of arterial stiffening by investigating the associations of 
advanced glycation end products (AGEs) with elastic and muscular artery stiffness. Any 
associations may offer a target for lowering arterial stiffness. 
PART 1: 
Arterial stiffness and Neuropsychiatric Disease
in chapter two of this thesis we assessed whether aortic stiffness is associated with a major 
depressive disorder or depressive symptoms in a population of middle-aged and elderly 
individuals (age 40-78 years) from the Maastricht Study.  In addition, we investigated 
whether these associations differ according to age and sex. We found that aortic stiffness 
was associated cross-sectionally with depressive symptoms and a major depressive 
disorder in middle-aged (40 – 60 years) men and to a lesser extent in middle-aged women. 
However, we did not find a significant association in elderly (> 60 years) men or women. 
Most previous studies have concentrated on elderly populations (> 60 years). We were, 
therefore, the first to show that aortic stiffness could contribute to the development of 
depression in individuals as young as 40-60 years. 
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in chapter three we investigated whether carotid artery stiffness is prospectively associated 
with depressive symptoms in elderly individuals from the Hoorn Study. In addition, we 
investigated whether these associations differ according to age and sex. All currently 
published evidence [8-11] is cross-sectional, and thus cannot confirm that arterial stiffness 
precedes the development of depression. We, therefore, investigated in a sample of elderly 
individuals (age 69.3 ± 6.3 years) whether (changes in) carotid stiffness were associated with 
self-reported depressive symptoms over eight years of follow-up. We found that neither 
higher carotid stiffness, nor an accelerated stiffening of the carotid artery were associated 
with more depressive symptoms after eight years of follow-up. We also did not find any 
differences according to age and sex. However, our study may have been underpowered by 
the low number of clinical depression cases and the high percentage of selective attrition 
throughout follow-up to assess any association. Nevertheless, the associations were weak 
and did not indicate any clinical relevance. 
in chapter four we assessed whether either carotid artery or aortic stiffening is 
prospectively associated with cognitive dysfunction in elderly individuals from the Hoorn 
Study. We investigated, in a sample of elderly individuals (age 67.6 ± 5.4 years), the 
longitudinal associations of carotid artery and aortic stiffness at baseline with three main 
cognitive performance domains after six years of follow-up. In this study carotid artery 
stiffness was not associated with attention and executive function, information processing 
speed or memory. In a smaller sample of the same study we found that aortic stiffness 
was, however, independently associated with lower processing speed. We concluded, 
therefore, that aortic stiffness may precede the development of cognitive dysfunction in 
elderly individuals. However, our study was small, and we could not analyse whether our 
associations were driven by changes in influential groups, such as type 2 diabetes patients 
or by the high percentage of selective attrition throughout follow-up.  
 
PART 2: 
AGEs and Arterial Stiffness
in chapter five we investigated whether advanced glycation end products (AGEs) are 
associated with elastic and muscular artery stiffening in the Maastricht Study. We also 
investigated whether the associations differed according to age, sex and type 2 diabetes. 
AGEs could accelerate arterial stiffening in old age and type 2 diabetes and the Maastricht 
Study has already shown that both tissue and plasma AGEs are associated with aortic 
stiffness and (ascending) aortic pulse pressure [12]. The cfPWV, however, represents the 
properties of the highly elastic descending and distal aortas; as well as of the muscular iliac 
and femoral arteries. AGEs may, however differentially affect elastic and muscular arteries; 
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however, this has scarcely been researched. We, therefore, investigated whether either 
tissue or plasma AGEs are associated with the stiffening of the solely elastic (ie. carotid) 
or the solely muscular (ie. femoral and brachial) arteries. We did not find any robust 
associations of either tissue or plasma AGEs with any of the stiffness indices; although 
tissue AGEs as measured by Skin Autfluorescence (SAF) was associated with carotid artery 
dilation. We concluded that our lack of significant associations of AGEs and the significant 
associations with aortic stiffness within the same Maastricht Study population could imply 
that the most elastic thoracic and abdominal aortas are more prone to AGE accumulation 
than the stiffer elastic carotid artery or the muscular femoral or brachial arteries. We also 
concluded that AGE accumulation could induce maladaptive changes of the carotid artery 
that may ultimately lead to its stiffening, as well as to atherosclerotic plaque formation. 
However, these theories have yet to be confirmed in larger, prospective studies.
in chapter six we discussed the key findings of the present thesis, their clinical and future 
research implications, as well as the any methodological shortcomings that may have 
hampered our studies.  
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Depressie, cognitieve dysfunctie en dementie zijn drie van de meest invaliderende en 
frequente hersenziekten op oudere leeftijd. Wereldwijd, krijgt meer dan 20% van personen 
ouder dan 60 jaar last van tenminste één van deze ziekten. Deze aandoeningen zijn 
verantwoordelijk voor 17,4% van de afname in kwaliteit van leven op oudere leeftijd en 
voor 6,6% van het verlies in gezonde levensjaren [1]. Dit is te wijten aan het chronisch 
beloop, de slechte prognose en de beperkte behandelmogelijkheden van deze ziekten [2,3]. 
De behandeling van depressie is bijvoorbeeld minder effectief op oudere dan op jongere 
leeftijd [2] waardoor meer patiënten last van depressieve symptomen houden ondanks 
hun behandeling. Bovendien kunnen aanhoudende depressieve klachten uiteindelijk tot 
een afname van cognitieve functie en zelfs tot dementie leiden [4,5]. Een milde cognitieve 
stoornis leidt in meer dan 20% van de gevallen tot dementie [6]. Dementie is onomkeerbaar 
progressief en leidt tot volledige zorgafhankelijkheid en vroegtijdig overlijden [2]. Meer 
onderzoek is dus nodig om behandelbare oorzaken van depressie en dementie uit te 
zoeken.  
Steeds meer onderzoek wijst uit dat verstijving van de slagaders en schade aan de kleine 
vaatjes in de hersenen een potentiële oorzaak van depressie, cognitieve achteruitgang en 
dementie zouden kunnen zijn. Slagaderverstijving verhoogt de kans op het ontwikkelen van 
hart- en vaatziekten (HVZ) en kan bovendien de kleine vaatjes in de hersenen beschadigen. 
in deel 1 van dit proefschrift hebben wij onderzocht of verstijving van de grote slagaders, 
zoals de lichaamsslagader (de aorta) en de halsslagaders (de carotiden) een oorzaak van 
depressieve klachten en cognitieve dysfunctie kan zijn. De meest betrouwbare maat van 
vaatstijfheid wordt gemeten in de grote lichaamsslagader; echter de halsslagader voorziet 
de hersenen van bloed; en zou dus het risico op het verkrijgen van hersenziekten meer 
direct kunnen beïnvloeden. In deel 2 hebben wij gezocht naar additionele mogelijkheden 
voor de behandeling van vaatstijfheid door te onderzoeken of versuikerde eiwitten, die in 
hogere concentraties voorkomen op oudere leeftijd en bij diabetes, geassocieerd zijn met 
verstijving van de vaatwand in de grote hals-, lies- en armslagaders.
  
DEEL 1: 
Vaatstijfheid en het ontstaan van depressie en een milde cognitieve stoornis
in hoofdstuk 2 hebben wij onderzocht of verstijving van de lichaamsslagader geassocieerd 
is met een depressieve stoornis of met meer depressieve klachten bij mensen van 
middelbare en oudere leeftijd in De Maastricht Studie. Wij onderzochten daarnaast 
of deze verbanden verschillen tussen mannen en vrouwen of variëren met leeftijd. Wij 
vonden dat verstijving van de lichaamsslagader geassocieerd is met zowel een depressieve 
stoornis, als met meer depressieve symptomen bij mannen, en, in mindere mate, vrouwen 
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van middelbare leeftijd. Wij vonden echter geen verbanden bij oudere personen (> 60 
jaar oud). Alle voorgaande studies hebben zich gericht op oudere personen; wij toonden 
voor het eerst aan dat verstijving van de lichaamsslagader een rol zou kunnen spelen in 
het ontstaan van depressie bij personen van middelbare leeftijd. Echter wij kunnen op 
basis van deze studie niet uitsluiten dat deze bevindingen op toeval berusten of dat de 
associaties juist de omgekeerde relatie weerspiegelen, waarbij depressie tot vaatverstijving 
leidt. Longitudinale studies kunnen wel laten zien dat vaatstijfheid voorafgaat aan het 
ontwikkelen van een depressieve stoornis. Dit sluit ‘reverse causality’ uit en zou daarmee, 
de aanname van een oorzakelijk bestand tussen vaatstijfheid en depressie ondersteunen. 
in hoofdstuk 3 hebben wij onderzocht of een (versnelde) verstijving van de halsslagader 
geassocieerd is met een toename van depressieve klachten over een vervolgperiode van 
acht jaar bij oudere mensen (> 60 jaar) die deelnamen aan de Hoorn Studie. Een dergelijk 
verband zou de aanname dat vaatstijfheid een oorzaak van depressie is ondersteunen. 
Wij vonden dat verstijving van de halsslagaders niet geassocieerd is met een toename van 
depressieve klachten acht jaar later. Een versnelde verstijving van de halsslagader tijdens 
de vervolg periode was evenmin geassocieerd met het ontwikkelen van meer depressieve 
klachten. Wij waren de eersten die deze relatie in longitudinaal verband hebben onderzocht. 
Echter hadden wij te weinig patiënten met een depressieve stoornis om dit verband volledig 
uit te kunnen sluiten; dus grotere studies zouden alsnog deze associatie kunnen aantonen. 
in hoofdstuk 4 hebben wij onderzocht of het hebben van meer verstijfde hals- of 
lichaamsslagaders in 2000-2001 geassocieerd is met een lagere prestatie op cognitieve 
testen ongeveer zes jaar later (in 2005-2009) in een oudere (> 60 jaar) groep deelnemers 
van de Hoorn Studie. Wij vonden dat verstijving van de halsslagader niet geassocieerd is 
met een lagere prestatie op testen voor de informatieverwerkingssnelheid, aandacht- en 
uitvoerende functies en geheugen. Verstijving van de lichaamsslagader was wel geassocieerd 
met een lagere prestatie op taken voor informatieverwerkingssnelheid zes jaar later. Wij 
concludeerden dat verstijving van de lichaamsslagader betrokken zou kunnen zijn bij het 
ontwikkelen van milde cognitieve stoornissen bij oudere mensen. Echter onze studie was te 
klein om vast te stellen of dit verband gedreven was door patiënten met diabetes. 
DEEL 2: 
Versuikerede eiwitten en verstijving van de hals-, lies- en armslagadders      
in hoofdstuk 5 hebben wij in de Maastricht Studie onderzocht of versuikerde eiwitten 
geassocieerd zijn met verstijving van de hals-, lies- en armslagader. De Maastricht Studie 
heeft eerder al aangetoond dat versuikerde eiwitten gemeten in weefsels of bloed 
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geassocieerd is met de verstijving van de lichaamsslagader [7]. Echter de grote slagaders 
bestaan uit meerdere segmenten met verschillende elastische eigenschappen: de elastische 
afdalende borst slagader, de buikslagader en de meer musculaire bekken- en liesslagaders. 
Versuikerde eiwitten zouden een verschillend effect kunnen hebben op het elastische en 
musculaire deel van de grote slagaders; echter dit is tot nu toe niet onderzocht. Toch is 
dit potentiele verschil van belang omdat de verstijving van zowel voornamelijk elastische 
als meer musculaire slagaders het risico op het ontwikkelen van Hart- en Vaatziekte (HVZ) 
kan verhogen [8]. Wij hebben dus onderzocht of versuikerde eiwitten gemeten in weefsels 
of in bloed geassocieerd zijn met de verstijving of met de diameter van de voornamelijk 
elastische halsslagader of de musculaire lies- en armslagaders. Wij vonden dat versuikerde 
eiwitten noch in weefsel noch in bloed geassocieerd waren met de verstijving van elastische 
of musculaire slagaders. Mogelijk hadden wij te weinig deelnemers om verbanden aan 
te tonen; echter, een eerdere studie [7] heeft in dezelfde populatie van de Maastricht 
Studie aangetoond dat versuikerde eiwitten wél geassocieerd zijn met de verstijving van 
de lichaamsslagader en met de polsdruk in de opstijgende borst lichaamsslagaders. Hieruit 
hebben wij herleid dat waarschijnlijk de meest elastische slagaderen, zoals de borst- en 
buikslagaders, het meest vatbaar voor de nadelige effecten van versuikerde eiwitten zijn. 
Deze hypothese zou nader onderzocht moeten worden. Wij vonden wél dat de hoeveelheid 
versuikerde eiwitten in weefsels geassocieerd is met een verwijding van de halsslagader. 
Dit zou mogelijk tot aderverkalking of verstijving van de halsslagader door de tijd kunnen 
leiden, maar deze mogelijke toevalsbevinding moet in grotere vervolgstudies bevestigd 
worden. 
in hoofdstuk 6 worden de resultaten van dit proefschrift samengevat en de mogelijke 
tekortkomingen van onze meet- en analytische methodes besproken. Bovendien worden 
de conclusies van onze bevindingen in dit hoofdstuk besproken, in relatie tot patiëntenzorg 
en wetenschappelijk onderzoek.
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Knowledge valorisation can be defined as the “process of creating value from knowledge, 
by making knowledge suitable and/or available for societal purposes, and suitable for 
translation into competitive products, services, processes, and new commercial activities” 
(adapted definition based on the National Committee Valorisation 2011:8). In this addendum 
we describe how society may benefit from the work conducted in this dissertation.
This two-part thesis focused on arterial stiffness, which has recently emerged as a risk 
factor for cardiovascular disease (CVD) [1,2], including coronary artery disease [3,4], stroke 
[4,5] and cerebral small vessel disease (CSVD) [6], and its role in the development of two of 
the most debilitating neuropsychiatric disorders of old age, namely late-life depression and 
cognitive dysfunction, as well as on its pathophysiology. The proportion of elderly individuals 
is expected to almost double from 12% to 22% between 2015 and 2050 [7] and more than 
20% of these individuals will suffer from at least one neuropsychiatric disorder, such as late 
life depression, cognitive dysfunction or dementia [7]. In past years, the vascular etiology 
of these disorders, has received growing scientific attention. According to these vascular 
hypotheses [8,9], accumulation of sub-cortical and peri-ventricular CSVD disrupts neuronal 
circuits, which, in turn, impairs cerebral affective and executive functions, thus resulting 
in depression and cognitive decline. In support of these theories, the development and 
the accumulation of CSVD has been cross-sectionally and longitudinally associated with 
depression [10], cognitive impairment [9], vascular-type dementia [9] and, in some cases, 
even Alzheimer dementia [11]. In the part 1 of this thesis we, therefore, expanded on these 
hypotheses by analysing the role of arterial stiffness in the development of depression 
and cognitive dysfunction in the hope to uncover additional targets for their treatment 
or prevention. In part 2 we then focused on the pathophysiology of arterial stiffening, in 
particular on the role of advanced glycation end products (AGEs), which may offer a target 
for lowering arterial stiffness in addition to blood pressure lowering medication.
Our findings were largely inconclusive as most of the associations were modest and 
predominantly non-significant. This may suggest that only very large reductions in arterial 
stiffness could effectively reduce the risk of developing neuropsychiatric disorders in the 
general population; though currently available arterial de-stiffening strategies may improve 
the treatment outcomes of depressive patients. This thesis nevertheless emphasises the 
need to develop more effective arterial de-stiffening strategies and, in the second part we 
showed that AGEs may preferentially influence the most elastic descending thoracic and 
abdominal aortas, but not the less elastic carotid or the muscular femoral and brachial 
arteries. Thus, the implementation of our results in additional scientific research might 
improve patient care in the future. 
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1. Arterial stiffness and depression
The first key finding of our dissertation is that aortic stiffness, as measured by the carotid-
femoral pulse wave velocity (cfPWV), may contribute to the development of depression 
and depressive symptoms in middle-aged (40 – 60 years) men and to a lesser extent in 
middle-aged women. Unfortunately, due to the cross-sectional design of the Maastricht 
Study we cannot prove causality, nor can we exclude reverse causality, thus, our results 
need to be confirmed by other (longitudinal) population-based studies before they are 
implemented in clinical practice. Nevertheless, this thesis does highlight the need to 
incorporate arterial de-stiffening therapies in the treatment of depression in middle-aged 
patients. Anti-hypertensive drugs, such as ACE-inhibitors, angiotensin receptor blockers and 
calcium-channel blockers lower arterial stiffness most effectively beyond blood pressure 
[12,13]. To date, two trials [14,15] have shown that in patients with MRI-confirmed vascular 
depression, the use of the calcium-channel blocker nimodipine in order to achieve optimal 
blood pressure in addition to anti-depressive medication reduces the time to remission of 
a major depression episode; however, these studies were small and should be confirmed 
in larger settings. Life-style interventions, such as aerobic exercise [16-19], dairy enriched 
[20] and low-sodium diets [21,22] can also decrease aortic stiffness; however, it is yet 
unknown whether these effects are clinically relevant. Therefore, depressive middle-aged 
patients with hypertension and a high aortic stiffness (ie. cfPWV > 10 m/s [23]) should be 
treated with de-stiffening antihypertensives in addition to adopting a healthy lifestyle in 
order to achieve maximal treatment effects. A possible issue in middle age is that aortic 
stiffness may occur in the absence of hypertension [24], in which case blood pressure 
lowering therapies should be carefully titrated in order to avoid hypotension and cerebral 
hypoperfusion. Furthermore, additional research is required to identify new drugs that 
lower arterial stiffness without affecting mean arterial pressure, such as compound 21 [25] 
and AGE-reducing therapies [26].  The second key finding of this thesis was that in elderly 
individuals (> 60 years) aortic stiffness is not cross-sectionally associated with depression; 
nor is carotid artery stiffening either cross-sectionally or longitudinally associated with 
more self-reported depressive symptoms after eight years follow-up. However, we cannot 
exclude that arterial de-stiffening therapies may have a positive impact on the outcome 
and prognosis of depression in the elderly as the studies included in this thesis may have 
been hampered by the small number of depression cases. Possibly restricting any arterial 
de-stiffening interventions to patients with MRI-confirmed vascular depression may be 
beneficial. Indeed, in his two studies with nimodipine, Taragano et al. [14,15] included only 
middle-aged and elderly patients with MRI-confirmed vascular depression.
Besides its therapeutic implications, additional population-based studies are needed 
to analyse whether aortic de-stiffening medication can prevent depression in middle-
aged and elderly individuals. Current data suggests that the mental health status of the 
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Dutch population aged 65 or younger over the previous decade has not changed, despite 
improvements in the treatment and prevention of CVD [27]. Similarly, despite intensified 
CVD risk factor management in the past 20 years, the prevalence of depression was similar 
in our study as to that reported by Beekman et al. in a systematic review in 1999 [28] 
and to that reported by Tiemeier et al. in the Rotterdam population between the years 
1997-1999 [29]. In line with these findings, the associations in this thesis were modest 
and predominantly non-significant, which might suggest that only very large reductions in 
arterial stiffness could effectively reduce the risk of developing depressive disorders in the 
general population. Therefore, this thesis emphasises the need to develop more effective 
arterial de-stiffening therapies, such as A-II type 2 receptor agonists and AGE inhibitors 
[25,26].
 
2. Arterial stiffness and cognitive dysfunction 
The third key finding of this thesis is that in elderly (> 60 years) individuals, carotid artery 
stiffness is not associated with any of three main cognitive performance domains of 
cognitive dysfunction after six years of follow-up. Aortic stiffening, however, was associated 
with a lower information processing speed, but not with a lower attention and executive 
function, or memory in a small sub-population. These differential associations should be 
confirmed in much larger study samples, as our study was too small to compensate for the 
selective attrition during follow-up and, also did not allow for the testing of interactions 
with age, sex and type 2 diabetes. Also, the lack of associations of carotid artery stiffness 
with cognitive dysfunction in our study is in accordance with the only other available 
community-based study [30]; however, both studies may have been hampered by the 
measurement of these two variables at only two time points. Possibly, larger observational 
studies that measure carotid artery stiffness and cognitive function at multiple time points 
would offer a better chance of identifying any associations. Also, some have suggested that 
cognitive dysfunction and dementia may not necessarily form a continuum [31], therefore 
the association of arterial stiffness with dementia should also be researched longitudinally 
in a similar fashion. 
Nevertheless, our current results may stimulate clinicians to lower blood pressure in elderly 
individuals with a high aortic stiffness. As opposed to depression, several large population-
based randomised controlled trials (RCTs) [32,33] have already shown that blood pressure 
reduction could modestly preserve cognitive function in the elderly. These small effects 
could be attributed to the adverse effects of intensive blood pressure lowering, which 
may excessively lower diastolic and mean arterial pressure [34-36], which, in turn, may 
adversely affect cognitive function [37]. This may be of especial importance in patients with 
arterial stiffness who may also suffer from impaired reactivity of the cerebral vasculature 
[38] and may thus be unable to maintain constant cerebral flow at lower blood pressure 
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levels [39]. Specific AGE reducing therapies and AT-II type 2 receptor agonists [25,26] could 
reduce arterial stiffness without affecting mean arterial pressure de however, additional 
research is required to confirm their safety and effectiveness.
3. AGEs and the stiffening of the carotid, femoral and brachial arteries 
The fourth key finding of this thesis is that neither tissue nor plasma Advanced Glycation 
End Products (AGEs) were associated with the stiffening of either the elastic carotid artery 
or the muscular femoral or brachial arteries. Although non-significant, our results offer 
additional insight in the pathophysiology of arterial stiffness and could have several clinical 
implications. The Maastricht Study already showed that both tissue and plasma AGEs are 
associated with higher aortic stiffness as measured by the cfPWV and central (ascending 
aortic) pulse pressure [40]. The cfPWV, however, represents the properties of the highly 
elastic descending thoracic and abdominal aortas, as well as of the muscular iliac and 
femoral arteries. Our lack of significant associations of AGEs within the same Maastricht 
Study population could imply that the most elastic thoracic and abdominal aortas are more 
prone to AGE accumulation than the less elastic carotid artery or the muscular femoral 
or brachial arteries. Thus, if confirmed in larger populations, our results may suggest that 
AGE-reducing therapies may be more effective in lowering aortic rather than carotid artery 
stiffness; and that they should therefore be included in CVD risk management strategies. 
Amongst others, ACE-inhibitors, statins and vitamins B 1 and 6 have been shown to have 
some AGE reducing properties [26]; however, no specific AGE-reducing drugs are yet 
available on the market. Clinicians could however inform individuals with a moderate and 
high CVD risk, as well as type 2 diabetes patients about the need to reduce dietary AGEs by 
cooking foods with water-based moisture (ie. steaming, stewing, poaching, and braising) 
and by avoiding processed, barbecued, grilled or fried meat. If these dietary changes are also 
shown to be beneficial in population-based settings [41], informational campaigns could be 
co-ordinated in order to raise awareness concerning this topic. Also, we cannot exclude 
that AGE reduction could also positively influence carotid artery stiffness, as our study was 
quite small and included relatively healthy T2D patients that were systematically treated 
with more antihypertensive and lipid-modifying therapies. Speculatively more prolonged 
exposure to higher concentrations of AGEs, such as occur in kidney failure patients or 
patients with poorly controlled T2D with micro-and macrovascular complications [42] 
could accelerate carotid artery stiffening. Indeed, plasma pentosidine was associated with 
carotid artery stiffness in a small sample of dialysis patients [43].  These hypotheses need 
to be confirmed first before they can be implemented in clinical practice. 
Lastly, we also found that tissue AGE accumulation as measured by Skin Autofluorescence 
(SAF) was robustly associated with a dilation of the carotid wall but not with its thickening, 
which implies a relative thinning of its wall. These changes are accompanied by a higher 
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wall stress; which will ultimately lead to arterial stiffening by accelerating elastic fibre 
degradation. Furthermore, carotid artery dilation could also decrease the wall shear stress 
[44], which, in turn could stimulate atherosclerotic plaque formation [45]. We cannot 
exclude that our findings are due to the play of chance, however if our results are confirmed 
in larger population-based studies it could be speculated that AGE-reducing therapies may 
reverse carotid artery stiffening and atherosclerotic plaque formation in its incipient stages 
prior to elastic fibre degradation.
 
4. Future research avenues
In  conclusion, in this valorisation addendum we expanded on the possible societal 
and clinical relevance of our findings. In this thesis we attempted to improve current 
understanding of the role played by arterial stiffening in the development of late-life 
depression and cognitive dysfunction. Most of the associations observed were modest 
and predominantly non-significant, which may suggest that only very large reductions in 
arterial stiffness could effectively reduce the risk of developing neuropsychiatric disorders 
in the general population. Physicians should nevertheless be aware of the possible adverse 
effects of aortic stiffening on the development of depression in middle-aged individuals 
and should encourage middle-aged depressive patients to adopt a healthy life-style and 
could consider adding de-stiffening antihypertensives in order to improve treatment 
outcomes. Furthermore, physicians should consider optimising systolic hypertension with 
de-stiffening antihypertensives in order to delay the development of cognitive dysfunction 
in the elderly. In the second part of this thesis we explored additional de-stiffening therapies 
and showed that AGEs could accelerate the stiffening of the most elastic descending 
thoracic and abdominal aortas. Physicians therefore also consider informing individuals 
with a moderate and high CVD risk, as well as type 2 diabetes patients about the need to 
reduce dietary AGEs.
Although the conclusions of this dissertation have several clinical and social applications, 
it should be noted that our significant results were based on cross-sectional data and 
that our longitudinal associations were largely inconclusive; thus, our knowledge is 
momentarily best implemented in additional scientific research that might improve patient 
care in the future. The Maastricht Study could offer some opportunities to analyse these 
research questions as it is one of the world’s largest observational, prospective population-
based cohort studies that focuses on the aetiology, pathophysiology, complications and 
comorbidities of type 2 diabetes mellitus [46].
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je wel voor het plannen van alle polyneuropathie afspraken en heel veel beterschap! 
Maggie: hartelijk dank voor de goede begeleiding voor het plannen voor de opleiding. 
Ivonne: hartelijk dank voor je hulp met alle bureaucratie rondom het afronden van de 
promotie traject. 
Het EpidM onderwijs in Amsterdam
Hartelijk dank voor het maken van een nuttig en duidelijk curriculum over epidemiologisch 
onderzoek. Bovendien zou ik graag jullie willen danken voor de tijd dat jullie hebben 
ingestoken voor het begeleiden van ons stages. Met jullie hulp en steun heb ik een 
basiskennis gekregen over het verrichten van epidemiologisch onderzoek.
Alle mede-promovendi 
Stefan: ik vond het geweldig om vaatstijfheid en remodelering met je te bespreken, ook al 
dit onderwerp voor geen van ons beide nuttig bleek te zijn. Marja: gefeliciteerd voor het 
verkrijgen van de co-morbitieiten artikel, ik hoop dat je hiervan zal blijven genieten tijdens 
je opleiding. Ben: je bent een van de grappigste kamergenoten die ik ooit heb gehad. Het 
was leuk om met je over alle mogelijke wetenschappelijke en niet-wetenschappelijke 
onderwerpen, inclusief Roemenië, te spreken. Ook Thomas, Pauline, Peggy, Fleur, Anne-
mariek, Eline, Tan-Lai en Sytze: heel veel succes in jullie toekomstige carrières.
Mijn vrienden
I would like to start by thanking two individuals who are completely unaware of my 
friendship, but who are scientifically as close to me as any member of my promotion team: 
dr. G.F. Mitchell and prof. dr. S. Laurent. 
Dear Garry F. Mitchell (aka. The GFM),
My BFG or BFA (Big Friendly (Scientific) Giant/ American) as I usually think of you. Your 
straightforward and clearly formulated articles have helped me understand arterial stiffness 
at every stage of my (scientific) development. Your passion for arterial stiffness has fuelled 
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my own interest for this topic. I regret not being able to meet you face-to-face, but I am 
glad we met in writing at least.   
Dear prof. S. Laurent, 
Your considerable work on arterial stiffness has added to my own understanding of the 
topic. Most importantly, however, I found that your style of publishing results of scientific 
inquires clearly and without bias a very good guideline for my own articles.  
Mijn familie
Mijn familie: dank jullie wel voor alle hulp en ondersteuning tijdens dit promotie traject. 
Mijn lieve moeder: je integriteit en je heldere interpretatie van de resultaten van 
epidemiologische onderzoeken hebben mij vanaf het begin van mijn leven vooruitgeholpen. 
Je hebt mij geleerd om het leveren van goede patiënt zorg nooit te vervangen door 
epidemiologisch onderzoek, hoe aantrekkelijk dat soms lijkt. Ik hoop dat je nu het afronden 
van dit promotietraject vanaf de hemel zult genieten.       
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PhD student in Internal Medicine at the Maastricht Study and the Academic Hospital in 
Maastricht, under the supervision of Prof. dr. C.D.A Stehouwer. During this research period 
she also obtained a cum laude degree of Master of Health Sciences in Clinical Epidemiology 
at the VU University, Amsterdam.  She is currently working as a resident in Cardiology at 
the Amphia Hospital in Breda. 
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